

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/47, 15/52, C12N 5/10, 5/16, 15/12, 15/19, 15/63, 15/64	A1	(11) International Publication Number: WO 00/61624 (43) International Publication Date: 19 October 2000 (19.10.00)
(21) International Application Number: PCT/US00/08980 (22) International Filing Date: 6 April 2000 (06.04.00) (30) Priority Data: 60/128,700 9 April 1999 (09.04.99) US 60/176,930 20 January 2000 (20.01.00) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). KOMAT-SOULIS, George [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: 48 HUMAN SECRETED PROTEINS (57) Abstract The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

48 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly,

proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins
5 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent
10 medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded
15 polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The
20 invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as

disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain
5 the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the
10 nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the
15 polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As
20 shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

25 A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to

sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x

5 Denhardt's solution, 10% dextran sulfate, and 20 μ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.

Changes in the stringency of hybridization and signal detection are primarily
10 accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH_2PO_4 ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 μ g/ml
15 salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the
20 inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above,
25 due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more

detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does
5 exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to
10 the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine
15 (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to
20 find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

25 In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a

particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares melanocyte 2NbHM and to a lesser extent in Soares fetal liver spleen 1NFLS; Soares_fetal_liver_spleen_1NFLS_S1; normalized infant

brain cDNA; Monocyte activated, re-excision; Stratagene hNT neuron (#937233);
 Smooth muscle, serum induced, re-exc; Soares placenta Nb2HP; Soares infant brain
 1NIB; Soares_parathyroid_tumor_NbHPA; 7TM-pbdd; Soares_NFL_T_GBC_S1;
 Soares ovary tumor NbHOT; Colorectal Tumor; Dermatofibrosarcoma Protuberance;
 5 Human T-cell lymphoma, re-excision; Soares retina N2b4HR; Human Normal Breast;
 Smooth muscle, IL1b induced; Human Osteoclastoma, re-excision; wilm's tumor;
 Human adult (K.Okubo); NCI_CGAP_Ov2; NCI_CGAP_Co10; NCI_CGAP_Co12;
 NCI_CGAP_GCB1; Human Fetal Dura Mater; Human Placenta; Adipocytes; Colon
 Tumor II; Primary Dendritic cells, frac 2; Human Osteoclastoma; Human
 10 Microvascular Endothelial Cells, fract. A; Spleen, Chronic lymphocytic leukemia;
 Hodgkin's Lymphoma II and Primary Dendritic Cells, lib 1.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
 59 as residues: Gln-21 to Gly-26, Cys-30 to Ser-38.

Many polynucleotide sequences, such as EST sequences, are publicly
 15 available and accessible through sequence databases. Some of these sequences are
 related to SEQ ID NO:11 and may have been publicly available prior to conception of
 the present invention. Preferably, such related polynucleotides are specifically
 excluded from the scope of the present invention. To list every related sequence
 would be cumbersome. Accordingly, preferably excluded from the present invention
 20 are one or more polynucleotides comprising a nucleotide sequence described by the
 general formula of a-b, where a is any integer between 1 to 215 of SEQ ID NO:11, b
 is an integer of 15 to 229, where both a and b correspond to the positions of
 nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a
 + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3608356 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "rab3-GAP regulatory domain [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

10  >gi|3608356 (AF004828) rab3-GAP regulatory domain [Homo sapiens]
    >sp|O75872|RAB3-GAP REGULATORY DOMAIN.
    Length = 1393

    Minus Strand HSPs:

15  Score = 356 (125.3 bits), Expect = 1.8e-30, P = 1.8e-30
    Identities = 70/70 (100%), Positives = 70/70 (100%), Frame = -2

    Q:  1012 GMELLARLPPTLCTWLKAMPQDLQNTVEVPIATTAKLVNKVIELLPEKHGQYGLALHLIE 833
          GMELLARLPPTLCTWLKAMPQDLQNTVEVPIATTAKLVNKVIELLPEKHGQYGLALHLIE
20  S:  1324 GMELLARLPPTLCTWLKAMPQDLQNTVEVPIATTAKLVNKVIELLPEKHGQYGLALHLIE 1383

    Q:   832 AVEAISLPSL 803
          AVEAISLPSL
    S:  1384 AVEAISLPSL 1393
25

```

The segment of gil3608356 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 107. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

30 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 108 which

corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares melanocyte 2NbHM and to a lesser extent in Soares fetal liver spleen 1NFLS; Soares_fetal_liver_spleen_1NFLS_S1; normalized infant brain cDNA; Monocyte activated, re-excision; Human Osteoblasts II; Smooth muscle, serum induced, re-exc; Stratagene hNT neuron (#937233); Soares placenta Nb2HP; Soares infant brain 1NIB; Soares_parathyroid_tumor_NbHPA; 7TM-pbdd; Soares_NFL_T_GBC_S1; Soares ovary tumor NbHOT; Colorectal Tumor; Dermatofibrosarcoma Protuberance; Human T-cell lymphoma, re-excision; Soares retina N2b4HR; Human Normal Breast; Smooth muscle, IL1b induced; Healing groin wound, 6.5 hours post incision; wilm's tumor; Human adult (K.Okubo); NCI_CGAP_Ov2; NCI_CGAP_Co10; NCI_CGAP_Co12; NCI_CGAP_GCB1; Human Fetal Dura Mater; Pancreas Islet Cell Tumor; Human Placenta; Adipocytes; Colon Tumor II; Primary Dendritic cells, frac 2; Human Osteoclastoma; Human Microvascular Endothelial Cells, fract. A; Spleen, Chronic lymphocytic leukemia; Hodgkin's Lymphoma II and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1005 of SEQ ID NO:12, b is an integer of 15 to 1019, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Pancreas Islet Cell Tumor.

 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 410 of SEQ ID NO:13, b
15 is an integer of 15 to 424, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

20 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Activated T-cell(12h)/Thiouridine-re-excision; Soares fetal liver spleen 1NFLS; and Soares infant brain 1NIB.

 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
25 related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1103 of SEQ ID NO:14, b
5 is an integer of 15 to 1117, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

10 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Activated T-cell(12h)/Thiouridine-re-excision and to a lesser extent in Human Primary Breast Cancer; NCI_CGAP_GCB1; H. Kidney Cortex, subtracted; T-Cell PHA 16 hrs; Human Hippocampus; Human adult (K.Okubo); NCI_CGAP_GC3 and NCI_CGAP_Kid5.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 63 as residues: Met-1 to Pro-6, Gly-73 to Thr-78.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of
20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 870 of SEQ ID NO:15, b
25 is an integer of 15 to 884, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

- 5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in T cell helper II; Human Jurkat Membrane Bound Polysomes; Human Osteoclastoma; Osteoblasts; Human Umbilical Vein, Endo. remake; Soares_testis_NHT; Keratinocyte; Soares infant brain 1NIB; Colon Tumor II; Human Amygdala; Human
- 10 Endometrial Tumor; Human Cerebellum; Soares_senescent_fibroblasts_NbHSF; Soares melanocyte 2NbHM; Epithelial-TNF α and INF induced; Smooth muscle, serum induced, re-exc; Macrophage-oxLDL, re-excision; Human Testes, Reexcision; Nine Week Old Early Stage Human; Soares placenta Nb2HP; NTERA2, control; Activated T-cell(12h)/Thiouridine-re-excision; Stratagene muscle 937209; Synovial
- 15 hypoxia; Macrophage-oxLDL; Pancreas Islet Cell Tumor; Smooth muscle, serum treated; Human fetal heart, Lambda ZAP Express; Activated T-Cell (12hs)/Thiouridine labelledEco; Soares_parathyroid_tumor_NbHPA; Synovial IL-1/TNF stimulated; pBMC stimulated w/ poly I/C; Human endometrial stromal cells-treated with progesterone; Stratagene HeLa cell s3 937216; Human Brain, Striatum;
- 20 Stromal cell TF274; Human umbilical vein endothelial cells, IL-4 induced; Colon Tumor; Human T-Cell Lymphoma; Adipocytes; NCI_CGAP_Kid6; Human Neutrophil, Activated; T Cell helper I; Bone Marrow Cell Line (RS4,11); Primary Dendritic Cells, lib 1; Weizmann Olfactory Epithelium; Soares retina N2b4HR; Smooth Muscle- HASTE normalized; NTERA2 teratocarcinoma cell line+retinoic
- 25 acid (14 days); Human Pineal Gland; Human endometrial stromal cells-treated with estradiol; H. Lymph node breast Cancer; NCI_CGAP_GCB1; Apoptotic T-cell;

- Human Uterine Cancer; Spinal cord; Synovial Fibroblasts (control); Human Thymus Stromal Cells; Human fetal heart, Lambda ZAP Express; Human Thymus; Macrophage (GM-CSF treated); Human Whole Six Week Old Embryo; Stratagene lung (#937210); Stratagene colon (#937204); Neutrophils IL-1 and LPS induced;
- 5 Soares breast 3NbHBst; Human Synovial Sarcoma; Colon Normal III; NCI_CGAP_AA1; NCI_CGAP_Co4; NCI_CGAP_Co10; Human Bone Marrow, treated; Tongue Normal; Whole 6 Week Old Embryo; Human Adult Spleen; Human White Adipose; Human Cardiomyopathy, subtracted; Smooth Muscle Serum Treated, Norm; Aorta endothelial cells + TNF-a; Soares_fetal_heart_NbHH19W;
- 10 Soares_pineal_gland_N3HPG; Human Lung Cancer, re-excision; Stratagene ovarian cancer (#937219); H. Kidney Cortex, subtracted; Glioblastoma; Human Osteosarcoma; Soares_pregnant_uterus_NbHPU; Jurkat T-cell G1 phase; Human fetal heart, Lambda ZAP Express; Brain Frontal Cortex, re-excision; Spinal Cord, re-excision; Human Infant Brain; Human Chronic Synovitis; Human Prostate; Mo7e
- 15 Cell Line GM-CSF treated (1ng/ml); STRATAGENE Human skeletal muscle cDNA library, cat. #936215.; CHME Cell Line, treated 5 hrs; Monocyte activated, re-excision; Human Activated T-Cells; normalized infant brain cDNA; Human retina cDNA Tsp509I-cleaved sublibrary; Bone Marrow Stromal Cell, untreated; Gessler Wilms tumor; Soares_fetal_liver_spleen_1NFLS_S1; Stratagene neuroepithelium
- 20 (#937231); Colon Normal II; breast lymph node CDNA library; Human Testes Tumor; Chromosome 7 HeLa cDNA Library; NCI_CGAP_HN3; NCI_CGAP_Lu5; Normal colon; Soares_placenta_8to9weeks_2NbHP8to9W; Neutrophils control, re-excision; Endothelial-induced; NCI_CGAP_Lu1; NCI_CGAP_Co11; Stratagene endothelial cell 937223; Smooth muscle, control; Spleen, Chronic lymphocytic
- 25 leukemia; Neutrophils IL-1 and LPS induced; Hodgkin's Lymphoma II; neutrophils control; Stratagene endothelial cell 937223; Human Hippocampus; Human

- Hippocampus, prescreened; Human Cerebellum, differentially expressed; Human Adrenal Gland; HL-60, PMA 1d, subtracted; Smooth muscle-edited A; Human Pediatric Kidney; Human Fetal Kidney; Human Astrocyte; Human Infant Adrenal Gland, subtracted; Kidney Pyramids; Pericardium; Human Macrophage; Lung
- 5 Mesothelium; Kidney cancer; Liver Tumour Met 5 Tu; Human Adult Heart, subtracted; Tongue carcinoma; Thyroid Normal (SDCA2 No); Larynx Normal; HPAS (human pancreas, subtracted); CD34+ cell, I, frac II; Tongue Tumour; Colorectal Tumor; Human Kidney; Human OB MG63 control fraction I; prostate-edited; Adipocytes, re-excision; HSC172 cells; Human Stomach; Human Neutrophils,
- 10 Activated, re-excision; Smooth muscle, control, re-excision; Human Fetal Bone; human colon cancer; Activated T-cells; Human Lung; Human T-cell lymphoma, re-excision; HSA 172 Cells; Stratagene pancreas (#937208); H. Whole Brain #2, re-excision; Apoptotic T-cell, re-excision; B Cell lymphoma; Human Epididymus; Human Amygdala, re-excision; Stromal-Osteoclastoma; Human Colon Cancer, re-
- 15 excision; Smooth muscle, IL1b induced; Alzheimers, spongy change; Human Osteoclastoma Stromal Cells - unamplified; Healing groin wound, 7.5 hours post incision; NTERA2 + retinoic acid, 14 days; Synovial hypoxia-RSF subtracted; LNCAP prostate cell line; Human Whole Brain #2 - Oligo dT > 1.5Kb; Human Stomach, re-excision; Ovarian Tumor 10-3-95; Human endometrial stromal cells;
- 20 Stratagene hNT neuron (#937233); Stratagene NT2 neuronal precursor 937230; Jurkat T-Cell, S phase; Synovial Fibroblasts (IL1/TNF), sub; wilm's tumor; Human Manic Depression Tissue; Human Neutrophil; Fetal Liver, subtraction II; H. Kidney Medulla, re-excision; TF-1 Cell Line GM-CSF Treated; Breast Cancer Cell line, angiogenic; NCI_CGAP_Co3; NCI_CGAP_Alvi1; NCI_CGAP_Br1.1; L428; Human
- 25 Osteoblasts II; Human Umbilical Vein Endothelial Cells, uninduced; Human Primary Breast Cancer Reexcision; Human Heart; Human Ovarian Cancer Reexcision; Merkel

Cells; Human Pancreas Tumor, Reexcision; Liver, Hepatoma; Human Activated Monocytes; Human Activated T-Cells, re-excision; Human Testes Tumor, re-excision; Hemangiopericytoma; Soares breast 2NbHBst; Rejected Kidney, lib 4; Human epidermal keratinocyte; Soares_NbHFB; Hepatocellular Tumor, re-excision;

5 Human Liver, normal; Human fetal heart, Lambda ZAP Express; NCI_CGAP_Pr24; NCI_CGAP_Pr25; Human pancreatic islet; Soares_total_fetus_Nb2HF8_9w; Stratagene lung carcinoma 937218; Resting T-Cell Library,II; 12 Week Old Early Stage Human; Human Substantia Nigra; Human Placenta; Brain frontal cortex; Chromosome 7 Placental cDNA Library; NCI_CGAP_Co8; NCI_CGAP_GC4;

10 NCI_CGAP_Kid3; NCI_CGAP_Pr12; Human Fetal Kidney, Reexcision; Primary Dendritic cells,frac 2; Human Fetal Lung III; Human Placenta; Bone marrow; Human Fetal Heart; human tonsils; Human Adult Pulmonary,re-excision; Endothelial cells-control; NCI_CGAP_Br2; NCI_CGAP_Co9; NCI_CGAP_GC1; NCI_CGAP_GC5; NCI_CGAP_Pr2; NCI_CGAP_Pr6; NCI_CGAP_Pr10; normalized infant brain

15 cDNA; Human Microvascular Endothelial Cells, fract. A; Monocyte activated; Human B Cell Lymphoma; Human pancreatic islet; Human pancreatic cancer cell line Patu 8988t; NCI_CGAP_Co12; NCI_CGAP_Brn23; Soares_NhHMPu_S1; NCI_CGAP_Ew1; NCI_CGAP_Kid5; and Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly

20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

25 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 629 of SEQ ID NO:16, b

is an integer of 15 to 643, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 gil1769491 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "kruppel-related zinc finger protein [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >gi|1769491 kruppel-related zinc finger protein [Homo sapiens]
      Length = 726

      Plus Strand HSPs:

20  Score = 1371 (482.6 bits), Expect = 4.9e-157, Sum P(3) = 4.9e-157
      Identities = 244/493 (49%), Positives = 319/493 (64%), Frame = +3

      Q:  330 RNLRNHGLERLCESNDQCGEALSQIPHLNLYKKIPPGVKQYQYNTYGVFMHRRSLKSP 509
          R+ R H E+ + N+ C +A S+ +L +++I G K Y+ + GK F+ SL
25  S:  214 RHQRTHTGEKPYKCNE-CEKAFSRSENLINHQRIHTGDKPYKCDQCGKGFIEG-PSLTRH 271

      Q:  510 ITVHTGHKPYQCQECGQAYSCRSHLRMHVTRTHNGERPYVCKLCGKTFPRTSSLNRHVRH 689
          +HTG KPY+C ECG+A+S R+HL H R H GE+PY C CGK F + H +IH
30  S:  272 QRIHTGEKPYKDECGRAFSQRTHLVQBQRIHTGEKPYTCNECGKAFSQRGHFMEHQKIH 331

      Q:  690 TAERTYECKQCGKAFIDFSSLSHLSHTGEKPYKCKEKGKAFSYSSTFRRHITHTGEK 869
          T K ++C +C K F + LT H + HTGEK YK ECGKAF+ STF RH + HTGEK
      S:  332 TGGKPFKDECDKTFTRSTHLTPHPKIHTGEKTYKNECGKAFNGPSTFIRHHMIHTGEK 391

35  Q:  870 PYKCKEAEAFSYSSTFRRHMIHTGEKPHKCKEKGAEAFSYSAPRRHMITHHTGEKPYEC 1049
          PY+C EC +APS S +H +HTGEKP+ C ECG++PSY S+ +H+ HTGEKPY+C
      S:  392 PYECNECGKAFSQHSNLTQHKTHTGEKPYDCAECGKSFSYWSSLAQHLKIHTGEKPYK 451

40  Q:  1050 KQCGKTFIYLLQSFRRHERIHTGEKPYECKQCGKTFIYPQSFRRHERTHGGEKPYECNCG 1229
          +CGK F Y S +H RIHTGEKP+EC +CGK F Y + +H++TH GEK YEC +CG

```

S: 452 NECGKAFSYCSSLTQHRRHTGKPPFECSECGKAFSYLSNLNQHQXTHTGEKAYECEECG 511
 Q: 1230 KAFSHPSSFRGHMRVHTGKPYECKQCGKTFNWPISLRKHMRTHTREKPYECKQCGKAFS 1409
 KAF SS H R+HTGKPY+C +CGKTF++ SL +H + HT E+PY+C +CG+AF+
 5 S: 512 KAFIRSSSLAQHQRIHTGKPYQCHECGKTFSYGSSLIQHRKIHTGERPYKCNCECGRAF 571
 Q: 1410 LSACFREHVRMHPEDKSYECKLCGKAF-YCHISLQKHMRRHTAEKLYKCKQCGKAFSWPE 1586
 + +H R+H K YEC CGKAF +C SL +H + HT EK Y+C +C K PS
 10 S: 572 QNIHLTQHKRIHTGAKPYECAECGKAFRHCS-SLAQHQKTHTEKPYQCNKCEKTFPSQSS 630
 Q: 1587 LLQQHVRTHTVEKPYECKECGKVPKWPSSLPIMRLHTGKPYQCKHCGKAFNCSSSLRR 1766
 L QH R HT EKPY+C EC K F + L H HTGKPY C C K F+ S+ L +
 S: 631 HLTQHQRIHTGKPYKCNCECDKAFSRSTHLTEHQNTHTGKPYNCNECRKTFPSQSTYLIQ 690
 15 Q: 1767 HVRIHTTEKQYKCN 1808
 H RIH+ EK + CN
 S: 691 HQRIHSGEKPPGCN 704

The segment of gil1769491 that is shown as "S" above is set out in the
 20 sequence listing as SEQ ID NO. 109. Based on the structural similarity these
 homologous polypeptides are expected to share at least some biological activities.
 Such activities are known in the art, some of which are described elsewhere herein.
 Assays for determining such activities are also known in the art, some of which have
 been described elsewhere herein.

25 Preferred polypeptides of the invention comprise a polypeptide having the
 amino acid sequence set out in the sequence listing as SEQ ID NO. 110 which
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following
 30 tissues/cDNA libraries: Larynx Tumor; Human Umbilical Vein Endothelial Cells,
 fract. A; HSC172 cells; LNCAP prostate cell line; Jurkat T-cell G1 phase; Human
 Adult Small Intestine; Colon Normal II; human tonsils; Human Microvascular
 Endothelial Cells, fract. A; Bone Marrow Cell Line (RS4,11).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
 35 65 as residues: Ser-6 to Gly-11.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1989 of SEQ ID NO:17, b is an integer of 15 to 2003, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil609278 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "XLCL2 [Xenopus laevis]." A partial alignment demonstrating the observed homology is shown immediately below.

```
>gi|609278 XLCL2 [Xenopus laevis] >pir|S52241|S52241 XLCL2 protein -  
African
```

```
clawed frog  
Length = 102
```

Plus Strand HSPs:

```
Score = 445 (156.6 bits), Expect = 2.3e-40, P = 2.3e-40  
Identities = 80/104 (76%), Positives = 94/104 (90%), Frame = +3
```

Q: 204 MSYFPIHCPDYLRSAKMTVMNTQPMEEIGLSPRKDGLSYQIFPDPSXFXRCCCLKDR 383
 MS+++PIHC DYLRSA+MTEV+MNTQ M+EIGLSPRKD SYQIFPDPS F RCCCLKDR
 S: 1 MSVFYPIHCTDYLRSAEMTEVIMNTQSMDEIGLSPRKD--SYQIFPDPSDFRCCCLKDR 58
 5 Q: 384 LPSIVVEPTEGEVESGELRWPPEEFLVQEDEQDNCEETAKENKE 515
 LPSIVVEPTEG+VESGELRWPPEEF+V ED++ C++T KEN++
 S: 59 LPSIVVEPTEGDVESGELRWPPEEFVVDKEDKGTCDQTKKENEQ 102

The segment of gil609278 that is shown as "S" above is set out in the sequence
 listing as SEQ ID NO. 111. Based on the structural similarity these homologous
 polypeptides are expected to share at least some biological activities. Such activities
 are known in the art, some of which are described elsewhere herein. Assays for
 determining such activities are also known in the art, some of which have been
 described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the
 amino acid sequence set out in the sequence listing as SEQ ID NO. 112 which
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following
 tissues/cDNA libraries: Human fetal heart, Lambda ZAP Express and to a lesser
 extent in T-Cell PHA 16 hrs; Soares fetal liver spleen 1NFLS; NCI_CGAP_GCB1;
 Human Testes Tumor; Soares infant brain 1NIB; Human Fetal Kidney, Reexcision;
 human tonsils; T cell helper II; Soares_pregnant_uterus_NbHPU; Colon Tumor II;
 Human Synovial Sarcoma; Human Fetal Lung III; Anergic T-cell; Spleen, Chronic
 lymphocytic leukemia; Activated T-cell(12h)/Thiouridine-re-excision; Human 8
 Week Whole Embryo, subtracted; Human retina cDNA Tsp509I-cleaved sublibrary;
 NCI_CGAP_Pr23; Pancreas Islet Cell Tumor; Soares breast 3NbHBst;
 Soares_total_fetus_Nb2HF8_9w; Soares_fetal_heart_NbHH19W; Bone marrow;
 Human Fetal Heart; Activated T-Cell (12hs)/Thiouridine labelledEco; Human Bone

- Marrow, treated; Bone Marrow Cell Line (RS4,11); Human 8 Week Whole Embryo; Nine Week Old Early Stage Human; Soares_parathyroid_tumor_NbHPA; H. hypothalamus, frac A, re-excision; Human Old Ovary; Brain, normal; Messangial cell, frac 1; Human Leukocytes; Human fetal heart, Lambda ZAP Express;
- 5 NCI_CGAP_GC4; NCI_CGAP_Ov8; NCI_CGAP_Sch1; Saos2, Dexamethosome Treated; Human OB MG63 control fraction I; Human OB MG63 treated (10 nM E2) fraction I; Human OB HOS treated (10 nM E2) fraction I; Human Pancreatic Carcinoma; Soares adult brain N2b4HB55Y; Human Epididymus; NTERA2 + retinoic acid, 14 days; Synovial Fibroblasts (III/TNF), subt; Spinal Cord, re-excision;
- 10 Human Infant Brain; Fetal Liver, subtraction II; Soares_placenta_8to9weeks_2NbHP8to9W; Apoptotic T-cell; Human Umbilical Vein Endothelial Cells, uninduced; Bone Marrow Stromal Cell, untreated; Human Fetal Brain; NTERA2, control; Stratagene lung (#937210); Soares_multiple_sclerosis_2NbHMSP; Resting T-Cell Library, II; Stratagene NT2
- 15 neuronal precursor 937230; Human Bone Marrow Stromal Fibroblast; Human Testes, Reexcision; Human Neutrophil, Activated; Endothelial-induced; Soares_fetal_lung_NbHL19W; Hodgkin's Lymphoma II and Osteoblasts.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

20 related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

25 general formula of a-b, where a is any integer between 1 to 2953 of SEQ ID NO:18, b is an integer of 15 to 2967, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human adult small intestine, re-excision; and Anergic T-cell.

 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 965 of SEQ ID NO:19, b
15 is an integer of 15 to 979, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

20 It has been discovered that this gene is expressed primarily in Human Stomach.

 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of
25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 624 of SEQ ID NO:20, b is an integer of 15 to 638, where both a and b correspond to the positions of

5 nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The computer algorithm BLASTX has been used to determine that the

10 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPIDle199791 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "5'-3' exonuclease [Mus musculus]." A partial alignment demonstrating the observed homology is shown

15 immediately below.

```
>gnl|PID|e199791 5'-3' exonuclease [Mus musculus] >sp|P97789|P97789 5'-3'
      EXONUCLEASE.
      Length = 1719

Plus Strand HSPs:

Score = 545 (191.8 bits), Expect = 1.2e-99, Sum P(2) = 1.2e-99
Identities = 113/188 (60%), Positives = 128/188 (68%), Frame = +2

Q: 1925 GSLGMNFPPLPSQVFANYPSAVXXXXXXXXXXXXXXXXXXXXSSSHLFGSMPWGPSVPVPGKP 2104
      GSLG++FPLP  +F NYP AV                      SSSHLFGS+ W P VPV G
S: 1534 GSLGVSPFLPPIFTNYPFAVPPGAVPPVFTQPTANIMPSSSHLFGSVSWRPPVPVAGNA 1593

Q: 2105 FHHTLYSGTMPAGGIPGGVHNQFIPLQVTKKRVANKKNFENKEAQSSQATPVQTSQPD 2284
      FH+  Y GTMP+AGG+PGGVH+QFIPLQVTKKRVAN+KNFENKEAQSSQATP+QT++P S
S: 1594 PHPSYPGTMPLAGGVPGGVHSQFIPLQVTKKRVANRKNFENKEAQSSQATPLQTNKPGS 1653

Q: 2285 SNIVKVXXXXXXXXXXXXXPIAQPASSFQVETASQGHSHHKSTPISSSRKSRKLAVN 2464
      S  K+                      AQP SS  VETASQGH S  +S P SSS+RKSRKLAVN
S: 1654 SEATKMTPEQESPFASSSSSQAAQPVSS-HVETASQGHVGSQPRSAF-SSSKRKRKLAVN 1711
```

Q: 2465 FGVSKPSE 2488
F VSKPSE
S: 1712 FSVSKPSE 1719

5 The segment of gnllPIDle199791 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 113. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have
10 been described elsewhere herein.

 Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 114 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

15 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Stratagene lung (#937210); Human Prostate, subtracted; NCI_CGAP_GCB1; Apoptotic T-cell, re-excision; Human Thymus; Monocyte activated and Nine Week Old Early Stage Human.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3002 of SEQ ID NO:21, b

is an integer of 15 to 3016, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 12

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. `sp|G545363|G545363` (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Retinoic-Acid-Induced Gene Product." A partial alignment demonstrating the observed homology is shown immediately below.

```
15 >sp|G545363|G545363 RETINOIC-ACID-INDUCED GENE PRODUCT.
    Length = 529

    Minus Strand HSPs:

20 Score = 575 (202.4 bits), Expect = 2.8e-134, Sum P(4) = 2.8e-134
    Identities = 112/122 (91%), Positives = 118/122 (96%), Frame = -1

    Q: 1036 TEMLSQPNHPSGEVKAENNIEMVGESQAARKVIVSVEDAVPTIFCGKIKGLSGVSTKNFSF 857
        TEM+SQP+HP E+KAENNIE++ ESQAARKVIVSVEDAVP IFCGKIKGLSGVSTKNFSF
    S: 408 TEMVSQPSHPGSELKAENNIEILSESQAARKVIVSVEDAVPAIFCGKIKGLSGVSTKNFSF 467

25 Q: 856 KREDSVLQGYDINSQGEESMGNAEPLRKPIKNRSIKLKKVNSQEIHMLPIKKQRLATFFP 677
        KREDSVLQGYDINSQGEES+GNAEPLRKPIKNRSIKLKKVNSQEIHMLPIKKQRLATFFP
    S: 468 KREDSVLQGYDINSQGEESLGNAEPLRKPIKNRSIKLKKVNSQEIHMLPIKKQRLATFFP 527

30 Q: 676 RK 671
        RK
    S: 528 RK 529

35 Score = 551 (194.0 bits), Expect = 2.8e-134, Sum P(4) = 2.8e-134
    Identities = 106/134 (79%), Positives = 116/134 (86%), Frame = -3

    Q: 1445 GLHPPKGTQTPLEKDELKPFIDILQKEYFQLSRHTVIRMGSENEALDLSMRKVPWLKAGE 1266
        GLH PKGTQT LEKDELKP DILQ KEYFQLSRHTVIRMGSENEALDLSMRKVPWLKAGE
    S: 272 GLHSPKGTQTTLEKDELKPLDILQKEYFQLSRHTVIRMGSENEALDLSMRKVPWLKAGE 331

40 Q: 1265 VSPPIFQEDAALDLSVAHRKSEPPPETLYDSGASVDSSGHTVMEKLPSCMEISFAPATS 1086
```

SPP+PQEDAALDLS+AAHRK+E PPETLY++ S D GHT++EKL SGME+ PAPA
 S: 332 ASPPVFQEDAALDLSLAHRKAEAPPETLYNNSGSADIQGHILEKLSSGMEPPAPAKC 391
 Q: 1085 HEAPAMMDSHISS 1044
 EA AMM+SH S+S
 S: 392 SEASAMMESHSSNS 405
 Score = 143 (50.3 bits), Expect = 2.8e-134, Sum P(4) = 2.8e-134
 Identities = 27/33 (81%), Positives = 29/33 (87%), Frame = -3
 Q: 1817 SSTIHNNLFQGAEDPEAQQLDLRIPSQPQSP 1719
 S+ IHNNLFQGAED EAQPQLDLRIP +PQ P
 S: 148 SNAIHNNLFQGAEDSEAQPQLDLRIPRKPQEP 180
 Score = 100 (35.2 bits), Expect = 2.8e-134, Sum P(4) = 2.8e-134
 Identities = 29/76 (38%), Positives = 34/76 (44%), Frame = -2
 Q: 1716 LPFEAVLQNLFPSQGHRSRAPTLSSASSWLCPCAPTAP*LPL---VPPGPTSHPLGAVSCNR 1546
 LPFEAVLQNLFP+QG P P P F PL VPP P +
 S: 182 LPFEAVLQNLFPQTQGS LGPPPCQPPPGYAPVPPQPFNSPLSPLVPPATLLVPYPVI-VPL 240
 Q: 1545 PLACASPYSHPHPGASE 1495
 P+ P P P ++E
 S: 241 PVPVPIPIPVVPVQSTE 257

The segments of splG545363IG545363 that are shown as "S" above are set out
 in the sequence listing as SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119 and
 SEQ ID NO. 121. Based on the structural similarity these homologous polypeptides
 are expected to share at least some biological activities. Such activities are known in
 the art, some of which are described elsewhere herein. Assays for determining such
 activities are also known in the art, some of which have been described elsewhere
 herein.

Preferred polypeptides of the invention comprise a polypeptide having the
 amino acid sequence set out in the sequence listing as SEQ ID NO. 116, SEQ ID NO.
 118, SEQ ID NO. 120 and/or SEQ ID NO. 122 which correspond to the "Q"
 sequences in the alignment shown above (gaps introduced in a sequence by the
 computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following
 tissues/cDNA libraries: Soares_pregnant_uterus_NbHPU and to a lesser extent in

Soares_fetal_heart_NbHH19W; Nine Week Old Early Stage Human; Human Infant Adrenal Gland, Subtracted; Soares_fetal_lung_NbHL19W; Crohn's Disease; Normal Ovary, Premenopausal; prostate-edited; Human Umbilical Vein, Endo. remake; Human Stomach, re-excision; Synovial Fibroblasts (II1/TNF), subt; Human Thymus; 5 Human Fetal Dura Mater; Spinal cord; H. Frontal cortex, epileptic, re-excision; Human adult (K.Okubo); NCI_CGAP_Lu5; Human Testes; Human 8 Week Whole Embryo and Human Cerebellum.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 10 related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 15 general formula of a-b, where a is any integer between 1 to 1856 of SEQ ID NO:22, b is an integer of 15 to 1870, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 13

It has been discovered that this gene is expressed primarily in Human Stomach, re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 25 related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1070 of SEQ ID NO:23, b is an integer of 15 to 1084, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares_fetal_heart_NbHH19W; Stratagene lung (#937210); Stratagene NT2 neuronal precursor 937230; Activated T-Cell (12hs)/Thiouridine labelledEco; Soares fetal liver spleen 1NFLS; Soares breast 2NbHBst; Stratagene NT2 neuronal precursor 937230; Normal colon; Soares melanocyte 2NbHM; NCI_CGAP_Co3; Smooth Muscle-HASTE normalized; Stratagene colon (#937204); Stratagene neuroepithelium (#937231); Colon Carcinoma; Osteoblasts; Human Cerebellum; NCI_CGAP_Pr1; Colon Normal II; breast lymph node CDNA library; Soares breast 3NbHBst; Human Testes Tumor; Human Synovial Sarcoma; NCI_CGAP_Co12; NCI_CGAP_GCB1; NCI_CGAP_Kid5; NCI_CGAP_Pr12; Activated T-cell(12h)/Thiouridine-re-excision; Human 8 Week Whole Embryo; Primary Dendritic Cells, lib 1; Human Primary Breast Cancer; NCI_CGAP_Co9; Human Gall Bladder, fraction II; Soares_fetal_liver_spleen_1NFLS_S1; Soares_testis_NHT; Soares_pregnant_uterus_NbHPU; Human Chronic Synovitis; Breast Cancer Cell line, angiogenic; Apoptotic T-cell; Human Uterine Cancer; Ulcerative Colitis; Human Whole Six Week Old Embryo; Soares_parathyroid_tumor_NbHPA; Macrophage-

oxLDL, re-excision; Human Gall Bladder; STRATAGENE Human skeletal muscle cDNA library, cat. #936215.; Soares_senescent_fibroblasts_NbHSF; normalized infant brain cDNA; Human Fetal Kidney, Reexcision; Human Microvascular Endothelial Cells, fract. A; Human B Cell Lymphoma; NCI_CGAP_Lu5; Human

5 Endometrial Tumor; Human Kidney, normal Adult; Signal trap, Femur Bone Marrow, pooled; Soares ovary tumor NbHOT; NCI_CGAP_AA1; NCI_CGAP_GC2; NCI_CGAP_GC3; NCI_CGAP_Pr3; NCI_CGAP_Pr6; NCI_CGAP_SS1; NCI_CGAP_Pr23; Lung Mesothelium; brain stem; Human Prostate Cancer, Stage B2; Human Prostate Cancer, Stage B2 fraction; Human Colon, subtraction; prostate-

10 edited; Human (HCC) cell line liver (mouse) metastasis, remake; Human Cardiomyopathy, subtracted; Adipocytes, re-excision; HSC172 cells; Smooth Muscle Serum Treated, Norm; Smooth muscle, control, re-excision; human colon cancer; Human Quadriceps; Human Adult Heart, re-excision; Human adult small intestine, re-excision; Human Colon Cancer, re-excision; Hepatocellular Tumor, re-excision;

15 Synovial IL-1/TNF stimulated; Soares_total_fetus_Nb2HF8_9w; pBMC stimulated w/ poly I/C; Human Umbilical Vein, Endo. remake; NTERA2 + retinoic acid, 14 days; LNCAP prostate cell line; Human Whole Brain #2 - Oligo dT > 1.5Kb; Human Stomach, re-excision; Human Osteosarcoma; Human Colon, re-excision; Stratagene hNT neuron (#937233); Myeloid Progenitor Cell Line; Synovial Fibroblasts

20 (IL1/TNF), subt; wilm's tumor; Human Adult Small Intestine; H. Kidney Medulla, re-excision; Mo7e Cell Line GM-CSF treated (1ng/ml); L428; Human Primary Breast Cancer Reexcision; Human Pancreas Tumor; Macrophage-oxLDL; Merkel Cells; Human Pancreas Tumor, Reexcision; Human Adipose; Human Rhabdomyosarcoma; Soares adult brain N2b5HB55Y; Bone Marrow Stromal Cell, untreated; Rejected

25 Kidney, lib 4; NTERA2, control; Gessler Wilms tumor; Stratagene muscle 937209; Smooth muscle, serum induced, re-exc; Pancreas Islet Cell Tumor; PC3 Prostate cell

line; H. Frontal cortex,epileptic,re-excision; Human T-Cell Lymphoma; Human Placenta; Adipocytes; Soares_multiple_sclerosis_2NbHMSP; Gessler Wilms tumor; Primary Dendritic cells,frac 2; Human Fetal Lung III; Human Testes, Reexcision; Bone marrow; Human fetal heart, Lambda ZAP Express; NCI_CGAP_Br2; NCI_CGAP_GC4; NCI_CGAP_HN3; NCI_CGAP_Brn23; Human Testes; Hodgkin's Lymphoma II and T cell helper II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2959 of SEQ ID NO:24, b is an integer of 15 to 2973, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

It has been discovered that this gene is expressed primarily in Normal colon tissue.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 522 of SEQ ID NO:25, b is an integer of 15 to 536, where both a and b correspond to the positions of
5 nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

It has been discovered that this gene is expressed primarily in the following
10 tissues/cDNA libraries: Human Fetal Lung III; and Activated T-cell(12h)/Thiouridine-re-excision.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 74 as residues: Thr-39 to Arg-47.

Many polynucleotide sequences, such as EST sequences, are publicly
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
20 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 729 of SEQ ID NO:26, b is an integer of 15 to 743, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

It has been discovered that this gene is expressed primarily in Activated T-cell(12h)/Thiouridine-re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 701 of SEQ ID NO:27, b is an integer of 15 to 715, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Thymus; and Neutrophils IL-1 and LPS induced.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 699 of SEQ ID NO:28, b is an integer of 15 to 713, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

5 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil2677843 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "RalBP1-associated

10 EH domain protein Reps1 [*Mus musculus*]." A partial alignment demonstrating the observed homology is shown immediately below.

>gi|2677843 (AF031939) RalBP1-associated EH domain protein Reps1 [Mus musculus]
 15 >sp|O54916|O54916 RALBP1 ASSOCIATED EPS DOMAIN CONTAINING PROTEIN
 (RALBP1-ASSOCIATED EH DOMAIN PROTEIN REPS1).
 Length = 743
 20 Plus Strand HSPs:
 Score = 1405 (494.6 bits), Expect = 2.4e-161, Sum P(2) = 2.4e-161
 Identities = 289/363 (79%), Positives = 298/363 (82%), Frame = +3
 25 Q: 141 LQQTWPELNQSS EDTAIVHPVPIRMTPSKIHMQEMELKRTGSDHTNPTSPLLVKPSD LLE 320
 L Q + + DTAIVHPVPIRMTPSKIHMQEMELKRT SDHTNPTSPLLVKPSDL E
 S: 382 LTQFDSNIAPADPDTAIVHPVPIRMTPSKIHMQEMELKRTSSDHTNPTSPLLVKPSDLSE 441
 30 Q: 321 ENKINSSVKFASGNTVADGYSSSDSPTSDEPIGSNVTRQRSHSGTSPDNTAXXXXXXXXXX 500
 ENKINSSVKF SGNTV DGYSSSDSF SDPEQIGS+VTRQRSHSGTSPDNTA
 S: 442 ENKINSSVKFPGNTV-DGYSSSDSPSPDPEQIGSSVTRQRSHSGTSPDNTAPPPPPPRP 500
 Q: 501 XXXXXXXXXXXLDMNRTFTVTGXXXXXXXXXXXXXXXXXXXXXXXXXXXXVHRPVDADGLITH 680
 LDMNRTF VTTG VHRPVDADGLITH
 35 S: 501 QPSHSRSSSLDMNRTFAVTTGQQQAGVVAHPPAVPPRPQPSQAPGSPVHRPVDADGLITH 560
 Q: 681 TSTSPQIQEIQPNFADFSPQFEVFAASNVD EQDDEAEKHPEVLPAEKASDPASSLRVAKT 860
 TSTSPQIQEIQPNFADFSPQFEVFAASN++EQD EAEKHPEVLPAEKASDP+SSLR A+
 S: 561 TSTSPQIQEIQPNFADFSPQFEVFAASNVDSEEQDSEAEKHPEVLPAEKASDPSSSLRAAQA 620
 40 Q: 861 DSKTEEKTAASAPANVSKGTTPLAPPPKPVRRRLKSEDEL RPVEDEHTQKTGVLAAVLAS 1040
 DSK EEKTA + PANVSKGTTPLAPPPKPVRRRLKSEDEL RP+VDEHTQKTGVLAAVL S

S: 621 DSKAEETATNPANVSKGTTPLAPPPKPVRRRLKSEDELRPDVDEHTQRTGVLA AVLTS 680
 Q: 1041 QPSIPRSVGKDKKAIQASIRRNKETNTVLARLNSELQQQLKDVLEERISLEVQLEQLRPF 1220
 QPSIPRSVGKDKKAIQASIRRNKETNTVLARLNSELQQQLKDVLEERISLEVQLEQLRPF
 5 S: 681 QPSIPRSVGKDKKAIQASIRRNKETNTVLARLNSELQQQLKDVLEERISLEVQLEQLRPF 740
 Q: 1221 SHL 1229
 SHL
 S: 741 SHL 743

10

The segment of gil2677843 that is shown as "S" above is set out in the
 sequence listing as SEQ ID NO. 123. Based on the structural similarity these
 homologous polypeptides are expected to share at least some biological activities.
 Such activities are known in the art, some of which are described elsewhere herein.

15 Assays for determining such activities are also known in the art, some of which have
 been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the
 amino acid sequence set out in the sequence listing as SEQ ID NO. 124 which
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a
 20 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following
 tissues/cDNA libraries: Stratagene lung (#937210);
 Soares_placenta_8to9weeks_2NbHP8to9W and to a lesser extent in
 Soares_NhHMPu_S1; Human Osteosarcoma; Soares breast 3NbHBst; Soares infant
 25 brain 1NIB; Normal Ovary, Premenopausal; Thymus; Human adult small intestine, re-
 excision; Soares_pregnant_uterus_NbHPU; Stratagene lung carcinoma 937218;
 Human Bone Marrow, re-excision; Human Brain, Striatum; Human Ovarian Cancer
 Reexcision; Macrophage-oxLDL; Human Hippocampus; Soares_NbHFB;
 NCI_CGAP_GCB1; Hepatocellular Tumor, re-excision; Resting T-Cell Library, II;
 30 Dendritic cells, pooled; NCI_CGAP_Pr22; Colon Tumor II; Human Testes,

Reexcision; human tonsils; Soares_multiple_sclerosis_2NbHMSP; Endothelial-induced; Activated T-Cell (12hs)/Thiouridine labelledEco;
Soares_fetal_heart_NbHH19W; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human Osteoclastoma; Human B Cell Lymphoma; Human pancreatic islet;
5 NCI_CGAP_GC4; Hodgkin's Lymphoma II and Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1457 of SEQ ID NO:29, b is an integer of 15 to 1471, where both a and b correspond to the positions of
15 nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

It has been discovered that this gene is expressed primarily in the following
20 tissues/cDNA libraries: Human Testes and to a lesser extent in Human Hypothalamus, schizophrenia, re-excision; Human Umbilical Vein, Endo. remake; L428; PC3 Prostate cell line and Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
25 related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1754 of SEQ ID NO:30, b
5 is an integer of 15 to 1768, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

10 It has been discovered that this gene is expressed primarily in Neutrophils control, re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of
15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 961 of SEQ ID NO:31, b
20 is an integer of 15 to 975, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

25 It has been discovered that this gene is expressed primarily in Neutrophils control, re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1034 of SEQ ID NO:32, b is an integer of 15 to 1048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

It has been discovered that this gene is expressed primarily in Neutrophils IL-1 and LPS induced.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 81 as residues: Pro-22 to Gly-29, His-48 to Ser-62.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1106 of SEQ ID NO:33, b is an integer of 15 to 1120, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

5 It has been discovered that this gene is expressed primarily in Neutrophils IL-1 and LPS induced.

 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1054 of SEQ ID NO:34, b
15 is an integer of 15 to 1068, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

20 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares_NhHMPu_S1; and Neutrophils IL-1 and LPS induced.

 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 83 as residues: Glu-25 to Ser-37.

 Many polynucleotide sequences, such as EST sequences, are publicly
25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
5 general formula of a-b, where a is any integer between 1 to 1258 of SEQ ID NO:35, b is an integer of 15 to 1272, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 26**

It has been discovered that this gene is expressed primarily in Neutrophils IL-1 and LPS induced.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
15 related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
20 general formula of a-b, where a is any integer between 1 to 522 of SEQ ID NO:36, b is an integer of 15 to 536, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

It has been discovered that this gene is expressed primarily in Neutrophils IL-1 and LPS induced.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 379 of SEQ ID NO:37, b is an integer of 15 to 393, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 28

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Neutrophils IL-1 and LPS induced; and neutrophils control.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 86 as residues: Met-1 to Gln-12.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 674 of SEQ ID NO:38, b is an integer of 15 to 688, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

It has been discovered that this gene is expressed primarily in Neutrophils IL-1 and LPS induced.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 87 as residues: Gln-14 to Ser-32, Pro-53 to Leu-60.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1416 of SEQ ID NO:39, b is an integer of 15 to 1430, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

15

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: stomach cancer (human); Human Ovarian Cancer Reexcision; and Human B Cell Lymphoma.

25

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1103 of SEQ ID NO:40, b is an integer of 15 to 1117, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

It has been discovered that this gene is expressed primarily in Neutrophils IL-1 and LPS induced.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1846 of SEQ ID NO:41, b is an integer of 15 to 1860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

It has been discovered that this gene is expressed primarily in Neutrophils control, re-excision.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 441 of SEQ ID NO:42, b is an integer of 15 to 455, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a
15 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Tonsil, Lib 3; Human Activated Monocytes;
20 Soares_testis_NHT and to a lesser extent in Soares_fetal_liver_spleen_1NFLS_S1; Aorta endothelial cells + TNF-a; Human Fetal Epithelium (Skin); Jurkat T-Cell, S phase; wilm's tumor; 12 Week Old Early Stage Human, II; T-Cell PHA 24 hrs; Human Activated T-Cells, re-excision; Human T-Cell Lymphoma; Liver HepG2 cell line.; NCI_CGAP_Alv1; NCI_CGAP_GCB1; Soares_fetal_heart_NbHH19W;
25 Soares_total_fetus_Nb2HF8_9w; Soares_senescent_fibroblasts_NbHSF; Colon

Carcinoma; Human Synovial Sarcoma; Human Osteoclastoma; Activated T-cell(12h)/Thiouridine-re-excision and Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1026 of SEQ ID NO:43, b is an integer of 15 to 1040, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain INIB and to a lesser extent in normalized infant brain cDNA; Soares retina N2b4HR; Soares_NFL_T_GBC_S1; Nine Week Old Early Stage Human; Human Epididymus; Soares_fetal_heart_NbHH19W; b4HB3MA Cot8-HAP-Ft; Stratagene fetal retina 937202; Stratagene liver (#937224); Human retina cDNA randomly primed sublibrary; NCI_CGAP_Pr3; Human 8 Week Whole Embryo, subtracted; Human Hypothalamus,schizophrenia, re-excision; Human Synovium; Soares_NhHMPu_S1; Soares_testis_NHT; H. Lymph node breast Cancer; Brain Frontal Cortex, re-excision; Human Infant Brain; Human colorectal cancer; b4HB3MK; TF-1 Cell Line GM-CSF Treated; 12 Week Old Early Stage Human, II; Human Heart; Human Fetal Brain; Human Adrenal Gland Tumor; Stratagene hNT

neuron (#937233); Human Liver, normal; Fetal Heart; Human T-Cell Lymphoma;
Soares melanocyte 2NbHM; Soares_placenta_8to9weeks_2NbHP8to9W; Human
Fetal Lung III; Human Testes, Reexcision; Human Amygdala; Monocyte activated;
Human retina cDNA Tsp509I-cleaved sublibrary; NCI_CGAP_GC2; Human Bone
5 Marrow, treated; NCI_CGAP_Co3; Activated T-cell(12h)/Thiouridine-re-excision
and Keratinocyte.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
92 as residues: Pro-26 to Ser-33.

Many polynucleotide sequences, such as EST sequences, are publicly
10 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:44 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence
would be cumbersome. Accordingly, preferably excluded from the present invention
15 are one or more polynucleotides comprising a nucleotide sequence described by the
general formula of a-b, where a is any integer between 1 to 3497 of SEQ ID NO:44, b
is an integer of 15 to 3511, where both a and b correspond to the positions of
nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a
+ 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

It has been discovered that this gene is expressed primarily in Neutrophils
control, re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly
25 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:45 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1516 of SEQ ID NO:45, b is an integer of 15 to 1530, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 36

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPIDle1355238 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Sand [Fugu rubripes]." A partial alignment demonstrating the observed homology is shown immediately below.

>gnl|PID|e1355238 (AJ010317) Sand [Fugu rubripes] >sp|E1355238|E1355238
SAND

PROTEIN.
Length = 520

Minus Strand HSPs:

Score = 1424 (501.3 bits), Expect = 4.2e-145, P = 4.2e-145
Identities = 274/405 (67%), Positives = 324/405 (80%), Frame = -3

Q: 1398 WRLHQKHVFLSEAGKPVYSRYGSEELSSMTGMVALVSPLEADKNAIRSIHADGKYKV 1219
WR H+KHVFLSEAGKP+Y+RYGSEELSSMTGMVALVSP+E+DKN IRSIHADG KV+
S: 116 WRSHRKHVFLSEAGKPIYTRYGSEELSSMTGMVALVSPVESDKNTIRSIHADGCKVI 175

5
10
15
20
25

Q: 1218 FVRRSPLVLVAVARTROSAXXXXXXXXXXXXXXXXXXXTGAQLSHIFQOKQNYDLRRLLSG 1039
F+ +SPLVLV V++T QS T QL+HIFQ KQNYDLRRL+G
S: 176 FLAKSPLVLVGVSQTYQSDKELLRELQYIYYQIVSLLTLQLNHIFQNKQNYDLRRLLAG 235

Q: 1038 SERITDNLQLMARDPSFLMGAARCLPLAAVRDTPVSASLQOARARSLVFSILLARNQLV 859
SE +TDNLL + RDP L+ A CLPL+ +VRD VS+SLQ A+A++LVFSILLA ++LV
S: 236 SEYLTDNLLHRLDRDPGLLLSAVTCLPLSNSVRDVVSSSLQAAKAKNLVFSILLAGDRLV 295

Q: 858 ALVRRKDQFLHPIDLHLLFNLIXXXXFREGEAWTPVCLPKFNAAGFFHAHISYLEPDTD 679
LVR+KDQFLH IDLHL+ NL+ FREGE WTP+CLPKFN AGFFHAHISYLE +D
S: 296 TLVRRKDQFLHHIDLHLMNLVGSSSSFREGEWTPICLPKFN TAGFFHAHISYLESASD 355

Q: 678 LCLLLVSTDREDFFAVSDCRRRFQERLRKRGALALREALRTPYYSAQVGIPDLRHFLY 499
LCL+LVSTDREDF +SDC++RF ERL KR A+ AL+EAL+ P YSV QVGIP+LRHFLY
S: 356 LCLILVSTDREDFNMSDCKQRFLERLTKRTAYQALKEALKCPSYSVEQVGIPDLRHFLY 415

Q: 498 KSKSSGLFTSPEIEAPYTSEEEQERLLGLYQYLHSAHNASRPLKTIYYTGPNENLLAWV 319
KSKSSGL+TSPE Y S+EEQERL+GLYQ LHS H+ RPL+ Y ENLLAWV
S: 416 KSKSSGLYTSPEFPELYQSDEEQERLMGLYQDLHSHLHPVRPLRFFYRCTNKENLLAWV 475

Q: 318 TGAFELMYCYSPLGTAKASAVSAIHKLWRWIRKEEDRLFILTPITY 184
T F+LY+C+SPLGTAK AVSA++KL++WIRKEEDRLFIL+PLTY
S: 476 TNGFQLYLCFSPGTAKAMAVSAVNKLLKWRWIRKEEDRLFILSPLTY 520

30

The segment of gnlIPIDle1355238 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 125. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

35

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 126 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares breast 3NbHBst; Early Stage Human Brain; Soares melanocyte 2NbHM; Activated T-cell(12h)/Thiouridine-re-excision; Sinus piniformis Tumour; Human Fetal Bone;

Soares adult brain N2b4HB55Y; Human adult (K.Okubo); NCI_CGAP_GCB1;
NCI_CGAP_Kid6; NCI_CGAP_Pr25; Human Adult Testes, Large Inserts,
Reexcision; and Soares_pregnant_uterus_NbHPU.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.

5 94 as residues: Pro-19 to Ser-28.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:46 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
10 excluded from the scope of the present invention. To list every related sequence
would be cumbersome. Accordingly, preferably excluded from the present invention
are one or more polynucleotides comprising a nucleotide sequence described by the
general formula of a-b, where a is any integer between 1 to 1638 of SEQ ID NO:46, b
is an integer of 15 to 1652, where both a and b correspond to the positions of
15 nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a
+ 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

It has been discovered that this gene is expressed primarily in the following
20 tissues/cDNA libraries: Stratagene liver (#937224); and Neutrophils control, re-
excision.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
95 as residues: Ser-41 to Ser-48, Arg-61 to Trp-68.

Many polynucleotide sequences, such as EST sequences, are publicly
25 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:47 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
5 general formula of a-b, where a is any integer between 1 to 1164 of SEQ ID NO:47, b is an integer of 15 to 1178, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 38**

It has been discovered that this gene is expressed primarily in Human Ovarian Cancer Reexcision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
15 related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
20 general formula of a-b, where a is any integer between 1 to 1107 of SEQ ID NO:48, b is an integer of 15 to 1121, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Neutrophils control, re-excision; and Soares infant brain INIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 811 of SEQ ID NO:49, b is an integer of 15 to 825, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Chondrosarcoma and to a lesser extent in 12 Week Old Early Stage Human, II; and Neutrophils control, re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

25

general formula of a-b, where a is any integer between 1 to 839 of SEQ ID NO:50, b is an integer of 15 to 853, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Resting T-Cell Library,II; CD34 positive cells (Cord Blood) and to a lesser extent in Human Testes, Reexcision; and Human Bone Marrow, treated.

10

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1705 of SEQ ID NO:51, b is an integer of 15 to 1719, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

15

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

25

gil191986 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "clathrin-associated protein [Mus musculus]." A partial alignment demonstrating the observed homology is shown immediately below.

5

```
>gi|191986 clathrin-associated protein [Mus musculus] >pir|S19693|S19693
AP47
      protein - mouse >sp|P35585|AP47_MOUSE CLATHRIN COAT ASSEMBLY
PROTEIN
10      AP47 (CLATHRIN COAT ASSOCIATED PROTEIN AP47) (GOLGI ADAPTOR AP-
      1 47
      KD PROTEIN) (HA1 47 KD SUBUNIT) (CLATHRIN ASSEMBLY PROTEIN
ASSEMBLY
      PROTEIN COMPLEX 1 MEDIUM CHAIN).
15      Length = 423
```

Minus Strand HSPs:

```
Score = 1209 (425.6 bits), Expect = 1.7e-223, Sum P(2) = 1.7e-223
20 Identities = 229/232 (98%), Positives = 232/232 (100%), Frame = -3

Q: 1703 AEIVGSIKMRVFLSGMPELRLGLNDKVLFDNTGRGKSKSVELEDVKFHQCVRLSRFENDR 1524
    +EIVGSIKMRVFLSGMPELRLGLNDKVLFDNTGRGKSKSVELEDVKFHQCVRLSRFENDR
S: 192 SEIVGSIKMRVFLSGMPELRLGLNDKVLFDNTGRGKSKSVELEDVKFHQCVRLSRFENDR 251

25 Q: 1523 TISFIPPDGEFELMSYRLNTHVKPLIWIESVIEKHSRISRIEYMIKAKSQPKRRSTANNVE 1344
    TISFIPPDGEFELMSYRLNTHVKPLIWIESVIEKHSRISRIEYMIKAKSQPKRRSTANNVE
S: 252 TISFIPPDGEFELMSYRLNTHVKPLIWIESVIEKHSRISRIEYMIKAKSQPKRRSTANNVE 311

30 Q: 1343 IHIPVPNDADSPKFKTTVGSVKWVPENSEIVWSIKSPPGGKEYLMRAHFGLPSVEAEDKE 1164
    IHIPVPNDADSPKFKTTVGSVKWVPENSEIVWS+KSPPGGKEYLMRAHFGLPSVEAEDKE
S: 312 IHIPVPNDADSPKFKTTVGSVKWVPENSEIVWSIKSPPGGKEYLMRAHFGLPSVEAEDKE 371

35 Q: 1163 GKPPISVKFEIPYFTTSGIQVRYLKIIEKSGYQALPWVRYITQNGDYQLRTQ 1008
    GKPPISVKFEIPYFTTSGIQVRYLKIIEKSGYQALPWVRYITQNGDYQLRTQ
S: 372 GKPPISVKFEIPYFTTSGIQVRYLKIIEKSGYQALPWVRYITQNGDYQLRTQ 423

Score = 978 (344.3 bits), Expect = 1.7e-223, Sum P(2) = 1.7e-223
40 Identities = 190/193 (98%), Positives = 192/193 (99%), Frame = -2

Q: 2274 MSASAVYVLDLKGKVLICRNYRGDMDSEVEHFMPILMEKEEEGMLSPILAHGGVRFMWI 2095
    MSASAVYVLDLKGKVLICRNYRGDMDSEVEHFMPILMEKEEEGMLSPILAHGGVRFMWI
S: 1 MSASAVYVLDLKGKVLICRNYRGDMDSEVEHFMPILMEKEEEGMLSPILAHGGVRFMWI 60

45 Q: 2094 KHNNLYLVATSKKNACVSLVFSFLYKVVQVFSEYFKELEESIRDNFVYIYELLDELMDP 1915
    KHNNLYLVATSKKNACVSLVFSFLYKVVQVFSEYFKELEESIRDNFVYIYELLDELMDP
S: 61 KHNNLYLVATSKKNACVSLVFSFLYKVVQVFSEYFKELEESIRDNFVYIYELLDELMDP 120

50 Q: 1914 GYPQTDSKILQEYITQEGHKLETGAPRPPATVTNAVSWRSEGIKYRKNEVFLDVIESVN 1735
    GYPQTDSKILQEYITQEGHKLETGAPRPPATVTNAVSWRSEGIKYRKNEVFLDVIE+VN
S: 121 GYPQTDSKILQEYITQEGHKLETGAPRPPATVTNAVSWRSEGIKYRKNEVFLDVIEAVN 180
```

Q: 1734 LLVSANGNVLRD 1696
 LLVSANGNVLR +
 S: 181 LLVSANGNVLRSE 193

5

The segments of gil191986 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 127 and SEQ ID NO. 129. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 128 and/or SEQ ID NO. 130 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Human Fetal Liver- Enzyme subtraction; Human adult testis, large inserts; Soares_pregnant_uterus_NbHPU; Soares placenta Nb2HP; NCI_CGAP_GCB1; Human Whole Six Week Old Embryo; Early Stage Human Brain; Human Cerebellum; Soares infant brain 1NIB; Smooth Muscle Serum Treated, Norm; Activated T-cells; H. cerebellum, Enzyme subtracted; Human Skin Tumor; Soares adult brain N2b4HB55Y; Alzheimers, spongy change; wilm's tumor; Human Infant Brain; Human Fetal Kidney; NCI_CGAP_GC4; Human Umbilical Vein Endothelial Cells, uninduced; Smooth muscle, serum induced, re-exc; Stratagene NT2 neuronal precursor 937230; Activated T-Cell (12hs)/Thiouridine labelledEco; Human B Cell Lymphoma; Bone Marrow Cell Line (RS4,11); Keratinocyte; Human Fetal Brain; Human Fetal Brain, normalized 50021F; Human Macrophage; Human Fetal Liver,

subtracted, neg clone; Human Fetal Liver, subtracted; Human OB HOS treated (1 nM
 E2) fraction I; Human OB MG63 control fraction I; Human (Caco-2) cell line,
 adenocarcinoma, colon, remake; LNCAP untreated; H. Epididymus, caput & corpus;
 H. Epididymus, cauda; Raji Cells, cyclohexamide treated; Human Normal Breast;
 5 Healing groin wound - zero hr post-incision (control); Human Synovium; Human
 Adipose Tissue, re-excision; Synovial hypoxia; Human Colon, re-excision; Brain
 Frontal Cortex, re-excision; Human Adult Small Intestine; Spinal Cord, re-excision;
 Fetal Liver, subtraction II; Human Jurkat Membrane Bound Polysomes; Human
 pancreatic islet; NCI_CGAP_Br2; NCI_CGAP_GC3; NCI_CGAP_Lu1;
 10 NCI_CGAP_Lu5; NCI_CGAP_Pr4; NCI_CGAP_Co12; NCI_CGAP_Kid3;
 NCI_CGAP_Kid6; NCI_CGAP_Brn23; Human Activated T-Cells; Human Adult
 Testes, Large Inserts, Reexcision; Human Hippocampus; Human umbilical vein
 endothelial cells, IL-4 induced; Human Activated Monocytes; Human
 Rhabdomyosarcoma; Bone Marrow Stromal Cell, untreated;
 15 Soares_multiple_sclerosis_2NbHMSP; Hemangiopericytoma; Human Adrenal Gland
 Tumor; Macrophage (GM-CSF treated); NCI_CGAP_Co3; PC3 Prostate cell line; H.
 Frontal cortex,epileptic,re-excision; Smooth muscle, serum treated; Adipocytes;
 Human Testes Tumor; Human Synovial Sarcoma; Primary Dendritic cells,frac 2;
 Bone marrow; human tonsils; Human Adult Pulmonary,re-excision; Monocyte
 20 activated; Spleen, Chronic lymphocytic leukemia; Hodgkin's Lymphoma II;
 Soares_fetal_heart_NbHH19W; Stratagene corneal stroma (#937222) and
 Soares_fetal_lung_NbHL19W.

Many polynucleotide sequences, such as EST sequences, are publicly
 available and accessible through sequence databases. Some of these sequences are
 25 related to SEQ ID NO:52 and may have been publicly available prior to conception of
 the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2363 of SEQ ID NO:52, b is an integer of 15 to 2377, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil179760 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "N-type calcium channel alpha-1 subunit [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

>gi|179760 N-type calcium channel alpha-1 subunit [Homo sapiens]
>gi|1809331 N-type calcium channel alpha1B subunit [Homo sapiens] {SUB 1-
94}
Length = 2237

Minus Strand HSPs:

Score = 175 (61.6 bits), Expect = 1.5e-08, P = 1.5e-08
Identities = 56/247 (22%), Positives = 110/247 (44%), Frame = -1

Q: 1340 PLFKNFIIFLVFLNTIILMVEIELLESTNTKLWPLKLTLEVAWXXXXXXXXXXXXXWLS 1161
P F+ FI+ ++ LNT++LM++ ++ + +L L+ K ++
S: 1471 PPFEYFIMAHIALNTVVLMMKF--YDAP----YEYELMLRCLNIVPTSMFSMECVLRKIIA 1524

Q: 1160 NFSV--FWKSAWNVFDFVVTMXXXXXXXXXXXXXTGQSVWLQLLRICRVLRSLKLLAQFR 987
P V +++ AWWVDFDV + T + L LR+ R R +KLL Q
S: 1525 -FGVLNYPRAWNVFDFVTVLGSITDILVTEIAETNNFINLSFLRLPRAARLIKLLRQGY 1583

```

Q: 986 QIQIILVLVRALKSMTXXXXXXXXXXXXXAVTGVYVFSEYTRSPRQDLEYHVFPDLPN 807
 I+I++ V++ K++ A+ G+ VF + H F
 S: 1584 TIRILLWTFVQSPKALPYVCLLIAMLFFIYAIIGMQVFGNIALDDDT SINRHNNFRTFLQ 1643
 5 Q: 806 SLVTVFILFTLDHWYALL-----QDVWKVPEVSRIFSSIYPILWLLGSIIPRSII 654
 +L+ +F T + W+ ++ + E F+ YF+ ++ L S + ++
 S: 1644 ALMLLFRSATGEAWHEIMLSCLSNQACDEQANATECGSDPAYFYFVSFIFLCSFLMLNLP 1703
 10 Q: 653 VAMMVTNFNQIRKE 612
 VA+++ NF+ + ++
 S: 1704 VAVIMDNFEYLTRD 1717

The segment of gill179760 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 131. Based on the structural similarity these homologous
 15 polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the
 20 amino acid sequence set out in the sequence listing as SEQ ID NO. 132 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Testes, Reexcision; Soares retina N2b5HR; HEL cell
 25 line; and Human Adult Testes, Large Inserts, Reexcision.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 101 as residues: Glu-25 to Leu-34, Gln-105 to Asn-112, Ser-146 to Phe-155, Cys-161 to Ser-173.

Many polynucleotide sequences, such as EST sequences, are publicly
 30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1689 of SEQ ID NO:53, b is an integer of 15 to 1703, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

15 gnl|PID|e1298800 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "putative phosphatase [Gallus gallus]." A partial alignment demonstrating the observed homology is shown immediately below.

20 >gnl|PID|e1298800 (AJ006529) putative phosphatase [Gallus gallus]
Length = 268

Plus Strand HSPs:

25 Score = 475 (167.2 bits), Expect = 1.2e-50, Sum P(2) = 1.2e-50
Identities = 90/138 (65%), Positives = 109/138 (78%), Frame = +1

Q: 589 MAAQGAPRFLLTDFDETIVDENSDDSIIVRAAPGQRLPESLRATYREGFYNEYMQRVFKY 768
MA+ P++LL FDFD TI++E+SDDSIIVRAAPGQ LPE +R++REGFYNEYMQRV Y

30 S: 19 MASSRPPKYLIVDFDGTIINESSDDSIIVRAAPGQALPEHIRQSFREGFYNEYMQRVLAY 78

Q: 769 LGEQGVVRPDLISAIYEAIPLSPGMSDLLQFVAKQGACFEVILISDANTFGVESSLRAAGH 948
+G+QGV+ D A+YE IPLSPGM DL QF++K FE+ILISDAN FG+E LRAAG

S: 79 MGDQGVKMGDFRAVYENIPLSPGMPDLFQFLSKNHELFEIILISDANMFGIECKLRAAGF 138

5 Q: 949 HSLFRRILSNPSGPDARG 1002
 +SLFR+I SNPS D RG
 S: 139 YSLFRKIFSNPSSFDKRG 156

 Score = 75 (26.4 bits), Expect = 1.2e-50, Sum P(2) = 1.2e-50
 Identities = 15/38 (39%), Positives = 24/38 (63%), Frame = +3

 10 Q: 987 AGCAWPSRAAATPCTALIQEAQKAEPSSFRASVVPWET 1100
 A A+P + P + QE +K +P +F+A+VVPWE+
 S: 217 ADVAFPRKGY--PMHQTQEMEKKQPGTFQATVVPWES 252

The segments of gnlIPIDle1298800 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 133 and SEQ ID NO. 135. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 134 and/or SEQ ID NO. 136 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Adult Testes, Large Inserts, Reexcision and to a lesser extent in Soares_fetal_liver_spleen_1NFLS_S1; Fetal Heart; CD34 positive cells (Cord Blood); neutrophils control and Soares fetal liver spleen 1NFLS.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 102 as residues: Pro-78 to Arg-84, Glu-136 to Val-141, Gln-148 to Asp-154, Pro-215 to Arg-221, Phe-235 to Arg-245, Cys-251 to Cys-258, Lys-298 to Lys-303.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1231 of SEQ ID NO:54, b is an integer of 15 to 1245, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

It has been discovered that this gene is expressed primarily in Neutrophils control, re-excision.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 103 as residues: Pro-29 to Tyr-36.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 811 of SEQ ID NO:55, b is an integer of 15 to 825, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 46

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares retina N2b4HR and to a lesser extent in Sinus

5 piniformis Tumour; Soares retina N2b5HR; Neutrophils control, re-excision and Monocyte activated.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 797 of SEQ ID NO:56, b
15 is an integer of 15 to 811, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

20 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil189369 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "ornithine
25 decarboxylase [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

>gi|189369 ornithine decarboxylase [Homo sapiens]
Length = 461

5 Plus Strand HSPs:

Score = 1207 (424.9 bits), Expect = 4.4e-122, P = 4.4e-122
Identities = 229/428 (53%), Positives = 314/428 (73%), Frame = +2

10 Q: 353 GFSTRDLLKELTLGASQATTDEVAAPFFVADLGAIVRKHFCLKCLPRVRPFYAVKCNSSP 532
GF+ +D+L + S ++D+ AF+VADLG I++KH +LK LPRV PFYAVKCN S
S: 17 GPTAKDILDQKINEVS--SSDDKDAFYVADLGDILKKHLRWLKALPRVTPPFYAVKCNDSK 74

15 Q: 533 GVLKVLALQLGLGFSCANKAEMELVQHIGIPASKIICANPCKQIAQIKYAAKHGIQLLSFD 712
++K LA G GF CA+K E++LVQ +G+P +II ANPCKQ++QIKYAA +G+Q+++FD
S: 75 AIVKTLAATGTGPDCAKTEIQLVQSLGVPPERIIYANPCKQVSQIKYAAANNGVQMHMTFD 134

20 Q: 713 NEMELAKVVKSHPSAKMVLCIATDDSHSLSCLSLKPGVSLKSCRHLLAKKHVEVVG 892
+E+EL KV ++HP AK+VL IATDDS ++ LS+KFG +L++ R LLE AK+ +++VVG
S: 135 SEVELMKVARAHPKAKLVRIATDDSKAVCRLSVKFGATLRTSRLLERAKELNIDVVG 194

25 Q: 893 SPHIGSGCPDPQAYAQSIADARLVFEMGTGLGHKMHVLDLGGGFPGTGAKVRFEETIASV 1072
SPH+GSGC DP+ + Q+I+DAR VF+MG E+G M++LD+GGGFPGE K++FEET V
S: 195 SPHVGSGCTDPETVQAIKDARCVDMGAEVGFSMYLLDIGGGFPGSEDVKLKFEEITGV 254

30 Q: 1073 INSALDLYFPEGCGVDIFAELEGRIYVTSAPTVAVSIIAKKEVLLDQPGREEENGSTSKTI 1252
IN ALD YFP GV I AE GRIYV SAPT+AV+IIAK VL +Q G ++E+ S+ +T
S: 255 INPALDKYFSDSGVRIIAEPGRYIVASAPTLAVNIIAKKIVLKEQTGSDDDEDESSEQTF 314

35 Q: 1253 VYHLDGEGVYGFNSVLPDNIPTPILOKXPXTEQPLYSSSLWGPVAVDGCDCVAEGLWLPQ 1432
+Y++++GVYG FN +L+D+ P+LQK+P ++ YSSS+WGP DG D + E LP+
S: 315 MYVNDGVYGSFNCILYDHAHVKPLLQKRPKPKDEKYYSSSIWGPCTCDGLDRIVERCDLPE 374

40 Q: 1433 LHVGDWLVFDNMGAYTVGMGSPFWGTQACHITYAMSRVAWEALRRQLMAAEQEDDVE--- 1603
+HVGDW++F+NMGAYTV S F G Q I Y MS AWE L +Q + +VE
S: 375 MHVGDWMLFENMGAYTVAAASTFNGFQRPRTIYVMSGPANE-LMQQFQNPDPFPEVEEQD 433

Q: 1604 GVCKPLSCGWE 1636
P+SC WE
S: 434 ASTLPVSCAWE 444

The segment of gi|189369 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 137. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 138 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human adult testis, large inserts and to a lesser extent in Human Fetal Kidney, Reexcision; human corpus colosum; Human Osteoblasts II; Human Hippocampus; Human Substantia Nigra; NCI_CGAP_GC4 and Soares infant brain INIB.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 105 as residues: Pro-4 to Gly-9.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of
15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1954 of SEQ ID NO:57, b
20 is an integer of 15 to 1968, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil2576347 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Gene product with similarity to KIAA0154 [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

10  >gi|2576347 (AC002400) Gene product with similarity to KIAA0154 [Homo
    sapiens]
        >sp|O14564|O14564 HYPOTHETICAL 67.1 KD PROTEIN.
        Length = 613

    Plus Strand HSPs:

15  Score = 704 (247.8 bits), Expect = 9.3e-69, P = 9.3e-69
    Identities = 137/138 (99%), Positives = 137/138 (99%), Frame = +3

20  Q:   18 VPLESVKPSSLPLIVYDRNGFRILLHFSQTGAPGHPEVQVLLLTMMSPAPQPVDIMFQ 197
        VPLESVKPSSLPLIVYDRNGFRILLHFSQTGAPGHPEVQVLLLTMMSPAPQPVDIMFQ
    S:  476 VPLESVKPSSLPLIVYDRNGFRILLHFSQTGAPGHPEVQVLLLTMMSTAPQPVDIMFQ 535

    Q:   198 VAVPKSMRVKLQPASSSKLPAPSPMLPPAVISQMLLLDNPHKEPIRLRYKLTFNQGGQPF 377
        VAVPKSMRVKLQPASSSKLPAPSPMLPPAVISQMLLLDNPHKEPIRLRYKLTFNQGGQPF
25  S:  536 VAVPKSMRVKLQPASSSKLPAPSPMLPPAVISQMLLLDNPHKEPIRLRYKLTFNQGGQPF 595

    Q:   378 SEVGEVKDFPDLAVLGAA 431
        SEVGEVKDFPDLAVLGAA
30  S:  596 SEVGEVKDFPDLAVLGAA 613

```

The segment of gil2576347 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 139.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 140 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares retina N2b4HR and to a lesser extent in Human retina cDNA randomly primed sublibrary; NCI_CGAP_GCB1; Soares_pregnant_uterus_NbHPU; Human Synovial Sarcoma; Soares infant brain
- 5 INIB; NCI_CGAP_Br2; NCI_CGAP_Kid3; Soares_fetal_heart_NbHH19W; Stratagene lung (#937210); breast lymph node CDNA library; Activated T-cell(12h)/Thiouridine-re-excision; Primary Dendritic Cells, lib 1; Soares_fetal_liver_spleen_1NFLS_S1; Dendritic cells, pooled; Human Adult Pulmonary, re-excision; Nine Week Old Early Stage Human; normalized infant brain
- 10 cDNA; Human adult (K.Okubo); Human retina cDNA Tsp509I-cleaved sublibrary; Liver HepG2 cell line.; NCI_CGAP_GC4; NCI_CGAP_Pr1; NCI_CGAP_GCB0; NCI_CGAP_Brn25; Soares_fetal_lung_NbHL19W; Soares_total_fetus_Nb2HF8_9w; Lung Mesothelium; Human colon carcinoma (HCC) cell line, remake; Activated T-cells; Human Thyroid; Mesangial cell, frac 2; Human Lung Cancer, re-excision;
- 15 Human Epididymus; Pancreas Tumor PCA4 Tu; pBMC stimulated w/ poly I/C; Healing groin wound, 7.5 hours post incision; Human Osteosarcoma; Human Bone Marrow, re-excision; Human Fetal Kidney; Stromal cell TF274; Soares_fetal_liver_spleen_1NFLS_S1; Liver, Hepatoma; Human Thymus; Bone Marrow Stromal Cell, untreated; Human Fetal Brain; Soares_testis_NHT;
- 20 Soares_NFL_T_GBC_S1; Soares_parathyroid_tumor_NbHPA; Stratagene fetal retina 937202; Smooth muscle, serum induced, re-exc; Soares_NhHMPu_S1; Fetal Heart; Colon Tumor; Resting T-Cell Library, II; Stratagene neuroepithelium (#937231); Bone marrow; human tonsils; Human Amygdala; Osteoblasts; and Human 8 Week Whole Embryo.
- 25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 106 as residues: Ser-16 to Pro-21.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2044 of SEQ ID NO:58, b is an integer of 15 to 2058, where both a and b correspond to the positions of

10 nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	H7TDB54	203959 4/26/99	Other	11	229	1	229	86	86	59	1	24	25	48
2	HOSEM81	203959 4/26/99	Uni-ZAP XR	12	1019	1	1019		227	60	1	13	14	66
3	HISAE16	203959 4/26/99	pSport1	13	424	1	424	73	73	61	1			11
4	HTXJD85	203959 4/26/99	Uni-ZAP XR	14	1117	1	1117	211	211	62	1	16	17	31
5	HTXKF95	203959 4/26/99	Uni-ZAP XR	15	884	79	875	330	330	63	1	28	29	78

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
6	HMAZ24	203959 4/26/99	Uni-ZAP XR	16	643	1	643		144	64	1			16
7	HPIBA24	203959 4/26/99	Uni-ZAP XR	17	2003	1	2002	49	49	65	1	22	23	24
8	HL YGB19	203959 4/26/99	pSport1	18	2967	1527	2966	1863	1863	66	1			14
9	HSIGM95	203959 4/26/99	Uni-ZAP XR	19	979	1	979	398	398	67	1			1
10	HROAP64	203959 4/26/99	Uni-ZAP XR	20	638	1	638	181	181	68	1	20	21	35
11	HTGGM44	203959 4/26/99	Uni-ZAP XR	21	3016	1	2761	179	179	69	1	18	19	84

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
12	HROBJ10	203959 4/26/99	Uni-ZAP XR	22	1870	1	516	108	108	70	1	19	20	57
13	HRODGG86	203959 4/26/99	Uni-ZAP XR	23	1084	1	1084		320	71	1	13	14	14
14	HWLAT50	203959 4/26/99	pSport1	24	2973	2488	2932	2741	2741	72	1			11
15	HWLBO67	203959 4/26/99	pSport1	25	536	1	536	42	42	73	1	28	29	39
16	HTXLC05	203959 4/26/99	Uni-ZAP XR	26	743	1	743	295	295	74	1	28	29	79
17	HTXLC45	203959 4/26/99	Uni-ZAP XR	27	715	1	715	359	359	75	1	22	23	50

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
18	HNHLD80	203959 4/26/99	Uni-ZAP XR	28	713	1	713	164	164	76	1	21	22	62
19	HODEA20	203959 4/26/99	Uni-ZAP XR	29	1471	1	1452	373	373	77	1	18	19	19
20	HTEMQ17	203959 4/26/99	Uni-ZAP XR	30	1768	1	1768	446	446	78	1			12
21	HNGKB09	203959 4/26/99	Uni-ZAP XR	31	975	1	975	313	313	79	1	25	26	27
22	HNGKT41	203959 4/26/99	Uni-ZAP XR	32	1048	1	1048	415	415	80	1	17	18	45
23	HNHMP15	203959 4/26/99	Uni-ZAP XR	33	1120	1	1120	51	51	81	1	22	23	63

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Portion	Last AA of ORF
24	HNHMP62	203959 4/26/99	Uni-ZAP XR	34	1068	1	1068	220	220	82	1	22	36
25	HNHMY76	203959 4/26/99	Uni-ZAP XR	35	1272	1	1272	25	25	83	1	26	55
26	HNHMYZ01	203959 4/26/99	Uni-ZAP XR	36	536	1	536	250	250	84	1	19	33
27	HNHND14	203959 4/26/99	Uni-ZAP XR	37	393	1	393	255	255	85	1	17	46
28	HNHND94	203959 4/26/99	Uni-ZAP XR	38	688	1	688	17	17	86	1	30	31
29	HNHOF09	203959 4/26/99	Uni-ZAP XR	39	1430	1	1430	539	539	87	1	22	66

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
30	HODEM38	203959 4/26/99	Uni-ZAP XR	40	1117	1	1117	527	527	88	1	23	24	72
31	HNHLZ47	203959 4/26/99	Uni-ZAP XR	41	1860	1	1860	177	177	89	1	23	24	34
32	HNGLD28	203959 4/26/99	Uni-ZAP XR	42	455	1	455	403	403	90	1			17
33	HTXLT36	203959 4/26/99	Uni-ZAP XR	43	1040	1	1038	189	189	91	1			13
34	HTXLY94	203959 4/26/99	Uni-ZAP XR	44	3511	698	1568	893	893	92	1	24	25	35
35	HNGMW45	203959 4/26/99	Uni-ZAP XR	45	1530	1	1530	452	452	93	1	28	29	43

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
36	HTXMXZ07	203959 4/26/99	Uni-ZAP XR	46	1652	189	1640	319	319	94	1	22	23	37
37	HNGNK44	203959 4/26/99	Uni-ZAP XR	47	1178	302	1178	611	611	95	1	18	19	74
38	HODET37	203959 4/26/99	Uni-ZAP XR	48	1121	1	1121		389	96	1	21	22	26
39	HNGNO53	203959 4/26/99	Uni-ZAP XR	49	825	1	825	467	467	97	1	17	18	34
40	HNGPJ25	203959 4/26/99	Uni-ZAP XR	50	853	129	853	544	544	98	1	22	23	25
41	HTEQG28	203959 4/26/99	Uni-ZAP XR	51	1719	1	1719		389	99	1	15	16	21

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Secreted Portion	Last AA of ORF
42	HTLGI89	203959 4/26/99	Uni-ZAP XR	52	2377	1205	2377	1802	1802	100	1	18	37
43	HTLGL33	203959 4/26/99	Uni-ZAP XR	53	1703	539	1703	763	763	101	1	20	174
44	HTLGY50	203959 4/26/99	Uni-ZAP XR	54	1245	1	1245	337	337	102	1	24	303
45	HNGKY94	203959 4/26/99	Uni-ZAP XR	55	825	1	825		290	103	1	15	51
46	HNGOY36	203959 4/26/99	Uni-ZAP XR	56	811	1	811	299	299	104	1	19	54
47	HTLIF11	203959 4/26/99	Uni-ZAP XR	57	1968	860	1968	933	933	105	1	33	38

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of 5' NT Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
48	HTXNV66	203959 4/26/99	Uni-ZAP XR	58	2058	1	2058		674	106	1	13	14	91

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is

identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted

translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

5 The predicted amino acid sequence can then be verified from such deposits.

Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

10 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate
15 sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a
20 deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

25 The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly

produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty.

Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA
5 sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential
10 properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide
15 coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of
20 these nucleic acid molecules (e.g., those fragments described herein).

Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or
25 alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence

shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%
5 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%
10 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified
15 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best
20 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by
25 converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to

calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

5 If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent
10 identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using
15 the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

20 For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number
25 of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly

matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject

sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said

5 global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

10 If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the

15 query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from

20 the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity

25 score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10
5 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100
10 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not
15 matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter
20 the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host
25 (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1 α . They used random mutagenesis to generate over 3,500 individual IL-1 α mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500

nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the
10 protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic
15 residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,
20 where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino
25 acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory

sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the

complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.

Preferably, these fragments encode a polypeptide which has biological activity. More

5 preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid
10 sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments
15 comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or
20 smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the
25 carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the

mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form.

Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a

polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

5 The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

10
15
20

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

25

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5 In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope
10 of the invention.

Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,

that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a

carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or

5 intradermal injection of emulsions containing about 100 μ g of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid

10 surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the

15 polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins

20 may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4- polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the

25 immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO

96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 5 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, 10 Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺-nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively 15 eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to 20 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. 25 Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in

its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM,

IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides

which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation

5 constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an
10 antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

15 Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention
20 features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation
25 (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described

supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

5 The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as
10 well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the
15 receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.
20 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al.,
25 Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998);

Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entirety).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques,

including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone,

including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments).

F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies,

including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol. Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve,

antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g.,

5 Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP

10 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods

15 known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

20 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the

25 human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.

The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a

selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the

nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then
5 amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is
10 known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable
15 to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

20 Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor,
25 NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John

Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes

from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the

antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be

5 used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or

10 light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or

15 light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain

20 thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the

25 antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently

purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the

generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

15 In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

20 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region

E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the

5 ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate

10 transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g.,

15 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which

20 possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell

25 line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science

260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215; and hygromycin, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci.*

USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS

89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins

consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988)). The polypeptides of the present invention fused or conjugated to an antibody having

5 disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A

10 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

15 identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995)).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the

20 tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which

25 corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given

5 treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable

10 substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish

15 peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material

20 includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{111}In or ^{99}Tc .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or

25 a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include

paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and
5 puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-
10 dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological
15 response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth
20 factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGF (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g.,
25 angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports
5 include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld
10 et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results,
15 And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

20 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can
25 be used as a therapeutic.

Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays,

complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasyolol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-

fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ^{32}P or ^{125}I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al,

eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One
5 example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by
10 scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of increasing amounts of an unlabeled second antibody.

15 Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include,
20 but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression
25 and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment

and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217

(1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY
5 (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters
10 operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the
15 antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

20 Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

25 In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be

accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct
5 injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see,
10 e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for
15 cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al.,
20 Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral
25 genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which

facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy.

Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection
5 to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,
10 electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth.
15 Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and
20 expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be
25 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the

therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

10

Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

15

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

20

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),

25

construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein

and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,

Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such

5 compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term

10 "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline

15 solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired,

20 can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as

25 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant

expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. **Diagnosis and Imaging**

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect,

diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body
5 fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder,
10 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With
15 respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier
20 thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell . Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting
25 protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody

assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

5 One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which
10 specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that
15 detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

20 It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially
25 accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of

Radiolabeled Antibodies and Their Fragments.” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In

yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI). Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by
5 binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of
10 the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

15 In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of
20 bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

25 The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip

sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

- 5 Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting
10 surface-bound anti-antigen antibody.

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion
15 proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present
20 invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

25 Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino

acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final
5 preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any
10 combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian
15 immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

20 Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively,
25 deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if

the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,

pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical

synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., et al., *Yeast* 5:167-77 (1989); Tschopp, J.F., et al., *Nucl. Acids Res.* 15:3859-76 (1987).

Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

5 In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1*
10 promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily
15 appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be
20 achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and
25 immortalized host cells of vertebrate origin, particularly mammalian origin, that have

been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra et al., *Nature* 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-

amino acids, designer amino acids such as β -methyl amino acids, α -methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random

positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus.

Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein

- 5 (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules.
- 10 Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl
- 15 group containing polymer is achieved.

- The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific
- 20 embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

- Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides
- 25 corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and

fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the

invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one
5 instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the
10 heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as
15 described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another
20 embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

25 Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper

polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different

5 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide

10 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are

15 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

20 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-

25 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

5 Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally,

15 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are

25 generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic

polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described
5 herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

10

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

15

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

20

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids
25 containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and

one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

- 5 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide
10 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

- Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using
15 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

- Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the
20 present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

- In still another embodiment, the invention includes a kit for analyzing samples
25 for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe

containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand
5 containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present
10 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the
15 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard
20 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

25 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the

polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for
5 obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a
10 solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms
15 (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention
20 that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,
25 thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose

derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ($T_{sub.m}$) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Gelman, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)).

5 Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelman et al., supra) It is likely that mutated or altered expression of specific genes is
10 involved in the pathogenesis of some leukemias, among other tissues and cell types. (Gelman et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelman et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia
15 cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb
20 proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of
25 hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. *Neurochem.* 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., *Nucleic Acids Research* 6: 3073 (1979); Cooney et al., *Science* 241: 456 (1988); and Dervan et al., *Science* 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., *Nucl. Acids Res.* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. *Neurochem.* 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more
5 restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

10 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a
15 unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR
25 Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an

identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene

expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.

In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:

The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,
Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells
5 or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a
10 predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

15 Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair
20 proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune
25 response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can
5 activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also
10 be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

15 **Gene Therapy Methods**

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This
20 method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

25 Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a

polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldegrün et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; 5 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters 10 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters, 15 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the 20 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, 25 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye,

gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

 In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant
10 invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,
15 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20 Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially
25 available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to

produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.

- 5 The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated.
- 10 SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and
- 15 then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca^{2+} -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell*, 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979)); detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA*, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980);
- 20 Szoka et al., *Proc. Natl. Acad. Sci. USA*, 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports
5 on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622,
10 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding
15 polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

20 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by
25 reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation,

the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which
5 include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can
10 be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for
15 many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt
20 to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993); Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther.,
25 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein

incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other
5 varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of
10 infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*,
15 using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is
20 limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell
25 integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found

in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper
5 viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its
10 genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO
15 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

20 Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting
25 sequence will be sufficiently near the 5' end of the desired endogenous

polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

10 The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, 15 topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The 20 promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor 25 alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth

factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.

5 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

10 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available
15 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the
20 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting
25 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue
5 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a
10 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.
15 Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a
20 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise
25 condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of

polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and
5 birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

Biological Activities

The polynucleotides or polypeptides, or agonists or antagonists of the present
10 invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

Immune Activity

The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by activating or inhibiting the proliferation,
20 differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases,
25 disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present

invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used

to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the

present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or
5 indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating,
10 differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases,
15 disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver,
20 pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or
25 agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

5 One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

 Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally
10 proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

 Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention
15 to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to
20 be treated utilizing a retrovirus, or more preferrably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating
25 cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule,

chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said
5 external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the
10 destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in
15 the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature
20 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating
25 and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in

the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to

5 abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at

10 the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as

15 decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

20

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a

25

mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may
5 be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the
10 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

15 In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

20 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or
25 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and

therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those
5 with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in
10 combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).
15 Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments
20 thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related
25 apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).

Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

10 Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4
15 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions
20 containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic
25 and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and
5 immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Cardiovascular Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the invention
10 may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and
15 Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such
20 as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogly of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac
25 arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular

hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, 5 rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial 10 block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic 15 junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve 20 insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, 25 endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis,

Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

5 Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

10 Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura,
15 allergic cutaneous vasculitis, and Wegener's granulomatosis.

 Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

 Polypeptides may be administered using any method known in the art,
20 including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the
25 art. Polypeptides of the invention may be administered as part of a *Therapeutic*,

described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

Anti-Angiogenesis Activity

- 5 The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive
- 10 processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization
- 15 including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-
- 20 203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).
- 25 The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the

polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers

5 described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide,

10 polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors,

15 including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example,

20 polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example,

25 intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a

catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in
5 treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions,
besides cancers, which involve angiogenesis. These diseases, disorders, and/or
conditions include, but are not limited to: benign tumors, for example hemangiomas,
acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas;
arterosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy,
10 retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular
glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia
(abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed
wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars
(keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial
15 angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations;
ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization;
telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound
granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided
20 for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising
the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of
the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides,
polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar
25 or keloid, in order to prevent the progression of these lesions. This therapy is of
particular value in the prophylactic treatment of conditions which are known to result

in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or

5 diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the

10 polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris

15 neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step

20 of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it

25 also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of

diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause),
5 toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-
15 angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent
20 complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing
25 front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the

cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should

be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist
5 and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or
10 agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be
15 treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example,
20 diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals,
25 arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma

fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochela minalia quintosa*), ulcers (*Helicobacter pylori*),

5 Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or
10 agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch
15 granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal
20 surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic
25 compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the

invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

5 Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic
10 compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied
15 after hepatic resections for malignancy, and after neurosurgical operations.

 Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may
20 be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

 The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive
25 Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator

Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan
5 Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin;
10 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum;
15 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

20

Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as
25 follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer,

melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic

cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

- 10 Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as
- 15 that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.
- 20

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.

Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-

Thiersch graft, omentoplastic graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

5 It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as
10 sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

15 The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or
20 polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

 The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial
25 thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The

polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

5 agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large

10 intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production

15 of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

20 Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to

25 prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from

smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention.

Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the

5 invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the
10 invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

15 In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or
20 prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

25 **Neurological Diseases**

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic

acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, *e.g.*, choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, *e.g.*, weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous

system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motor-sensory Neuropathy (Charcot-Marie-Tooth Disease).

Infectious Disease

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae),

Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a

5 variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox,

10 hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or

15 antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or

20 agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to,

25 include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium,

Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae
 (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia
 (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter,
 Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic
 5 E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella
 (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix,
 Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales,
 Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter,
 Gonorrhea, Meningococcal), Meisseria meningitidis, Pasteurellaceae Infections (e.g.,
 10 Actinobacillus, Hearnophilus (e.g., Hearnophilus influenza type B), Pasteurella),
 Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp.,
 Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g.,
 Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal
 families can cause the following diseases or symptoms, including, but not limited to:
 15 bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis),
 gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia,
 prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as
 Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease,
 Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,
 20 meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy,
 Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo,
 Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g.,
 cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.
 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used
 25 to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific
 embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention

are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, 5 Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium 10 ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, 15 and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering 20 an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

25

Regeneration

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or

conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

Chemotaxis

10 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then
15 fight off and/or heal the particular trauma or abnormality.

 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system
20 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

25 It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules

could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

5

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit
10 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural
15 or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

20 Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially
25 containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

5 Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a
10 standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

15 Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for
20 example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides
25 can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

5 As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein
10 microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be
15 employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol.*
20 *Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide
25 sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the

invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or
5 more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal
10 growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

15 Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

20 Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally
25 proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the

compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this
5 procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured.

10 Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase,
15 ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers.

The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays
20 can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the

25 invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a

biological activity , and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are
5 directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of,
10 any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional
15 embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

Targeted Delivery

In another embodiment, the invention provides a method of delivering
20 compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one
25 embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention

(including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which
5 modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by
10 using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids
15 expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any
20 other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically
25 labeled. Following incubation, free agent is separated from that present in bound

form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

20

Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered

(see, for example, O'Connor, *Neurochem.*, 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988).

Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, *Neurochem.*, 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide.

A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense

RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or
5 a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard
10 in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early
15 promoter region (Bernoist and Chambon, Nature, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A., 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., Nature, 296:39-42 (1982)), etc.

20 The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,
25 forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation

may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be).

- 5 One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

- Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary
- 10 to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA.
- 15 Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six
- 20 nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

- The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-
- 25 stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization,

etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci., 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs

5 corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3' . The construction and production of hammerhead ribozymes is well

10 known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to

15 increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo.

20 DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of

25 the ribozyme to destroy endogenous messages and inhibit translation. Since

ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic
5 cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular
10 cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

15 The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with
20 overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present
25 invention.

Other Activities

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as

5 thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells
10 of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's
15 disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent
20 skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone
25 marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

5

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

10 The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing,
15 utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive
20 capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins,
25 minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide
5 sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3'
10 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3'
15 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the
20 nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

5 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

10 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA

Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said
5 step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue
10 or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by
15 a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a
20 nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted
25 protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any,

comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA

5 Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least
10 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said
15 panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA
20 clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

25 Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of

positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence
5 at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

10 Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino
15 acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted
20 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the
25 amino acid sequence of the secreted portion of the protein encoded by a human cDNA

clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained

in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is
5 at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide
10 comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit
15 with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules
20 in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted
25 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in

Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y

wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5 Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

 Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino
10 acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

 Further preferred is a method of making a recombinant vector comprising
15 inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

 Also preferred is a method of making an isolated polypeptide comprising
20 culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of
25 SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and

said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a

representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
5	HTXKF95	15	834438	AA742405, AA814605, AA831751, AA917582, C01813
8	HLYGB19	18	838083	T93787, T93832, R02324, R02426, R14799, R40110, R40110, H14227, H20744, H20745, H25817, H30465, N31953, N53121, N54405, N58286, W19151, W56021, W79663, W81374, N90614, AA034333, AA036712, AA040473, AA045487, AA057344, AA116133, AA116132, AA282579, AA480917, AA553569, AA595479, AA604051, AA761562, AA805537, AA808345, AA927339, AA908734, N55949, W22022, W22981, N86776, N88499, N88847, N89101, AA094393, AA218662, AA248097, AA249082, AA449050, AA449764, AA545751, AA630084
11	HTGGM44	21	842856	T66948, H68969, H70945, W01997, AA651951, AA486772, AA486949
12	HROBJ10	22	836368	N69016, W00683, W80423, W80551, AA045082, AA045398, AA121289, AA121303, AA121460, AA121351, AA128005, AA128046, AA770598, C01114
14	HWLAT50	24	840753	T59935, T60005, T94060, T94807, R12134, R13592, R13984, R15067, R18682, R39888, R40044, R42065, R42065, R40044, H24857, H24856, H26768, H26878, H27071, H27083, H27280, H38069, H38068, H43549, H49286, H49287, H50233, H52356, H80481, H81400, N35033, N42998, N45042, N56943, N72103, W00326, W70202, W74130, W74251, W75944, W79668, W96207, W96300, AA011404, AA011461, AA130873, AA130928, AA135472, AA135543, AA149732, AA149667, AA165372, AA171564, AA171885, AA196636, AA196918, AA224416, AA224477, AA226902, AA226950, AA227012, AA227198, AA460317, AA461608, AA463604, AA428061, AA229560, AA470541, AA470662, AA470998, AA481296, AA488941, AA513255, AA524148, AA524950, AA527313, AA548195, AA565671, AA592919, AA595472, AA618435, AA639597, AA714302, AA807641, AA809494, AA827604, AA829809, AA831013, AA831011, AA831396, AA847756, AA862089, AA876627, AA876966, AA863295, AA879161, AA927418, AA935861, AA938598, AA970339,

				AA974538, AA991176, AI032131, AI089946, N55983, AA643976, AA650180, AA211249, AA216524, AA218934, AA219650, AA219705, AA219772, AA448361, AA487921, AA488036, AA448218, AA678876, AA723067, AA772223, AA772307, AA777674, AA778272, AA861852, AA868284, AA868497, AI038225, AI051796, AI087122, AI092200, AI093254, Z25362, Z42751, F02226, F00374, AA693475
25	HNHMY76	35	838256	AA406499
33	HTXLT36	43	843477	W88912, AA280698, AA483331, D12023, AA722378, AA846547, AI024136, AI038218, AI038546
34	HTXLY94	44	844165	T71056, T71127, T77487, R12554, R19030, R19553, R37456, R38376, R44017, R44017, H06869, H06910, H09010, H09577, H10893, H11083, H11171, H15409, H15465, N27096, N35843, N40504, W92504, AA019977, AA019947, AA020911, AA085086, AA176911, AA179065, AA470413, AA630822, AA659600, AA991920, W22289, W27911, W28989, AA644598, AA716695, AA722786, AA846714, AA906000, AA972096, AA983733, AI081914, T10127, T10126, T24063, T24459, Z44777, F05434, F09096, F13261, F10863, F10959, F13366
36	HTXMZ07	46	834881	R13050, R19093, R40481, R49704, R49704, R40481, H21771, H21772, R88601, N67515, W03512, AA043271, AA743402, AA827387, AA857790, C01211
37	HNGNK44	47	834949	T71014, T71076
42	HTLGI89	52	835069	R10049, R10928, R16694, R23244, R23321, R78483, R78526, H17382, H24067, H24175, R87506, R87588, R98861, R98946, H80425, H80426, N50148, N62476, N79196, N80670, W07699, W73606, AA031930, AA032048, AA062669, AA099581, AA101981, AA137081, AA136972, AA226922, AA226886, AA468656, AA557715, AA622587, AA632148, AA766390, AA768482, AA811085, AA847774, AA862807, AA864754, AA934612, AA975165, AA995577, AI001138, AI095065, C06239
43	HTLGL33	53	835020	H86566
46	HNGOY36	56	834936	H40858, H41082, R85722, H84118, AA013478, AA018827, AA019064, AA020955, AA021259, AA054258
47	HTLIF11	57	843506	R15136, AA974141

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

- 10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being
- 15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>		<u>Corresponding Deposited</u>
<u>Plasmid</u>		
20	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSport 2.0	pCMVSport 2.0
	pCMVSport 3.0	pCMVSport 3.0
25	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Altting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Altting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention

does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional
5 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample
10 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ
15 ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular
20 Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection
25 agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for

bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the
5 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and
the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the
desired cDNA using the deposited cDNA plasmid as a template. The polymerase
chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction
mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is
10 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25
pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR
(denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation
at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated
thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
15 the DNA band with expected molecular weight is excised and purified. The PCR
product is verified to be the selected sequence by subcloning and sequencing the
DNA product.

Several methods are available for the identification of the 5' or 3' non-coding
portions of a gene which may not be present in the deposited clone. These methods
20 include but are not limited to, filter probing, clone enrichment using specific probes,
and protocols similar or identical to 5' and 3' "RACE" protocols which are well
known in the art. For instance, a method similar to 5' RACE is available for
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et
al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a
population of RNA presumably containing full-length gene RNA transcripts. A

primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

5 This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order
10 to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

 This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is
15 used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

20 **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

 A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

25 **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P^{32} using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose

gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

5 A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product
10 into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning
15 sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which
20 expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid
25 culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The

cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

5 Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from
10 QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then
15 washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-
20 NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50
25 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:

- 5 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

- 10 DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or
15 Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

20 **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

- 25 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield

of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

5 The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

10 The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

 Following high speed centrifugation (30,000 xg) to remove insoluble particles,
15 the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

 To clarify the refolded polypeptide solution, a previously prepared tangential
20 filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a
25 stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are
5 equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the
10 polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS
15 contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus

Expression System

20 In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40")
25 is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak

Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

5 Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-
10 39 (1989).

 Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does
15 not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

20 The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

 The plasmid is digested with the corresponding restriction enzymes and
25 optionally, can be dephosphorylated using calf intestinal phosphatase, using routine

procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of

a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of ³⁵S-methionine and 5 uCi ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and

signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long
5 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV1, HIV1 and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),
10 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

15 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the
20 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker
25 is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers,

the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

5 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,
10 with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

 Specifically, the plasmid pC6, for example, is digested with appropriate
15 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

 A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.
20 Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

 The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%
25 agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG

domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
5 CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
10 ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG
15 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

20 The antibodies of the present invention can be prepared by a variety of
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells
expressing a polypeptide of the present invention is administered to an animal to
induce the production of sera containing polyclonal antibodies. In a preferred
method, a preparation of the secreted protein is prepared and purified to render it
25 substantially free of natural contaminants. Such a preparation is then introduced into
an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells,

and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of
5 further protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂
10 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced
15 using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson
20 et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening

Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution
5 (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered
10 Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x
15 Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods
20 described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem
25 I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates
 5 off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in
 10 DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl_2 (anhyd); 0.00130 mg/L $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$; 0.050 mg/L of $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$; 0.417 mg/L of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 311.80 mg/L of KCl; 28.64 mg/L of MgCl_2 ; 48.84 mg/L of MgSO_4 ; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO_3 ; 62.50 mg/L of $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$; 71.02 mg/L of Na_2HPO_4 ; .4320 mg/L of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$; .002 mg/L of Arachidonic Acid ; 1.022 mg/L
 15 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml
 20 of L-Asparagine- H_2O ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- H_2O ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- H_2O ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0
 25 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 H_2O ; 99.65 mg/ml of L-

Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and
5 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed
10 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end
15 of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants
20 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the
25 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the
5 Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six
10 members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in
15 tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are
20 generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-
25 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)

Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn
5 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines
10 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

			<u>JAKs</u>		<u>STATs</u>	<u>GAS(elements) or ISRE</u>	
	<u>Ligand</u>	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
35	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	

CSF-1	?	+	+	-	1,3	GAS (not IRF1)
-------	---	---	---	---	-----	----------------

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCG
GAAATGATTTCCTCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCGAA
TGATTTCCTCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCGCCCATTCT
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT
25 AGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter

5 molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and

10 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-

15 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using Sall and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding

20 as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and

16. However, many other promoters can be substituted using the protocols described

25 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-

2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

5 **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP
10 activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate
15 stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing
20 concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in
25 RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life

Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final

5 concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentacin, and 1% Pen-Strep. These cells are treated with
10 supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being
15 screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

20 After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

25 The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul

samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve
5 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,
10 stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.
15 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct
20 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

25 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM

KCl, 375 μ M $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 μ M CaCl_2 . Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

5 The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 μ g/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 μ g/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described
10 growth medium, with a final density of 5×10^5 cells/ml. Plate 200 μ l cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 μ l of the supernatant prepared by the protocol described in Example
11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml
interferon gamma can be used which is known to activate U937 cells. Over 30 fold
15 induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are
20 activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12
25 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl

phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

5 The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

10 5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1
15 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

20 PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and
25 resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of

apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTCCGGGGACTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5' : CTCGAGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCATCTGCCATCTCAATTA
 5 GTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATT
 TCCGCCCCATGGCTGACTAATTTTTTTTATTTATGTCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATT
 CCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT : 3' (SEQ ID
 NO: 10)

10 Next, replace the SV40 minimal promoter element present in the pSEAP2-
 promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and
 HindIII. However, this vector does not contain a neomycin resistance gene, and
 therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP
 15 cassette is removed from the above NF-KB/SEAP vector using restriction enzymes
 Sall and NotI, and inserted into a vector containing neomycin resistance. Particularly,
 the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the
 GFP gene, after restricting pGFP-1 with Sall and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are
 20 created and maintained according to the protocol described in Example 13. Similarly,
 the method for assaying supernatants with these stable Jurkat T-cells is also described
 in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to
 wells H9, H10, and H11, with a 5-10 fold activation typically observed.

25 Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP
 activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the

following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

10 A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

25 To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4

second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca^{++} concentration.

5

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

15 Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, 20 members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the 25 following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr
5 with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of
10 cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

15 To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM
20 HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane
25 bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on

ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times.

Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

- Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and
- 5 incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

10 **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

- As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be
- 15 used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by
- 20 substituting these molecules for Erk-1 or Erk-2 in the following assay.

- Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against
- 25 Erk-1and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any

of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyn filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and

translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a

5 Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their
10 particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in
15 Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled
20 water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

25 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room

temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard
5 curve.

Example 23: Formulation

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or
10 disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

15 The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus
20 determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01
25 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a

dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray.

"Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials

(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,
5 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped
10 Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang
15 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the
20 optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

25 Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

- 5 Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- 10 Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by
- 15 reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

- The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or
- 20 biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

- The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the
- 25 Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG,

and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,

5 Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,

10 whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic

15 mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in

20 combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either

25 concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are

administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors.

Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™

5 (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to,
10 CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

15 In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™,
20 RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICLOVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™
25 (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention

are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

5 In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,
10 erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are
15 not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide, methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may
20 be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone
25 marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™,

5 IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™.

In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are
10 administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives,
15 pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

20 In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin,
25 mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU,

lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol

5 diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

10 In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered
15 with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4,
20 IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

25 In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may

be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as
5 disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as
10 disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in
15 International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

20 In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

25 In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth

Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in
5 combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 24: Method of Treating Decreased Levels of the Polypeptide

The present invention relates to a method for treating an individual in need of
10 an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be
15 treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

20 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

25 **Example 25: Method of Treating Increased Levels of the Polypeptide**

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy-Ex Vivo

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long
5 terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set
10 forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is
15 maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue
20 culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

25 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media,

containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

5 If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

10 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

15 Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650,
20 published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting
25 sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be

sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends.

- 5 Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested
10 with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol
15 precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are
20 known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or
25 any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining
5 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains
10 approximately 3×10^6 cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with
15 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the
20 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap
25 (Bio-Rad). The final DNA concentration is generally at least 120 $\mu\text{g/ml}$. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette,

and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 μ F and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 28: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622,

5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al., *Pharmacol. Res.* 35(6):517-522 (1997); Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997); Schwartz et al., *Gene Ther.* 3(5):405-411 (1996); Tsurumi et al., *Circulation* 94(12):3281-3290 (1996) (incorporated herein by reference).

5 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

10 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in
15 Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

 The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain
20 sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to
25 provide production of the desired polypeptide for periods of up to six months.

 The polynucleotide construct can be delivered to the interstitial space of

tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an

aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 29: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA
5 expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies
10 specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate
15 lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to
20 produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of
25 polypeptides of the present invention, studying diseases, disorders, and/or conditions

associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

Example 30: Knock-Out Animals.

5 Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional
10 polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express
15 polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &
20 Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

 In further embodiments of the invention, cells that are genetically engineered
25 to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are

administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using

5 recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited

10 to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the

15 invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or

20 vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which

25 prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing

for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and “knock-out” animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

Example 31: Production of an Antibody

10 a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle’s modified Eagle’s medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10

g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 μ g/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding to polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and are used to immunize an animal to induce formation of further protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214

(1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

5

b) Isolation Of Antibody Fragments Directed Against
Polypeptide(s) From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library.

A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10⁹ E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III

particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in
5 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10¹³ transducing units/ml
10 (ampicillin-resistant clones).

Panning of the Library.

Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately
15 10¹³ TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately
20 neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection.
25 This process is then repeated for a total of 4 rounds of affinity purification with tube-

washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders.

Eluted phage from the 3rd and 4th rounds of selection are used to infect *E. coli*

5 HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones
10 may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

15 Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed
20 development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation,
25 differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-

superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed Staphylococcus aureus Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse

(1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 33: T Cell Proliferation Assay

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ^3H -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 μl /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1 $\mu\text{g}/\text{ml}$ in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ($5 \times 10^4/\text{well}$) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200 μl). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100 μl of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 μl of medium containing 0.5 μCi of ^3H -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of ^3H -thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FCyRII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10^6 /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for

IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)).

The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules.

- 5 Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with
- 10 improved monocyte cytotoxic activity, cytokine release and phagocytosis.

- FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal
- 15 antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

- Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or
- 20 alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American
- 25 Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 μ g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 μ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H₂O₂ produced by the macrophages, a standard curve of a H₂O₂ solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 35: Biological Effects of Polypeptides of the Invention

Astrocyte and Neuronal Assays

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

Fibroblast and endothelial cell assays:

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or

without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released. Subsequently, MPP⁺ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989).

Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

5 Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic
10 neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde
15 after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

 Since the dopaminergic neurons are isolated from animals at gestation day 14, a
20 developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

25 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 36: The Effect of Polypeptides of the Invention on the Growth of

5 Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at $2-5 \times 10^4$ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8
10 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the
15 invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was
25 performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000

cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF₁₆₅ or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al. In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell

Proliferation Stimulatory Effect

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for

individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 39: Stimulation of Endothelial Migration

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 μ m (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 μ l of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber, 2.5×10^5 cells suspended in 50 μ l M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO₂ to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by

counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.


The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of KNO_2 (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and H_2SO_4 . The specificity of the Iso-NO electrode to NO is previously determined by

measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C.

- 5 The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions.
- S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per 1×10^6 endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See,
- 10 Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

15

Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis

- Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to
- 20 form capillary-like structures (hollow structures) when cultured *in vitro*.

- CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium
- 25 (200 ml/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then

replaced with 300 mg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. β -estradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the

inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

5 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10 Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse

In vivo angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After
15 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold
20 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde,
25 embedded in paraffin and used to produce sections for histological examination after

staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

5 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10 **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these

rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

- 10 The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

Example 45: Effect of Polypeptides of the Invention on Vasodilation

- 15 Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14-week old spontaneously hypertensive rats (SHR). Data are expressed as the mean \pm SEM.
- 20 Statistical analysis are performed with a paired t-test and statistical significance is defined as $p < 0.05$ vs. the response to buffer alone.

- The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
- 25 invention.

Example 46: Rat Ischemic Skin Flap Model

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ

5 hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

10 The experimental protocol includes:

a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).

b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).

c) Topical treatment with a polypeptide of the invention of the excisional wounds
15 (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.

d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 47: Peripheral Arterial Disease Model

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of
5 the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- c) The ischemic muscle tissue is collected after ligation of the femoral
10 artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
15 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 48: Ischemic Myocardial Disease Model

20 A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- a) The heart is exposed through a left-side thoracotomy in the rat. Immediately,
25 the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

c) Thirty days after the surgery, the heart is removed and cross-sectioned
5 for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10

Example 49: Rat Corneal Wound Healing Model

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- 15 a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- 20 d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.
- e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the
25 invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing

5 Models

A. *Diabetic db+/db+ Mouse Model.*

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound
10 healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

15 The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al. Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria.

20 Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration
25 abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*,

Lab Invest. 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model
5 may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study.
10 Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

15 Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and
20 iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to
25 treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the

healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular

permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors*. 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors*. 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50

mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8).

The wound area on day 1 is 64mm², the corresponding size of the dermal punch.

Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

5

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

10

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

15

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20 **Example 51: Lymphadema Animal Model**

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and

25

histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital.

- 5 Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's
- 10 Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

- Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the
- 15 lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

- Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are
- 20 then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

- Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving
- 25 a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca^{2+} comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

5 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10 **Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both
15 normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and
20 extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

 Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of
25 inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- α induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- α treated ECs when co-stimulated with a member of the FGF family of proteins.

5 To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂. HUVECs are seeded in 96-well plates at concentrations of 1×10^4 cells/well in EGM
10 medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

15 Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 μ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are
20 aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca⁺⁺ and Mg⁺⁺) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-
25 1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution

of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with

5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 (10^0) > $10^{0.5}$ > 10^1 > $10^{1.5}$. 5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is

10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [

15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the

20 invention.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

25 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

Applicant's or agent's file reference number	PS548PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>68</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 26 April 1999	Accession Number 203959
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input type="checkbox"/>	This sheet was received with the international application
Authorized officer	

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	

ATCC Deposit No. 203959**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

ATCC Deposit No.: 203959

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group
- 5 consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a
 - 10 polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
 - 20 having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

5

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

10

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

20

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 5 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
- 10 10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence
15 included in ATCC Deposit No:Z;
- (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
- (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- 20 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in
25 ATCC Deposit No:Z;
- (g) a variant of SEQ ID NO:Y;

- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

5

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

10 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

15 (a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

20

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

25 (c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 48 Human Secreted Proteins

<130> PS548PCT

<140> Unassigned

<141> 2000-04-06

<150> 60/128,700

<151> 1999-04-09

<150> 60/176,930

<151> 2000-01-20

<160> 140

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga gcccaaattct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg	60
aattcgaggg tgcaccgtca gtcttcctct tcccccaaa acccaaggac accctcatga	120
tctcccgac tcctgaggtc acatgcgtgg tggaggacgt aagccacgaa gaccctgagg	180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg	240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact	300
ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg	360
agaaaacccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc	420
catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct	480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga	540
ccacgcctcc cgtgctggac tccgacggt ccttcttcct ctacagcaag ctcaccgtgg	600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc	660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc	720
gactctagag gat	733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1 5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct ttttgcaaag cctagggc 27

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8
 <211> 12
 <212> DNA
 <213> Homo sapiens

<400> 8
 ggggactttc cc 12

<210> 9
 <211> 73
 <212> DNA
 <213> Homo sapiens

<400> 9
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60
 ccatctcaat tag 73

<210> 10
 <211> 256
 <212> DNA
 <213> Homo sapiens

<400> 10
 ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct 60
 caattagtca gcaaccatag tcccggccct aactccgccc atcccggccc taactccgcc 120
 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
 cttttgcaaa aagctt 256

<210> 11
 <211> 229
 <212> DNA
 <213> Homo sapiens

<400> 11
 ggcttggtgt ggggcaccag cagagggcaa agtcatactc ctgcactgac agtggtcgtg 60
 aagagaatga aatatgaaga aagctatgaa tagttggaaa ttcggggggc tgtgcttact 120
 cctgattatt tcagtttggc taaaacagag ctggcatcaa ggaagggtt gttgtgatga 180
 ttccagagag ggtgactctc agggagttgc ccaccaggcc cacgaagcc 229

<210> 12
 <211> 1019
 <212> DNA
 <213> Homo sapiens

<400> 12
 tttttttttt tttttttttt tacataagtt ttacaagata atacattttt acagtgcacct 60
 gatgtggata caactttgca acttggcaaa aagcaaactt taacttacat tataattaat 120
 ttgctgcatt ttacacatct ctgattctca attttggcaa gtacaacagg ttaagggttc 180
 tatttagtgt ccccttctga tgaatatgat gatcttgaac ccattcttcc tcctcaagca 240
 cgggtcatcct cctctgatgg caacagcaga acctctggga aaggaacctt tcggtatcca 300
 gaactcccag gtggcagccc agtgtgggat ttggagcatg acaacaaagg cattttctca 360
 acatttacta aaggagagtg ggggtgttcta tacgctactg atggggactg tacatgaaca 420
 catttaaatt gaattacaac aacatttttag ataggaaata tagaatctta taagaacata 480
 atctaaatta taaccaattt taaatagcaa agtttaacaa taaagctact taagtgtttg 540
 aattagaaat aaacagtaaa acatctgtat taattataac agagttgaca tttgttatat 600
 tttatcttca gtattaacca aaggagtggga atttagccag ggttgcaactt tttaaaagtt 660
 gtatatactt ttattttattt tacaaaagga aaaaaaaga catacttttc ccataaaatt 720
 ccaggtctta ctatgtaaaa taaccatgca ctacttcatt ttataatcat aatttttagac 780
 tatttccagt aggttaagtgt cataaagaag gaagagatat ggcttcaca gcttcaatga 840
 ggtgtaaggc tagaccatat tgcccatgtt tttctggtaa aagctcaatt actttattta 900
 ctagttagc tgttggttga attggcactt cagtgttttg aaggtcctgg gggtcattg 960
 ctttcagcca agtacacagt gtgggtggaa gtctggcaag cagctccatt cctcgtgcc 1019

<210> 13
 <211> 424
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (409)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (416)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (417)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (421)
 <223> n equals a,t,g, or c

<400> 13
 ccggttggtc tcgaactcct gacctcaagt gatccacctg cctcggcctc ccaaaatgct 60
 gggattacag gcatgagcca ctgcgtctgg tccttggctg tttcttagsc ccactcctgg 120
 cagtgtctct tctcttcagc tatgactggg gagtagatga ccgtgcttgt ttctgacaca 180
 cagcacagtg tcctctctgt acacaagctg gtgggttcaag ggccaatggt tccagagaga 240

tagtggttcc	cttccttccc	tcctcaccaa	taggcagcct	caggcctttt	ctgtgtataa	300
ctgtgtatat	agacataaaa	acctacaaat	gtgaaataaa	tctatgctat	ctttcatagt	360
gttaccacaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaang	gggggnnccc	420
ntta						424

<210> 14
 <211> 1117
 <212> DNA
 <213> Homo sapiens

<400> 14						
ggcacgagga	gaactaagca	ttaggagaag	cagcatgggg	ctcaacagtg	aagtgacttg	60
ttccaggcgg	gtcctcagga	gtggctgtgc	agccccagtc	acttttcatc	acaccggaga	120
gggacgcaca	accccagtc	tgtttagttg	cagatatacc	gagaaggagg	agccacacc	180
gaccttaagg	tcacttgggc	cctgaatcct	atgcctctcg	ttccactgct	tctcagttgc	240
cctcctacct	ggctggccag	gtttggagtc	tctctcccct	gctctggcat	tccagtcttg	300
gcctgaagca	cgctatgcct	ctcatacagt	ctgccttttc	taggggtcaa	gcagcatccc	360
aagttctggt	gagatgcagc	ttgcagtcca	ggaggacaac	ggtaaccccc	atcttcccat	420
gtttttcttg	ctttaagccc	tcccctaagc	tttcacatat	aatcaccagg	ggttcagaaa	480
ttgtcagcca	gttctcctta	tgctttaagt	agattttctt	ggggccagat	gtcttgaaaa	540
acgctctcct	gactcagcag	ttcctggaat	ttttggccta	tcatttatct	cactgttctg	600
agtttacttg	taagcctctt	ggcttaatgt	ttgaatcaag	atgagcagta	ataacagctt	660
cttgtgtacc	aattactcag	aactcactta	aattgcctta	acacttttta	aatgttctta	720
cacatttgaa	attcttttag	gagggatttc	cagaactttc	ctaaatttct	ccacccatgg	780
catgacagta	cttagagggg	caagaagttc	aatttttagaa	taagctcttc	tgggcgcgat	840
ggctcatgcc	tgtaatccta	gcactctggg	aggccaaggc	gggtagaatg	cttgagccca	900
ggagtttgag	actagcctgc	aatatgcgaa	accctgtctc	cacaaaaagc	cagacatagt	960
ggtgcatgcc	tgcagtccca	gctacttggg	ggcgctgagt	tgtgaggatc	acctgagccc	1020
aggaggcaga	ggctatagtg	agccacgatc	gtgccactgc	actccagcct	gggtgacagg	1080
gtgagacgct	gtcgtctcaa	aaaaaaaaaa	aaaaaaa			1117

<210> 15
 <211> 884
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (873)
 <223> n equals a,t,g, or c

<400> 15						
ggccgacgcc	tgggggtgtg	agctgcccc	ccgccacccc	gtgggagagt	ggatcaagaa	60
gaaaaaacct	ggcccgagag	tcgaagggcc	gccccaggcc	aacagaaatc	accggcctt	120
acctctgtcc	ccacccttac	cttccccac	ataccgcccc	ctgcttgggt	tcccaccca	180
gcgcttgccg	ctgctcccg	tcctgtcccc	acagcctcct	cctcccatte	tccatcacca	240
gggaatgcc	cggttccac	agggcccc	agatgcctgt	ttttcctcag	accatacttt	300
ccagtcggat	caattctatt	gccattcaga	tgtccctca	tcagcccatg	caggtttctt	360
cgtcgaagac	aattttatgg	ttggctctca	gctgcctatg	cccttcttcc	ccacaccccc	420

ttatcagcgg	cctgccccag	tggtacatag	gggttttggc	aggtatcgtc	cccgtggccc	480
ctatacggcc	tggggacagc	ggcctcgacc	ttcaaagaga	agggccccag	ccaatcctga	540
gccaaggcct	caatagacgg	acctaggcct	tatttcctct	ttatgaacat	ggattggaca	600
gatctgacac	ttcctttcca	ttgcttggcc	tgaacagact	gaccttgta	acttaagcct	660
ggagtccatg	cctcgtcttc	cttttgttca	ttgctgttac	caagaaagcc	aaggaaagagc	720
agcctgactc	attcttcttg	gctgcagcct	cttccccact	tcctgggagt	gacccagcgt	780
tattcctgcc	tcctcactcc	tattctcttt	gcctttgtgt	aaaaataaaa	tggaaataaa	840
caagttgcac	agaaaaaaaa	aaaaaaaaaa	aancccaagg	gggg		884

<210> 16

<211> 643

<212> DNA

<213> Homo sapiens

<400> 16

ggcacgagac	aaaacaccat	gacacctatt	ttcaaagtct	tcccagggca	acccagcgca	60
cctgcagggc	agtccggagg	tggggcaggg	tgggaaagga	ggcctcctaa	cttccaatcc	120
aggacgctct	ccatgttgtc	tgaggccctt	gtgatcccat	ctcttggett	cttcgtctcc	180
tctctctgtt	ctgaccagtg	gcctctttcg	gcccagccca	gctcatggct	ctcggcggcc	240
ttcccaggcc	ccgcttttga	cttttggcag	cctcttcagg	cacagaactt	gatctccagt	300
cggcctctgc	aggcccggcc	tcctgcctct	cgaaggcctg	cacggggccg	gcctcggcct	360
cggcctcggc	ctcacagcgg	actctccacg	cccagctaac	tctcgcctca	ctgcggcctc	420
cccagtccaa	agctcctgcc	tttcggccac	ttcggcaggt	ccagctcctg	cctgccagtg	480
gcctcttttag	gcccagctca	ttctcacgtc	ggccattcca	ggccccgtgt	ttcccttccg	540
gcagcctctt	ggcctctaata	ttgtttatct	tttgtgtata	aatcccaaaa	tattgaattt	600
tggaatattt	ccaccattat	gtaaaaaaaa	aaaaaaaaaa	aaa		643

<210> 17

<211> 2003

<212> DNA

<213> Homo sapiens

<400> 17

ggcacgagaa	gaaatcgccc	cgggacatgg	actcagtgg	ctttgaggat	gtggctgtgg	60
acttcaccct	ggaggagtgg	gctttgctgg	attctgctca	gagggacctc	tacagagatg	120
tgatgctgga	gacctttcag	aacctggcct	cagtagatga	tgaaactcaa	tttaaggcca	180
gtgggtcagt	ttctcagcag	gatatttatg	gagagaaaat	acccaaggaa	tctaaaaatag	240
ccacgttcac	cagaaatggt	tcctgggcct	ctgttttagg	aaaaatttgg	gacagtctta	300
gcatcgaaga	tcaaaccaca	aaccagggga	gaaatctcag	aatcatggg	ttggagagac	360
tctgtgaaag	taatgatcaa	tgtggagaag	ccctcagcca	gattccacat	cttaatctgt	420
acaagaaaat	tccacctgga	gtaaaacagt	atgaatacaa	cacgtacgga	aaagtcttca	480
tgcacgcg	cacatccctc	aagagtccca	tcacagttca	cactggacac	aaaccatatc	540
agtgccagga	atgtgggcag	gcctacagtt	gtcgttcaca	cctaagaatg	catgtgagaa	600
cccacaatgg	agagagaccc	tatgtgtgta	aattatgtgg	gaaaaccttt	cctcgtactt	660
cctccctcaa	tcggcatgta	aggattcaca	ctgctgagaa	aacttacgaa	tgtaagcaat	720
gtgggaaagc	ctttattgac	ttctcaagtc	ttactagtca	tctcagaagt	cacaccggag	780
agaagccata	taagtgtgaa	gaatgtggga	aagctttcag	ttattcctca	acgtttcgaa	840
gacacacaat	aacacacact	ggcgagaagc	catataaatg	taaggaaatg	gcggaagcct	900
ttagttattc	ctcaactttt	cgaagacata	tgatttcaca	cactggagag	aagccacata	960

aatgtaaaga	atgtggggag	gccttcagtt	attcttcggc	ttttcgaaga	cacatgataa	1020
cacacactgg	agagaaaccc	tacgaatgca	aacaatgtgg	gaaaaccttc	atttatctcc	1080
agtcctttcg	aagacatgaa	aggattcaca	ctggagagaa	accctacgaa	tgcaaacagt	1140
gtgggaagac	cttcatttat	ccccagtcct	ttcgaagaca	tgaaaggact	catggtggag	1200
agaaacccta	tgaatgcaac	cagtgcggga	aagcattcag	tcacccctcc	tcctttcgag	1260
gacacatgag	ggtgcacact	ggagagaaac	cctatgagtg	caagcaatgt	gggaaaactt	1320
tcaattggcc	catatcttta	cgaaaacata	tgagaacaca	tactagagag	aaaccctatg	1380
aatgtaagca	gtgtgggaaa	gccttcagct	tgtctgcttg	ctttcgagaa	catgtgagaa	1440
tgcaccctga	agacaaatcc	tatgaatgca	agctatgtgg	gaaagctttc	tattgccaca	1500
tatccttaca	aaaacatatg	agaaggcata	ccgcagagaa	actctataaa	tgcaagcagt	1560
gtgggaaagc	tttcagtttg	cctgaacttt	tgcaacaaca	tgtgagaacg	cacactgtag	1620
agaagcccta	tgaatgtaag	gaatgtggga	aggtcttcaa	atggccatca	tctttacca	1680
tacatatgag	actgcacact	ggagagaaac	cttatcaatg	taagcattgt	gggaaagcat	1740
tcaattgttc	ctcatcctta	aggcgacatg	tgagaataca	cactacagaa	aaacagtata	1800
agtgtaatgt	aggacatcct	cctgcaaagt	aattcatgtg	cagtgcctca	gaaaagtcac	1860
accaggagag	agatctgatc	aaagtgtgaa	atatggtgtt	gcctttatga	gttccttatc	1920
ctgaaagtgg	acactcaagg	agtgtgtctg	tagttcattt	gcaaataaac	atttagttga	1980
aaaataaaaa	aaaaaaaaaa	aaa				2003

<210> 18

<211> 2967

<212> DNA

<213> Homo sapiens

<400> 18

ggggactcag	tggagcagcg	gggagttgtg	tcacacctgc	cgacgtcget	agccgtgggg	60
ctgtcctggg	aaggcggacg	gcgagcgccc	ggtgtccgca	ctcgcccgcc	tgccgtgccc	120
gtctgcgccc	gtgtcatcct	cactcgggac	gcagggaccg	tttttaaatc	acaggggagc	180
gtgtcagcct	gccctaggac	ttcatgtcta	tatatctccc	cattcactgc	cccagactatc	240
tgagatcggc	caagatgact	gaggtgatga	tgaacaccca	gcccattggag	gagatcggcc	300
tcagcccccg	caaggatggc	ctttcctacc	agatcttccc	agaccctca	rattttracc	360
gctgctgcaa	actgaaggac	cgtctgccct	ccatagtggg	ggaaccaca	gaaggggagg	420
tggagagcgg	ggagctccgg	tggccccctg	aggagttcct	ggtccaggag	gatgagcarg	480
ataactgcga	agagacagcg	aaagaaaata	aagagcagta	gagtccctgt	ggactcccat	540
gggtcatacc	agccagcatc	tgttcctgaa	ctgtgttttt	cccatcatga	cggaagaaga	600
gagtgaagccg	caattgttct	gaaaatgtca	aacgaggcct	ctgttttgca	cctgcagatc	660
accgagttgg	ttttcttttc	ttttcttgcc	tttttttttt	tttgaaattt	gccgagcagt	720
ggagccctct	gacaatttgc	aaggccctct	gagaaaggaa	gctgcttaga	gccagggggg	780
tagtgggtga	ggggagcgag	tgtgtttttt	gagatcatta	tctgaactca	ggcagcctag	840
tagaggcagt	ggtgggattc	caatgggtct	tgggtgggtg	gaggtggggc	atgtgcaaag	900
caagcaagga	acatttgagg	taagaaaaca	aacatgaggc	aaaagaaaaa	atacatgttt	960
ttaagaaaac	attgagcaga	gaactgcagc	caggatgcgc	tcagcagaca	ttcactctgg	1020
ctgctgggac	atcagaaaac	aaagtcttca	tctctctctc	cagtttcacc	cacccacccc	1080
tttgctttca	tttcaggtgt	gttggtctat	atgacaggga	ggagagtaaa	ggagagcagg	1140
agcaattggc	tgcctgcaaa	gccagctgga	ggtgaagtgc	aggaaaggaa	aggtcacccc	1200
attctactcc	atggcctctc	tgtctccagc	tgtggtaggc	tcacatagcc	agtgtgatcg	1260
gtttttaaga	ggcagtgctt	ttcagctttt	ctccctgata	tatccatttt	gcttcccagc	1320
acttttttagg	agtagtgaga	gcacttccctg	cccttggttg	aagccccagg	gtggacactc	1380
agcacgaagg	tctctccctt	aactgctgcc	cttccaagac	ttgctcccg	gatggagtgg	1440
gcgtggtctt	ccaggctggc	ccttccttct	cctcaccgcc	accttccctg	ccccagcccc	1500

agcagccatg	ggtacatggg	tccccagctc	acctatggat	tcccgccagt	ctgcccagct	1560
gcagtactca	cgccccatgg	gggatcttgg	tctgtttttc	ttgtgggagc	ctagtggaga	1620
gcagacgtgg	ctttttatgt	gtcttgttgg	ggaggtgact	tgcatggtgg	ggacaaggct	1680
gtcgtggcaa	ccttgggata	gagtttgaga	ctaaaggatg	tcatagagac	cctggcttct	1740
ccccatgttg	ttcccgga	agggcagaag	ggaggcatgg	caagggacct	ctgctgtcct	1800
tactcaacag	tggtcctcat	ccctcccccac	ctcccactgc	ttcctgcaag	ggcaccagtt	1860
gtatgagaaa	gttggccttt	ggacttagga	tttcttattg	tagctaagag	ccatctgaag	1920
cagcaggttg	caggacaaat	gcttcagtc	gccgagagca	gtaccgtgtg	gccaagagggt	1980
ggactcagag	ccttccttga	gctaaactcg	gccaaccaag	gcacgcagca	tgtcccctca	2040
ggtctccagt	cagtccaggt	tgaccctcag	ttctggacgt	gtgtatatag	ctgtatttaa	2100
tacctcaagg	tcattgtggc	tctggggatg	ccggggcagg	aggacgaggg	tgcgctgtgg	2160
acacagcagt	ccgcggaatt	ccgttctggg	aagccaatgg	tcgccggcac	cccttgcttc	2220
ctccctctgt	tgtctgectg	tgtgacacac	atcaatggca	ataacttctt	ccaactcctc	2280
gcagaagtgg	gagaggccgg	cagcctgcac	cgagaggggc	tttctctctt	cttgctcccc	2340
gcttcgttct	gttttggtcg	cagagagtgg	ttcatccata	ctctcattcc	ctcgcctccc	2400
cttgtggacg	ggggtcttgc	cttttcaatt	cctgtgtttt	ggtgtcttcc	cttatctgct	2460
accctgaatc	acctgtcctg	gtcttgctgt	gtgatgggaa	catgcttgta	aactgcgtaa	2520
caaactactt	ttgtgtatgt	gtctgtttat	gggggtgggt	tattattttt	gctggtccct	2580
agaccacttt	gtatgacctg	ttgcagctcg	agcaggccag	gggctgacag	ctaattgtcag	2640
gaccctcagc	ggtggagcct	gctgggggga	ccagctgct	cttggaacaag	tggctgagct	2700
cctatctggc	ctcctctttt	tttttttttc	aagtaatttg	tgtgtatttc	taactgattg	2760
tattgaaaaa	attcctagta	tttcagtaaa	aatgcctgtt	gtgagatgaa	cctcctgtaa	2820
cttctatctg	ttcttttttg	aggtcaggg	agaaactagc	attttttttt	ttccaaacta	2880
ctttttgtca	ctgtgacagt	tgtaataaaa	gtttgaaaat	gctttccaaa	aaaaaaaaaa	2940
aaaaaaaaaa	aaaaaaaaaa	aaaaaaa				2967

<210> 19

<211> 979

<212> DNA

<213> Homo sapiens

<400> 19

ggcagagct	cccgtggagc	actcaggaaa	cgctccttca	cccctcaatt	ctgctctcac	60
acaccccgctc	acacatagac	tcacatacac	caagcagaga	ggagcaaaga	gaaggaccat	120
gtaagacaat	cacggacatg	gcgttagaag	gaaactgaga	aacgctctac	aagagttcga	180
tgtattacat	tatttttaat	ttagatgaaa	ttcacataac	acaaaattta	ccattttaaa	240
gtgtacgtac	acttcagtg	cttttcatat	attcacagt	ttgtgcaacc	actaccctta	300
tctagttcaa	aaatattttc	agttctcccc	tcctccagca	tctgggaagc	atccattcac	360
cttcagctc	tgtggctttg	caggttctag	acatttcatg	taaatgcagt	catataatat	420
gtggtttttt	gtgtctggct	tttttcattt	agcataatgt	tttcaagggt	tatccatgtt	480
gtaacatgta	ttctttttaa	aaaaatttta	atgtgtaaaa	tatacatatc	ataacattta	540
cctttttaatc	attcataagt	acacaaatca	gtggcatgag	gtggctccctt	cccaatgttg	600
tgtgtctatc	accactgtct	gttttcagaa	ctttgtcatc	atcatcccca	acagaaaccc	660
tgtacccatt	aaacagtaac	tcccggccag	acgcggtgct	cacgcctgta	atcccagtaa	720
ttccagcact	ttgggaggcc	gaggtgggcg	gatcacaaag	tcaggagatc	gagcccatcc	780
tggccaacac	ggtgaaaccc	cgtctctact	aaaaatacaa	aaaattagcc	gggcatgggtg	840
gcgcacgcct	gtagtcccag	ctactcggga	ggctgaggca	ggagaattgc	ttgaacccaa	900
gaagtggaga	ttgcagtgg	ccaagatcac	gccactgcac	tccaacctgg	gtgacagagt	960
aagactgtcc	aaaaaaaaaa					979

<210> 20
 <211> 638
 <212> DNA
 <213> Homo sapiens

<400> 20
 attacgccaa gctcgaaatt aaccctcact aaaggggaaca aaagctggag ctccaccgag 60
 gtggcgccg ctctagaact agtggatccc ccgggctgca ggaattcggc acgagattaa 120
 ccatcagctt gggctgcaac agaggaaaag cagtgatttg gcagtgccaa tgggactcag 180
 atgggtaccc agctcctttt ttgtctatgc tcaattttta tccccctatg tgtggagttg 240
 gactacatat tcttgaagca gtcttcccta aataatcttg tagtctagct aatgtcaaat 300
 gtttaatttg caatgagctg aaattgcctc tccaacaagg gccatttgg atgccacttg 360
 ttctgtgctg ccaggtagat ctatgtccat gtgctttaac aggcagttga gtgtggagag 420
 ggatgacacc ctctcttggg aataaaactg aatatatgcc acgccacctt cccttagagt 480
 agagttgatg gaatccctac aggcacagcc aagagccttc ttagacaagg cattttgctg 540
 ttgttctttt aatagtctcg ggtctttatt tgactcaaac cgaacactgc acgtctctca 600
 tatttaaaaa aaaaaaaaaa aaactcgagg gggggccc 638

<210> 21
 <211> 3016
 <212> DNA
 <213> Homo sapiens

<400> 21
 gacagattaa tgtccctgta aatctgataa tgataaatat agcataaagg tgttatattc 60
 aaatggattt taatttttct ccaaactaat atttacataa atgtatgtaa actatttgag 120
 ttatgtggag ttccagttag ttttcttttg tgtatgtctc aacaaatgtt tagtgttaat 180
 gcttgtcagc tcacattttc ttttcttttg ttttgtaaga ttactttctt cccttctctt 240
 ctctcttacc tccattacct tcttttactc cccttctctc ccttctcttt tctctctctt 300
 ctattccttc tcttaccctt ccttctcccc tttgtccttc cttcccctgy ctctgatctc 360
 attccctcct cccatgccct cctcactatt ccccttcccc tgcctctttc ctcagcctct 420
 ctttcttttt taatattgcc tccctccctc ccttcccttc cttccttctt tcttttttcc 480
 tcttctcttt ccaccacact ttttattttt tcagactggc ttaatgaaca gtctagtgat 540
 agaaagtggg aaaaataagt tatagtagat ctatatagct atataatcca gtatatccaa 600
 tataatagaa tattatgcaa taattacaaa ctatgctttt tgtgcttctt catatctacc 660
 tcatgcccct catatttttc atcttcatat tctgtcattt accaaatcct atgaaaaataa 720
 tctctcaaat tcatcctttc ctatctcctt catcttcaca tctgcattt gctaaatcct 780
 agaatttttc aaattcattc ttttcatttc tctaccatc ccccmatttc cccttamcag 840
 amctattaaa atagctgccc tgagttggtc ttgactattc ttctatttag ccmataggct 900
 atggscatat tttaatcgtc cttaaagccca gktctcatca gattacyacc tgcttaaacc 960
 tttctgttac tggtgccc a tttcctacca acttaatata ataccgtagt cttcagtgac 1020
 ttgcagatta tggtctaac ctgctttttt agttctctca agctccattt tacccttaac 1080
 ttccagtggg acttgctttc tgcttccatg tcttttttcc cactatttgc tttgcctgga 1140
 gtacttaact tcttagtctg ccctttagaa cctacctcct tcgaggccca attcagatgc 1200
 cacccttcca ttttctctat tattatctaa gtgtctcttc tcccccttat ctatgttata 1260
 aattccttaa gttcagagac tgtgtcttga aattctctga atttttaaca cagtgccttg 1320
 ctattataaa tatttggtag ttttaattgt gcagtaaaca cttccattta tgaaaatttc 1380
 tgttttcttg tctctagtta aagaagagtg taagagtcct aaagctgagt gttgggccca 1440
 aaaaatgtcc aataagcagc ctaactctgg aattgagaac tttttagcat ctttgaatat 1500

ctccaaagaa	aatgaagtac	agtcattctca	tcatggggag	cctccaagtg	aagagcattt	1560
gtcaccacag	tcatttgcca	tgaagggaac	acggatgctt	aaagaaattc	taaaaattga	1620
tggtctaac	actgtggacc	ataagaatga	aatcaaacag	attgctaattg	aaatccctgt	1680
ttcctctaac	agaagagatg	aatatggatt	accctctcag	cctaaacaaa	ataagaaatt	1740
agcatcttat	atgaacaagc	ctcacagtgc	taatgagtac	cataatgttc	agtctatgga	1800
caatatgtgt	tggcctgccc	ccagccagat	ccctcctgta	tccacaccag	taactgaact	1860
ttctcgaatt	tgttcccttg	ttggaatgcc	acaacctgat	ttctcctttc	ttaggatgcc	1920
acagggctcc	ttaggcattga	atttcccttt	gccttcacaa	gtatttgcaa	attatccttc	1980
agctgtacca	cctggaacca	ttcctccagc	ctttccccc	cctactgcta	atataatgcc	2040
ttcgtcgtct	catctctttg	gctcaatgcc	atggggacca	tcggtgccag	ttcctgggaa	2100
gcccttccat	catactttat	attctgggac	catgcccag	gctgggggaa	taccaggggg	2160
tgtgcaaat	cagttttatac	ctctgcaggt	tactaaaaaa	agggttgcaa	acaaaaagaa	2220
ctttgagaat	aaggaagccc	agagttctca	agccactcca	gttcagacta	gccagccaga	2280
ttcttccaac	attgtcaaag	taagtccacg	ggagagctca	tcagcttctt	tgaagtcctc	2340
tccgattgct	caacctgcat	cttcttttca	agttgaaact	gcctctcaag	gccatagtat	2400
atctcaccat	aagtcaacac	caatctcttc	ttcaagaaga	aatcaagaa	aactggctgt	2460
taattttggt	gtttctaaac	cttctgagta	aatttggtc	ttagaattaa	gttaatttct	2520
tctctttcca	tctacctttt	tataaataca	tatctatgtc	tcataaaaaat	tagaatgtac	2580
tattttaaaa	taatatgtgt	aaattgaaat	ttttttcatt	tttaagtatt	caggcacttt	2640
tcatgctgtt	taaaagactg	tgtatcaa	tgtgcacttt	aagtatgtgc	agtttgttgt	2700
atgtcaatta	tacctcaata	aatctgta	aaaaaactaa	attaaacctt	gcattaaaaat	2760
aatatcacag	tatcagtggg	ctaaacatta	aatgtacca	ctctaatacat	tggcctcatg	2820
attgaagcat	cctgaactat	gaattagaca	tcagttagca	ataataagca	ttttttacac	2880
tatcattgag	grataattac	atggagcatg	aaatttggtc	ctccagtgat	aacttactga	2940
atgtggattt	tatttctctt	tttaatgatg	tagaaaatgc	aggagaatgg	ctcttatttt	3000
atgtgtggtt	tttaac					3016

<210> 22

<211> 1870

<212> DNA

<213> Homo sapiens

<400> 22

gggagcctca	ggcacttgaa	actcacctcg	ctgtcccttt	tctttgccac	ttatttattt	60
atttatttta	caaatgaaat	ttaaaaaacc	caaggccaaa	gtgggaaatg	acttgctcaa	120
ggtcatccat	attcctaacc	ctcctttttac	tggggcatag	ggcaatattt	tccaatatgc	180
ctgaaaagct	taggtctcta	atcacagata	acttacagct	tttcacaagc	aagagttttg	240
gccaaattat	gccagttaag	gaatgtaaat	tttataaatg	atgaaatact	gcaaccaatt	300
agtgcaca	aacattttatt	gtgaaatatt	catcctaccc	tttattaggt	attacatcat	360
caaagcactt	tgtggcaatg	aaaatagctt	tttttacc	tctaattcac	ccaatattcc	420
attaaagctg	caaaaaatgt	gcaatctgct	tgaaaaaatg	gttgctctta	tttactcatt	480
tgtgaaaagt	caaaaaattaa	aaaagaaaat	gatactagca	tacagggcct	ctagagccaa	540
ttcacctttc	catttcccaa	ctactcccca	aaataattaa	caaagataat	ttgttttaaa	600
tgccttttta	taaaaccaat	gcacctttcc	ccatattata	atcatacaaa	ttttaaaaag	660
ccgttattta	ctttcttgga	aaaaaggttg	ccagccgttg	ttttttgatt	gggagcatgt	720
gtatttctctg	ggagttcact	ttcttttaact	ttatgctccg	gtttttgatg	ggtttcctaa	780
ggggctctgc	atttcccatg	gactcttccc	cttggtgtgt	gatgtcatag	ccctgaagca	840
cggagtcttc	tcttttgaag	gagaagtttt	tgggtggacac	ccctgagagg	cctttgatct	900
tgccacagaa	tatggttagc	acagcatctt	cgacagagac	aatgaccttg	gccgcctggg	960
actcgccccc	catctcaatg	ttattttcag	ccttgacttc	gccgctgggg	tggttgggct	1020

```

ggctgagcat ctcggtamgc atcactgctg ctgatgtgac tatccatcat ggctggggcc 1080
tcatgggacg tggcaggggc aaaagaaatt tccatgccac tgggaagttt ctccatcact 1140
gtgtgacctg agctgtccac tgatgcacca ctgtcataca gtgtctcagg gggaggctcg 1200
gatttccggg gggctgccac tgacagggtct agggctgcat cttcctggaa gattggggga 1260
ctgacttcac cagccttgag ccagggcact gacttcatgg agagatccag ggcctcgttc 1320
tcacttccca tcttaatgac cgtgtggcgg ctgagctgga agtactcctt aggctggagg 1380
atgtcaaagg gcttcagttc atctttttcc agaggggtct ggggtgcctt aaaggggtgc 1440
aggccgaagg aagatggtgg cttggggaaa ctggagctga acttggttc agaactctga 1500
ggcaccggga tggggatggg aatagggact ggcacaggca aggggacgat tacaggatac 1560
ggcaccaaga ggggtggctg tgggaccagg ggggacaagg gggagctaaa aggctgtggg 1620
ggcacagggk catagccagg aggaggctga cagggtgggg gcccgagagt gccctggga 1680
gggaaacaaa ttctggagca cagcttcaaa tggcaaagtg ggctctgcgg ctggctgggg 1740
atcctcaggt ccaggagctg gggctgggce tcgggtcct ccgctccctg gaagaggttg 1800
ttgtggatgg tactggagcg gacgcgtggg cggacgcgtg ggcggacgcg tgggcggacg 1860
cgtgggtcga 1870

```

<210> 23

<211> 1084

<212> DNA

<213> Homo sapiens

<400> 23

```

ggtttcatca gtatgattat actcctaggt gaaaaaaaaag atggagacaa gggaaaaaat 60
gaagttaacg aataaaacaa atgttatttc agatcacggc cctgtgtgtg ttactaagga 120
aagatataag gatttataac atataattgt ttccattta tttttatgaa ggaattaaag 180
aaattatcag aaaatactaa aagggaacaa agcattttaa aaacattcca acaatggcat 240
gctgcttttt atacagtatg cagtgaagtt ccttgcattt caaaggcaag ggtagctaaa 300
tctgcctcag ccccttagcg ttctgtacta cccttatctt gccatttaca acatgaaagt 360
ataataatct atttacatgc tggatatata cactatgagt ttctgacaaa catggcacat 420
cttgggtgta gttcatttat tctacaaata cttattcaat gtctactatg tgccaggcac 480
acttttgtag attttgata catcaggtaa gaatataaat acctctgccc catgaacctt 540
acattctacc tatattgcaa agttcctagc acatcgtaga tttcttctca tggtcataag 600
atgtctgcac caattctaag catcacatct tcatagaaaa gcatccaaaa caggarggaa 660
aaattagaag caaaagggtt ttctcctttt gggcctttct tttcatagga aagaaaatct 720
ttcccagaac cctcaaacat gtgatctgga ccaaacactg gctggcaaaag agtggaaattt 780
cttaagtctg agcaacaaga agaaaaccgt taccataact accaactcac ctgcatctgt 840
gccatgtgct tgcctgccca cctataacta aggatgagct gtttgtagtc ttaggtcaac 900
tcctccactt gtgccttgga tcctgccgca cgccccatc acctacttgc ggacattact 960
ccaacagttc ttttctttct gtcctgtatt atcaaatttc tgttcttact ggattttcat 1020
gctctttcat cattatgaaa gcatgcagta atttcttcat taaaaaaaaa aaaaaaaaaa 1080
tcga 1084

```

<210> 24

<211> 2973

<212> DNA

<213> Homo sapiens

<400> 24

```

gggaaacagg aagaagtatg gtgggggctg gggtagactc ccctggagcc aagcctatcc 60

```

agctaacaag	agctccctgg	ggctgggtcac	agctgggtca	tgatgctgaa	cttgaaagtt	120
tttttgtttt	tgtttttgtt	ttgtgggtcc	tccaagatat	aggtacatga	agtttaggtt	180
aaaggggtgg	gattctttat	ttttattttt	gtattgtatg	tgtaagaat	tactctgttg	240
ttcacctttt	gctttttgca	ctgtttgttc	tcttatctgt	attttgagct	tagtgctagg	300
actgaraggc	tgcaccatag	ggaatgtatg	ggagatgggt	aggggtgcc	gtgaggggtg	360
cgtggaggag	aggcctgggc	tcctctactg	gatctacact	ctgtcccagg	tttttagatc	420
ccactgagcc	cagctgactg	aaaacaagga	cagtcagggt	gaaacttctt	ttgccagaag	480
tgtggcctga	gttgaatttc	tgggaggatg	acgcagatgt	ctgctgcaga	gctgggctga	540
gagttctgca	gtctagctct	gacttaggtc	aggggcctgt	tggctctctca	ttggacgttt	600
ttgggtctca	ctcatgctta	ctgaaacatt	gtgccaagaa	actctgtggg	atttgtgtcc	660
cttaaaccag	actcactttt	ctgaaaaatc	tccattgttg	aggagaggct	gctcaatcga	720
caccccgagt	tctcatgact	gggaagatag	ttttcttcag	gtgtcaatgg	cgtagactc	780
ccaggaagac	tagccctgcc	cacaggcmac	ctgttggttt	gagagcgtgt	tcgtgttctc	840
ttgccctccc	tgccctaagag	ctactgggat	cacgttagcg	ggcatttagg	ctttgatgag	900
agggcacagt	ttgagttagg	tttacctccc	cctttctgtg	cctgggaact	gtttgggtcca	960
gctttagaac	tgtggttttg	acttccttat	ctcttgggag	aagcttctgt	tttaaggaaat	1020
ttctcttccc	tcttctcctg	cctctagcct	ctcctggaaa	ggcctggata	tggtttctaa	1080
aatctcagct	tgaacttca	gaaaacagca	gcagtatttt	ccttttccta	gtgctaaaaat	1140
ccctttccct	agaaattggc	tcaccttggg	aaaccagggt	aaagaatcag	caggttctct	1200
gccctcccta	ggggttgggg	aaggaccac	cccggtcagc	acagtgcctt	ttcctctcct	1260
gctctgagcc	aggggtgggg	attccctcta	gattcagggt	tgggcagggt	tcctatagtc	1320
cctgccatgg	ggctgcttcc	ctgtcccttc	cctccccttt	gctggcctac	tctggcataa	1380
ttcaagtgtc	ttcttgccct	ggggatccct	agtggcatca	aatggcaaca	tggaatattg	1440
tcctccatgc	ccctccagaa	ggacctagga	gagtaggtga	gctttccaaa	gtgagagacg	1500
aatctttctt	tctttttttt	tttaaagggt	aggatgggtg	tgctttgggc	tttctccttc	1560
tgtggccccc	gaggaaggag	agactgaggc	aaggcaagt	gatagtacac	tgaagcagaa	1620
ccggaaacac	ccaggaactg	ttcagaaatc	tcagaagaaa	tctgcttctc	ttcgatggaa	1680
agatataatt	aacgatcaaa	gagctctaag	aaaattgcaa	agaagcctta	atgttcaagc	1740
tttagaaaga	tcagagcaat	ttttctcttt	cagtccaaac	taagactctc	tgtattttaa	1800
tctctctggg	gcaagagggt	tagatttcct	cattttgtta	tgagactaga	ttggtaccag	1860
tagatcagct	gcctagcgag	ggcaggtttc	ttctttgcat	ctgtgtggct	tgcttccagt	1920
ctggcctgtc	ctttccagct	gccttttgtc	tagcctgcta	tggggggcca	gattatcttg	1980
ataagagcag	gtgatttggg	gactagctgg	gttggcagga	aaagagcagg	atggatctct	2040
tgggacaggt	tccccagga	gtataaacac	aaggagccag	gattgtgctg	gcagccaagg	2100
aaacagtagt	gcctgtttga	gttggcagag	agggccttgg	cacctcttgc	atccaggcag	2160
tcttgtgaga	tgggggcaca	tagcactggg	gaaagcagaa	ctccattctc	acctctattt	2220
tgagcttcag	tgctttattt	cagtatgagg	aaaaacaaca	acaaactgaa	gtgcgctttc	2280
cgctctttca	aaggacaact	gtcgggaagg	gagagccgag	ttgcgaggta	ggaggggagc	2340
actggcaggg	agagacattc	ttgactcctc	tcttccctgg	tgtgttgtga	tccagggaaat	2400
gaaaagaaat	ttgaccctgg	attggttctc	tccttggact	taaggaaatct	taccttttcc	2460
ttccacaaaag	ttctcccagg	caaggaccag	ctgcccattc	tgagcccagg	gcagcctctt	2520
caaccattat	tggctctaacc	tggcttgtca	ggaaaccaag	cccacccttc	cacattgggc	2580
ctggctgtc	tattctgtac	caagtactgg	agaaaaagca	tcaagttctt	agcccttgta	2640
gcttctaccc	tagtttccca	tcctctctct	gtggaggcca	aaccaactct	ttgccagcag	2700
ccacaacatg	cattgacagc	ggcacagtga	gatataactg	atgggctttg	aacctggttg	2760
gccgggggaag	ctgtaggggt	ggatagagct	ggctttcctt	ctgggctgtc	tccatctgac	2820
cctacccctt	ccatgtccca	ccccactccc	acaaaaaagt	acaaaatcag	gatgtttttc	2880
actgtccatt	gctttgtgtt	ttaataaaca	atttgcagtg	acaaaaaaaa	aaaaaaaaaa	2940
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa			2973

<210> 25
 <211> 536
 <212> DNA
 <213> Homo sapiens

<400> 25
 gatttgaaga gggcttgcct tccaacctat aggcactata tatgcttttg gaaaaagtaa 60
 ttaggttaag atgcagttgt tttgttttgc tttgtttttc ccttagctgg gttggggttt 120
 ctagcagcaa tgatgtacag gtggatcttt tttcacatta aactaccag ctgctccatg 180
 gctatagtgc ttaggaatat ctcagaattt caacagatct atcagctgca atatctagga 240
 gtcttgccaa cacagagaca cattcacatg ctgaaaagag catgagttga aggcacagct 300
 ggggactttt gatgcaggtc cagaactgga tgggtgtgaa gccattagag atatttaaata 360
 tgtccagaat ttcaggctct gctttaaaaa ctaggctaca aaccctcatt cagaaagagg 420
 tcagtaatat gcctgtgagt tagaaagata ctggaacat ttcaatgcca aaagtaacat 480
 ttttttccag aatgctatga ctaaattttt taaaaaaaaa aaaaaagggc ggccgc 536

<210> 26
 <211> 743
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (718)
 <223> n equals a,t,g, or c

<400> 26
 gtcctgawca ccgcactcct catcgtcctc acctaccctg cctggacctt catcgactgc 60
 ctggactcgg ccagccccct cttccccgtg tgtgtcatag ttgtgccatt cttcctgtgt 120
 tacaattacc ctgtttctga ttactacagc ccaaccggg cggacaccac caccattctg 180
 gctgccgggg ctggagtgc cataggatc tggatcaacc atttcttcca gcttgatcc 240
 aagcccgtg aatctctccc tgttattcag aacatccac cactcaccac ctacatgtta 300
 gttttgggtc tgaccaaatt tgcagtggga attgtgtgga tcctcttggg tcgtcagctt 360
 gtacaaaatc tctcactgca agtattatac tcatggttca aggtggtcac caggaacaag 420
 gaggccaggc ggagactgga gattgaagtg ccttacaagt ttgttaccta cacatctgtt 480
 ggcactctgc ctacaacctt tgtgccgatg cttcacaggt ttctgggatt amcctgagtc 540
 tcaaacagtt ggaaactagc ccactggaca tgaaagccaa gacataggaa agttattggg 600
 aggcaaactc tgacaactta tttttcttta acaacaacaa aaagtcatat ggctgtcttg 660
 ctactaccag ataaatgatg ctgctgtgtg aaaggaaaaa aaaaaaaaaa aaaactcnag 720
 ggggggccgg taacaaattc ccc 743

<210> 27
 <211> 715
 <212> DNA
 <213> Homo sapiens

<400> 27
 gcccctttta tttgcttcat tgtgcaatgg tataattttt atgcttttct attttcctgc 60
 tttaaagagc ttttaaagt tctgaggctc tgccaagggt ttattacatt taaccctttg 120

tccctgcttt	cttttctggt	cctgaggtct	cctattggtg	tcacaggcag	gtgctttgca	180
tgccaactct	gatttatccc	tgatgggcc	ttatgacgat	atgaggcaac	agttggtttg	240
acttagcctg	tggcagaggc	agctgcacac	atgtgggagg	gatatgaact	tctgagaaaa	300
gagaaaatcc	catgttgtag	ccgactctaa	taggccagga	acgagctttg	ccattggaat	360
gtggcagtc	tgcctctgca	ggtttgttt	gctgatagaa	ggctctggaac	ctggggcgct	420
ccctgcattc	cctggctctc	ccagcagtag	gcatgggctg	acgggtgtccc	atgtggaagg	480
ccttggtctc	ctcatgaagt	gtggcctgta	atcagcctca	gcggcaagcc	tttactgttc	540
tctggttttg	tccggattct	cttttgtcgt	ctacacctg	acccatgccc	tcccaggccc	600
tggctggggc	tgtactccag	agcaataggc	ttcccagaat	ctccagtctc	acttccatag	660
caccagtgga	ggcttctgct	gccacaccct	gtctggaggc	actgacctcc	ctcga	715

<210> 28

<211> 713

<212> DNA

<213> Homo sapiens

<400> 28

tgcaggaatt	cggcacgagg	agactcttaa	cccccgcaa	attatccagg	ttaaaaacat	60
acgtgagctt	cagaaagggt	gaacatagcc	atggctgaga	atcgttgtgg	attatcatga	120
taggaaattg	acatgcttat	gggtgttctg	tcctttgggg	ttgatgtcag	ggagccaagt	180
ggttgcacta	tttctgctgt	gtgtccgaat	ttctaaagta	atatccgtgt	attgtttgga	240
gagcggactt	ttttgcttta	ctcctacttt	tacagaaaag	aatttttttt	ctcaagcaac	300
aaaacatttg	gtctctgggt	tcaaagagga	ctttattata	ttagaattat	aaagctttag	360
ttaggaataa	gtgttgga	ttattaaatc	aatttactgc	aggctgggca	tgggtggctca	420
cgctgtaat	cccagccctt	tgggaggcca	agactagtag	tctccaattc	cattccatca	480
cttgaggcca	tgagttcaag	accagtctgg	ccattgtggt	gaaactccgt	ctctactaaa	540
gacataaaaa	ttagcatggt	ggcctgcacc	tataatccca	gctactccgg	aggctgaggc	600
aggagaatca	cttgaatcca	tgaggcagag	gctgcaatga	gccaagatcc	tgccactgca	660
ctctagccta	ggcgacagcg	ccagactttg	tctcaaaaaa	aaaaaaaaaa	aac	713

<210> 29

<211> 1471

<212> DNA

<213> Homo sapiens

<400> 29

ggcacgagct	tcctgaaagc	ttaatgccca	aactgattga	tttggaagat	tcagcagatg	60
ttggggatca	gccagggtgag	gtaggttatt	caggetctcc	tgctgaagct	cctccaagca	120
agtcaccatc	gatgccatca	ctaaaccaga	catggcctga	gctgaatcag	agcagtgagg	180
atactgctat	tgttcatcca	gttcccattc	gtatgactcc	aagcaaaatc	cacatgcagg	240
aaatggaact	taaaagaact	ggcagcgatc	atacaaatcc	cactagccca	ttacttgtga	300
aaccatctga	ccttttagaa	gaaaataaga	taaattcatc	ggtgaaattc	gcttctggta	360
atactgtagc	agatggttac	agtagttcag	actcttttac	ttctgacca	gaacagatcg	420
ggagcaatgt	aactcgtcaa	aggtctcatt	caggaacgtc	gcctgataac	actgcaccac	480
cacctcccc	tccaaggcca	cagccctctc	attctagatc	atcatcttta	gatatgaatc	540
ggacctttac	agtcaccaca	ggacaacaac	aggctggagt	tgttgcccat	cctcctgcag	600
tgcctccaag	accacagccc	tcacaggctc	ctggctctgc	tgtgcatcgc	ccagtggatg	660
ccgatggcct	cataactcac	actagtacct	cacctcagca	gataccagag	caaccaaatt	720
ttgcagattt	cagtcagttt	gaagtatttg	ctgcatcaaa	tgtaaacgac	gaacaagatg	780

atgaagccga	gaaacatcca	gaagtcctgc	cggctgaaaa	agcttctgat	cctgcaagtt	840
ctcttcgagt	tgccaaaaca	gatagtaaaa	ctgaagaaaa	gacagctgct	agtgtcctg	900
ccaatgtgag	caaaggcaca	acaccacttg	ctccaccacc	taaacctgtt	cgaagaagat	960
taaaatcaga	agatgaatta	aggccagaag	ttgatgaaca	tacacaaaag	acgggtgtct	1020
tagctgctgt	tcttgcátca	caaccttcta	ttcccagatc	tgttgggaaa	gataagaaa	1080
ctattcaggc	atcaattaga	cgtaataagg	aaaccaacac	cgttttggcc	agattgaata	1140
gcgaattgca	gcaacaatta	aaggatgttc	ttgaggagag	aatttccctg	gaagtcaac	1200
tggaacaact	tcgaccattc	tctcacctat	aagccaattg	ccgttaactg	tgaacatact	1260
tgtttttaag	tggttttggg	ttcaaagcca	atttgagagac	ctagacattc	agctcactgc	1320
ttactcaac	attaaatttt	atgattctgt	tttgccctat	atgttcaccg	ttgtatttaa	1380
gtatctttta	ttttttaatt	tcgacaataa	aaaggtcagg	atggcgtttt	ctggaaaaaa	1440
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	a			1471

<210> 30

<211> 1768

<212> DNA

<213> Homo sapiens

<400> 30

cgcggtccca	acccttcccc	atggccgacc	ctgaggagtt	gcaggtttct	tcgccgcccc	60
cgccgcctcc	ctcttctccc	tcctcttcag	acgcctctgc	agcatcttcc	ccgggcggcc	120
cagtgagttt	gggctggcca	gttccgagca	ggagcagcgg	cccaacggtg	gaccagctgg	180
aggaagtgga	gctgcagatc	ggagacgcag	ccttttcatt	aaccaaactt	cttgaagcca	240
catctgcagt	atcagctcaa	gtggaagaac	ttgccttcaa	atgtacagaa	aatgcacggt	300
tccttaaaac	gtggcgggac	ctcttgaaag	aaggctatga	ttctttgaaa	cctgatgact	360
gatttggcat	acttcgttgt	ttaataatga	ctgcaataat	tcatacttct	tatgtcatat	420
tttgtacatg	taccacacat	ataggatgac	ctctgtccag	cagttctgta	tatactcaga	480
atgaaatttt	tcttggtttt	cttggttttt	gtgaaagcag	aataccgatg	ctatttttgt	540
tgccgaccag	tacttgtttg	tccttaaaata	ctttatgcct	ctgaactttc	atagaatcct	600
ttatgaaagt	taacttcatc	aatagacggt	taatattaat	agagccacag	tgctaccagt	660
agcaactag	gtagaccatt	atttggtttg	caacaagatg	ctaagcatgg	cagactttga	720
agttgcgttt	catcttaagg	accaagggag	gtaactttaa	ggttgccagt	ggtggatcca	780
gctccgtag	gctaagttgt	ctacagctaa	tgatttgtgc	tttattctat	atccccagca	840
cctaaaacag	ggtcacacaa	cattcactaa	atgtttgttg	aataaaagag	ttaacaaaca	900
taattgaaag	ctttttttct	tcctatatatt	agcatgaaga	ctgtcattgt	ttctctagga	960
aatgtatgaa	tctgaacttt	tttgacttga	agaaaaacat	tcttttttta	cagagatttg	1020
gactttgatg	ataggtttta	aaaatatatg	ataaatattt	tttgtacttg	tttgattttt	1080
ttttaaaagac	tttacttcag	aaagggaaa	actgtttaga	aagaatgcat	attttttccc	1140
tatttatttc	tgtggttact	gcttttgtag	tttaacagtg	tttgattttg	atatttgtat	1200
atgtttgatt	gctatcttta	aagtgcctta	tcagatttat	ggctctgtgc	tattactttt	1260
tgagctttgc	aagtttgtga	cataataatt	ctaaagaagt	tactttgttt	gcaatgcatc	1320
aaatttaaat	gatgtgattt	tttttgtatt	atttgatctt	agtgcagtg	ttctattttg	1380
catcctgtat	cttatgttgc	ttttggtgtt	ttgtgtgtgt	tgtcaacgat	taagccaact	1440
aattctctac	catatataac	ttctggacat	ttttgataca	acatcttaat	tctttgtaga	1500
tatggagata	ggtacagaac	tatattctaa	tgccccacaa	tggggctatg	agaggggaca	1560
gatggatggg	caaagaatag	ttttgtttta	catattaggt	catagttctt	gattagtttt	1620
tttagttaaa	gataaacaca	taggggtgtga	tttctatacc	aaagatatgc	ttatttcagt	1680
attagaaaaa	tattcttctt	acatctcctg	aaaattgcaa	tttttaaaat	gtgtaaaaat	1740
aaattattat	taaaagcaaa	aaaaaaaaa				1768

<210> 31
 <211> 975
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (401)
 <223> n equals a,t,g, or c

<400> 31
 ggctgcagga attcggcacg agcttcaatg aaatttatag aaaagactct cacaagtacc 60
 attgaatata gttttctgat gattttgaga tcgtagtatt tgactgggta agaattccga 120
 acttcagtga aaaaactgaa ctcaaaaaac tactaaccga acatcaagca gaataagaat 180
 tattacatgg gactaaagca atgaaagatt atgattttat gacttttttg tttggcacat 240
 ggcttattct ttcattgttc attttccaca ttaatttttt ttttctttca gctatctaca 300
 gtttacggga atattgggaag gtgtactttt gtgtgcagaa ttgaaatttt ttttctccc 360
 tacctgatcc ctccagagtt tggagactat ttgtgagtat ncttatttca ataacaatat 420
 agttatttgc ttacatttaa gaagaatcta ttctctttct aataggacac aattggaaac 480
 attggccata ttaccaaggc ttgtcctgac atgtcctatt ctgagatatg accagattgc 540
 tctaaggaat taaagttgac ttataaaagc caattaaaac cccttggaat atctatcttg 600
 atatcttga taaataatta acatgggtga ttacaggtg agaaaaaatg tcacttcctg 660
 agaggccctg gaacctgaat atatttttgg gaaccttgag aagagaagta ttcactcaag 720
 tttaaaggta ttacaggcac aatttgaggg tgactcctcc ttggattggc tcccagcct 780
 caagaggctt tcaaaagttt aatctgagat tccttgtgaa aagttccagc aaagcaaat 840
 tgaaaatgag cttatatgat taatcatcat ttgtgtgtac ttctgtaaat tattaggcaa 900
 agtataacaa gcctaaaact tattttgcaa acaaattagt tttattgtga ttaactttgg 960
 taaaaagggg ggaac 975

<210> 32
 <211> 1048
 <212> DNA
 <213> Homo sapiens

<400> 32
 tgcaggaatt cggcacgagc caccacccca gccattatc tctattgatc ctcaactcaa 60
 ccttgcaaaa taggtagcgt attccagtgg agaaactgag gcacaaagag gtgaaagacc 120
 tttcctgtca cagttaggaa agtggcagaa gccgtatttg aaccacagca ggtctccctc 180
 tgaagtccac acacgtcagc gcctctgtgt tgtctctttg ccagcacagg gctccctgga 240
 gccagagat gggggtggtg acttgaaagg gttggcaagc ctgggctcct ccagcgaaaa 300
 ttcccttggc cctgggcatt cctaagcgag aagaggctca atcctatttt ctctcctaa 360
 ttggatgcct tttattcctc ctccctaatt gaagtctggt cattgctggt tgccatggca 420
 gcagccaaaag cgctcatctc actgtggctt gtctctgcct gcggccaatg ggaaacctcc 480
 tttcccatat acggtgggga catggagtgt caggctgtcg tattctggtg gctggaggag 540
 gagaggaagt gagatgggag gaaaaaggcc tgcctctcc cagcagaga ctccggacag 600
 caggatgtgt ggaatcccca gtctgttttc agccaggcag caacagcatc tgtactgagt 660
 tgagtctatg tgtctaccag tgggctaaga acttcatgtg cagtatctca tttaatcttc 720
 gtgatggccc caggaagata agggatcaag gccagaaaag gctaagtaag ctgccaggtc 780
 atccaaggag aaaatggcaa agcctggatt tgaacagaga ctccagcttc cttatgtgta 840

gccatctcac	catgctactt	ctcagggggt	tactatgagt	gtctctcatg	tccccagacc	900
cagattacag	gtttggagga	atacacagcc	caccttccca	atategcagg	caacagttcc	960
accaaagtc	ctgcatggca	tcacagggag	cctagttgcc	cactgctcta	ctgctgagct	1020
caatgccacc	cagcccgggc	tctctcga				1048

<210> 33
 <211> 1120
 <212> DNA
 <213> Homo sapiens

<400> 33						
gggctgcagg	aattcggcac	gaggcagcag	agagagcctg	ggttggagcc	atgaggctgc	60
ccctgcgtca	ctctgcctcc	ttggaagctt	ctgtgtctcg	ggttcttcat	acgcccagtg	120
gcagggatgg	accaggcacc	ccttgcaatc	cttctggaca	aatgtgccac	tgtcctatga	180
aaataaaagg	acaccactca	agctccagga	ggcagaacct	taactcaaat	ctgagccaat	240
aaacaatgtc	actctagcac	caaagtctat	ttcaaaatgc	aaactatttg	aaatatctta	300
tttttggtaa	atgctttatt	ttggaaatgg	gtttttgttg	ttgtttccct	gaagagagtt	360
cagatcagca	aagcaagtag	ctttggagaa	gacaccttta	gacgaggact	cctgtgaatc	420
agcaggacag	cgtagaggga	cattaggtga	gccacagggt	ggagcaggat	gggagggcag	480
aggcttctgc	ttcagaattg	aagccgaagg	aaagtaatgc	tgtgggtgtt	actggagaca	540
aaaggaacca	aacaagaaaa	atctggagag	gcaaagtgtg	atgtcttaat	agatttgggg	600
gtcacactct	ttaaaaatgg	gtcccaaagc	aaagctctca	aaacttcatt	aaaagaaaa	660
tcttacattt	gacaagtga	ctggacagag	gagctaccag	gacattggcc	cccttgctgt	720
gcacctgcac	tgtgcatcac	agctcacgtc	gtgtttgtta	cactttgtca	cctcacattt	780
tattataaag	gtcattcccc	tgttaaaaa	agagcgcggt	atgacagcgc	ctagtgaatt	840
gtagtgtctt	tagggaggaa	caaaaatgga	cataaatgaa	tacaaagaaa	agattacctg	900
aaactgggag	caaatcaaag	taaaaatgta	gggatagggt	gttgctttct	tttaaaaaga	960
taatgctgtc	aggattaaag	tgagaagaat	ttaattttca	tttcagcctg	aacactagtt	1020
ttactttcag	aaaggttctt	ggtgccaaagc	tgtgacactt	ttgcctttgt	gggtatacac	1080
acttggtacc	cttgcttagc	actgtggaag	aggaagtctc			1120

<210> 34
 <211> 1068
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1060)
 <223> n equals a,t,g, or c

<400> 34						
gctttgaccg	gacagacaga	tacttagata	gctggcaaaa	cattatttct	aggtatgttt	60
gtgaatattt	ttccagaaaa	gtttaatatt	taaatcagta	aactcagtag	acaaaaccta	120
ccctggacaa	cgcgagtga	cctcgtccaa	tcccttgagg	ccccagaaga	ataaaaaaag	180
aggaagggtg	catttactct	ctcttcagtt	ggaacatcta	tgtctccttg	cctcagacat	240
tggacatgga	atctcctggt	tctcaggcct	ttggcctcca	tggttacacc	agcaccaccac	300
ctggttcgca	ggccatcagt	ctcagactaa	attacagcac	tgggtttcct	atttctccac	360
tgtgacggc	atgccttggg	gctttgggct	tctataatta	tatgagccag	ttcccataaa	420

caatcacttc	tcatatatct	atatatacct	attggttctg	tttttctgaa	gaccctaata	480
cagccccata	gcactatatt	tttatttttt	ctaaaacatt	taaacagcct	atttttttag	540
agtcatttat	gtaggtatcc	aattctctca	tgaacgcctc	aaggccagaa	attcaatcca	600
ttttawtttt	gccattgccg	cagaggaggc	acactgtagc	tagtcaataa	gtggttgtag	660
aaggaattga	gactgataga	tctataaacc	cactttctgt	ggtacatgca	gtctatatcc	720
aatattccgt	gcagcttact	ccacaagtga	gaggagggtc	taagcttttg	agcataggga	780
tggttttaga	aaataattac	atttaaaaag	caaaatggag	acctgttgag	aataaataaa	840
gtcttgtttc	ttatagttgt	gaatctttta	tatcaagact	tcacctgaaa	aactgctaga	900
ttgtgcttca	aagcactgta	agttctagcc	ctggttctat	aatgttatct	aagatattta	960
tcatcattga	gttctctgga	ctcaatgttc	ttatccgaaa	attgaaggag	tcagatataa	1020
tcatttttaa	aatgttttcc	aaaccaacat	cctaaagtcn	actctcga		1068

<210> 35

<211> 1272

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1209)

<223> n equals a,t,g, or c

<400> 35

ggaactttta	aaactcctca	gagaatgaga	gaaaacttta	ccgcgaaggt	gtggctggcc	60
attcctttcc	tcgcgttggg	gtttctctgt	gtcagcgagc	ctcggtacac	tgatttccga	120
tcaaaagaat	catcatcttt	acctttgggg	aaaacaggaa	gagggatggg	gctttatcaa	180
tcacatactt	agcccaaaca	agtgccttgg	cctcctcaga	aatttaaaaag	gtagaaaaaa	240
atggacatat	ccccttttta	gaagcttcca	catcacatat	ttttyaaaaa	gtattttacat	300
ttcagctgtc	atgcaaatac	acagttttgc	caacttcttt	ctcctttgct	ctggcactgg	360
cattaacatt	cttcctcact	gtggccctgg	aaatcctcac	actaatgaag	cagcagaaaag	420
gcccatacaca	ctgcactggg	gtgtggtctt	cgcatttcct	tgactttctt	ttcttttttg	480
ttctttcttt	tttttttttt	tgagacaaaag	tcttgctctg	tcaccagggc	tggagtgtctg	540
tggcgcaatc	ttggcttaac	tgcaacctct	gcctcggtt	caagtgatcc	ttctgcctca	600
gcctcccaag	tagctgggac	tacaggttca	caccaccatg	cctggctaaw	ttwtgtattt	660
tttagtagag	atgggggttt	accatgttgg	ccaggctggg	ctcgaactcc	tgacttcaag	720
tgatccgccc	gccttggcct	cctgaaatgc	tgggaattata	ggtgtgagcc	accatgcctg	780
gcttccttgc	ctttcctttg	tgagacacgg	caacagccca	aggggtctca	gatgctgacc	840
ctcagcagag	ggcacctcct	ggggccatgg	ctgtgtagct	gggggcatct	ggcctcacat	900
cctagttgag	tgttggtgtc	caggtggctg	gtgcaggcac	ccgcccttct	tcacttttgc	960
atgtcttctg	tggcctgcct	gactggagcc	agttgtcagg	gtccttgaga	gctgactgtg	1020
ggcacctctt	cctgacccca	cgctcgggtga	catcagctgg	gagcttgcca	tcagccaggg	1080
tgggagcatt	tacgccacag	aacctggcac	atgtacagg	ccaggacttt	gtccttttcc	1140
ttttctggga	gttggtctag	cagcgtgtct	ctgttggtct	gttccccctt	ctgcagggtc	1200
atgtggccnt	gcctgccggc	cctccgtccc	cgctccagga	ctaacctctg	tggagggaat	1260
cacctaactc	ga					1272

<210> 36

<211> 536

<212> DNA

<213> Homo sapiens

<400> 36

tgcaggaatt	cggcacgagg	taactctgag	ccagtggccc	ccaaggtggc	agaacaggtg	60
tcagccacat	ctagaaggag	gcctagggac	ctgcaggggtg	ccacccttgg	tgaggcggct	120
gtgggccacc	cttggtgagg	cggctgtggg	ctgtgggtga	ggcagcccct	tggtgagggg	180
ctgggaggag	tgggcttctc	tcggcctggc	tgggagtcca	ggtgccaggg	tcactaagac	240
aggcctggca	tgcgggtgtg	gaggctggca	tggtttgctt	gggcatgggt	ggggcatggg	300
acaagctgca	caggtgtgca	gagcactctc	cacatagtca	ctccctctta	ggaaaagact	360
ccttcctcca	cttgagaggg	catcaggcca	gcagggacca	gacgttcgcc	taatccagag	420
gctgtccccc	accagataag	ggcgtagcca	ggcatgctgt	ttaccatccg	tcctcaccaa	480
ggactctgtg	gccataaaaa	gagcagggct	tcaccagctc	gagggggggc	ccggtg	536

<210> 37

<211> 393

<212> DNA

<213> Homo sapiens

<400> 37

aattcggcac	gagctcacct	gtccactagc	agctggacgg	gaaaatggca	aggggtcatt	60
tcctgtactg	taccgtgagg	cagtgattag	ctacgtgtgg	ctcgtccaac	tagagatgtg	120
ctgtgagtg	aagatgcaca	ctggatttct	aaaactttgt	gcaaagaaaa	gggaaatata	180
taattagtaa	tttcatatgg	attctgtgtt	gaaatgacaa	tatttttaggt	ttttgagcta	240
agtaaaaata	cattatgaaa	attagtttca	ccttttttat	tctacttctt	aaaaatgtgc	300
ttgctgctag	aaaattttaa	atgatagatg	tggcccatat	tatgtttctg	tgtgatagac	360
tgctctggat	caagagtcgg	caaactatgg	ccc			393

<210> 38

<211> 688

<212> DNA

<213> Homo sapiens

<400> 38

ggcacgagca	gggagaatga	gactgagaga	caggagggca	ggagaaggte	agagacaact	60
tttgcttctg	aggctgctgc	tgaggacttc	attttggggc	gttgttttct	gagccccaac	120
agaaggaagg	aagcctctcc	ctccaggggt	cagtcctggg	cctcaagggc	accctcgaag	180
caggcagctc	agctcacaga	gctcccctcg	gccatgtcct	ccacctgccc	ttcctttgtc	240
cagcacctca	cctgcacaca	cctgtctgga	gagtccccaa	ggttgagag	ctgctgagtc	300
agctgggccc	agcacacagc	gcaacacttc	cttgtgcctc	ctaaccagga	tgggcgacac	360
cagcccattt	tatggatggg	acaagaagaa	gctgggctga	caagcccaac	atagtggagc	420
cagcaacagg	cttttactct	cctctctgtc	tctttgtctc	tctcctccac	cgcacctcca	480
tccgctccat	tctcctctct	gcacatcagc	ttcccagaca	atattcttgg	tttctgtggc	540
tcccaaactg	aagcttcccc	acagtggctg	caactatcca	gacctggggc	cacacttggg	600
cctccaggca	ggggatctag	tgatcacttt	ctggctatgt	catcaggcca	acttggctga	660
gctctgccct	ccttatctct	cctctccc				688

<210> 39

<211> 1430

<212> DNA

<213> Homo sapiens

<400> 39

gcagcctcca	gagtaaagt	aaggcgcaaa	gcctcatgca	aacatcgagg	aatgccttca	60
ttgtttcgag	gtctctcttc	ctggcctccc	aagcccactc	cctgccccaa	gtgccaccct	120
tccctggcac	ctgatccctg	aggacgttgg	gtcctggggg	gggggacctt	gggctcttcc	180
tctgggtccc	aggagccccc	tccccactct	gtggcccccag	ctccagactt	ggcaaggcaa	240
gccggagtga	ggtttctcca	ctccctccca	agtgtctgtc	tggcggctcc	cgaaataaaa	300
atcaaagtgt	ggcttggtcaa	agggagcggg	gtgggagaag	cagcggcagc	agggctgggg	360
cttcattctt	tccattgtaa	cttcacctcc	taacctctgg	cattttaatt	atgtctccta	420
ccccctcac	tctgcctggg	ccaggggggt	agctcacctc	tccctctagc	ctgggagggg	480
gcagctgctg	cctggacccc	cagtccccgg	cctgtctcgg	ggaatctggg	tggcggccat	540
gctgggggtg	tggcctcag	gtccctccca	gcttctccag	tctcagaggg	gcctggagag	600
gggcccagcc	cccagacagc	cagccgacac	ctcaagttcc	atgtgtgaat	cattagtctt	660
cacaccact	gctccattta	gtggtggcca	ctgtcctaag	gcaaggcacg	gcaggtcac	720
cagcccattc	tatggatgac	ttagccatca	tcgtctgcag	ggccaagcct	gggcccaggc	780
ctatcgctct	tggttctgca	ctctttccaa	acccaggaag	acgggcaaga	acagctcagg	840
cctgataatt	tgccttatct	cttcgagtgt	ccgttttttt	ccaatggtaa	gtgatggaaa	900
gcattatttt	gatactaaaa	catacaagga	catagcatgg	ggtagggaag	aaaatgcctg	960
tgaagtttca	aggtagaaaa	caaatcctca	aggaagatct	cgtggggctc	tctgcaggcg	1020
ggccccaggg	agtagcatcc	tcctccttgg	catggctgtg	gactggagtg	agatgcagtc	1080
atatgtgttt	gtagccagtt	tgtgcagacc	caaggctgct	gtggaagatg	ccagtgggtg	1140
ctgggtgctg	ggtgctggca	ggcagccttg	gcccacccca	ggatgcagag	gccttcttcc	1200
ctccaaggcc	cacagtggga	gtcctgccga	ctctctccgt	ctcctgggga	gggaaacctc	1260
cacaggacaa	gcagcctgtg	tgggggtggg	ggctgcctcc	acggacagtg	caggcacagg	1320
gcaaccttga	ctgtgagccc	agggccagca	cccaaccacc	ccaactgagg	cttcctctcc	1380
atcctctggg	aggtcccccg	ccacactgcc	ttagaggccc	agcccctcga		1430

<210> 40

<211> 1117

<212> DNA

<213> Homo sapiens

<400> 40

gggtgtgtgg	ctcagacact	tgtgtcctca	cctgccacag	tgggaatgct	ttgtgcggga	60
aatccagaag	ttgcaacagg	aagacaagt	ccagaagaac	aagctggaca	gctacttttg	120
ggaaaatgga	ttcaggaggg	aggagacatg	atagcaaac	cacgtatgtg	tttgacactt	180
tgagctatgt	gcatgcttca	tcttgataaa	gataaaacct	ttaaaaaaat	cacttaagta	240
gtatagaaa	tataaaataa	agtttatcag	ctattatact	aaataatact	gaatgcaagc	300
tctatatttt	actaagtgt	aatgggctga	atttgactgt	ttaagaacag	tttatcagat	360
tggattattc	aacctgtatt	tatcattttt	gctacaagca	tctattgccc	tttcttctag	420
taaagtacct	gatttggatt	tgcggatttc	cccggttaga	tgagattggc	agaactgctc	480
atcaaagttc	acggctctcc	aagaaactga	catgtgactc	taagctatgc	cattaggacg	540
tctgcttcct	agacttttat	tcttcctcat	agtacatac	agactgggag	tactcgggac	600
tgagtcatcc	cagctattac	aatatgagga	aactgtccat	ctgttctgcc	acctggacct	660
cttcgctacc	catttgctct	actttcttta	ctggaaaatt	ttcctactgg	ttctatctta	720
cgaattcctt	ttctgtttta	actagttagt	ctatttcagt	tgcctatagc	caatgaactc	780
taactgatac	agttgaaacc	tccaataaga	ttcagctgga	taagagaaaa	agaaagatta	840
aaatgaaagg	tgtgtgtata	aatgtatgta	agtaagcaag	caagataggt	aaaaacaaaa	900

agaaagcaga	acttaaaatc	cacaaaacag	aattttaagtt	gaaaggcatt	agaaacaaac	960
agggtcatta	tgaaatgata	aaatatatga	ttcataagga	agatgtaaca	gtctaggatg	1020
aaaaacaaaa	acaaaaacaa	aaaaacccta	gcaaacagaa	cctcccagtc	tcagcagtca	1080
aatacaattg	cataaaaaaa	aaaaaaaaaa	actcgag			1117

<210> 41

<211> 1860

<212> DNA

<213> Homo sapiens

<400> 41

gtaaatactg	aaatgtcaaa	gtgaaatctc	ctaactacat	ctcactatag	ccacagattt	60
ccaacattac	ttcatttttg	ttatactttg	gatgactttt	taccagact	cctttgtccc	120
atTTTTTaaa	aggacagaca	cggtagattg	agcttaattt	taatgttctc	tctaaaaatgc	180
taataattat	ggctcaatta	ttacagtggg	tttcttggtg	gagttttctc	ccttttagctg	240
ctctaaattg	tgagtggat	agagtcacag	agcttacttg	attattcacc	cagtccactg	300
ctgatgctac	gtgtttcttc	aggacctgtc	ctttagaata	cttcccagag	gcaagcacat	360
ggttgcctat	attaaagcca	cctgtatata	acttgctaa	tcctcttgt	caacacttgc	420
cctcattgtg	actacagaat	cactttttct	agtttttaaa	attgttatcg	taagactgtg	480
cttggaata	ttcccaggga	ttagtatgat	gattttgttg	gggtggttg	agatacattt	540
gccaatgctg	caatgttaaa	atttccatga	caacttataa	aataaatact	ttgatctctt	600
tatcagccat	caatgttaac	atataaaatc	agctgaatta	aagttaagac	tatgtaaaca	660
gatgactaga	accycttctt	aagtaaaaat	atgtgggtgg	ycccttaatt	acktgycatt	720
ggaaatttgt	aatycttttc	aattttctga	acatatgcac	aattttacta	ttctaaaaaa	780
ataactattc	ataactactc	acttattttc	tcctttcacg	cacttctaata	ttttggaaga	840
agtgatggc	atttgttccc	tataactctt	gccatctata	tccacctgga	tccgtagcaa	900
tttggttctt	atctgaacta	ctacgatgaa	ctgcactcaa	aattacattt	gatgtgatac	960
acacagtaac	tcaattcttt	ctttgctttc	atcttttgca	atcatctacc	tccctatgca	1020
gtctggacaa	atactgtcaa	attcctaaca	gcacatcat	tagcactgtt	gaaatccttc	1080
catcatttag	tagatgctaa	gcctgtgttg	tccttcattg	scctgagatg	ctatgcagtt	1140
tatctgcttg	cacacttcag	atgcaaaaaca	tagatgggaa	aagtaaggaa	gcatactgat	1200
ttgcattcct	acataattgt	atgctttact	gtttctcctg	atgcttctgc	ttccaattgc	1260
catcttcacc	ttcgtcatct	ctagcttcct	actttactct	cctcagtcac	tgttcattct	1320
tagcctctga	tttctatcac	ttcttttgct	gtccaatttg	tgcttmatmw	atttctttcc	1380
tcaaatacct	ctccagcatc	attatgtc	aaaattattt	gccctgagaa	tctcttgctc	1440
ttcccctgct	ttgtgctgca	gggagactga	ttcttatctc	actgtgtcag	ctgcattcca	1500
gccagagtcc	acatatgagt	ggctctggta	agagattgga	aggccgaaga	ttctggtagt	1560
tttcttgctca	gtggctgtct	cttctcctac	ctactgtctc	tacaagaaag	gcctgcaaag	1620
gtttacactc	ctgctatgtg	acatctgagc	ttctggtaaa	tctcattctc	cccttgctccc	1680
tctgtctggg	agtggaaatgt	ttcctgacat	cgctagtctg	tgtgtggctt	cactgttgat	1740
ttgactgctt	tcacttttct	gtcatcagta	taaccaaaac	cctgcagaaa	actgcctctg	1800
ttgtaaatac	ttaaggtggg	ttttgttctt	ggttggatcc	ttaagaacac	aaaatcattc	1860

<210> 42

<211> 455

<212> DNA

<213> Homo sapiens

<400> 42

ccccgggct	gcaggaattc	ggcacgaggt	tttattagtt	tccttggatt	gggtttcaac	60
cttctcctgt	atctcactgg	gcttctccgc	catccagatt	ctgattctgt	gtctgtcatt	120
tcggacattt	catttctggg	ggagttattg	aggtagtttg	tggaggtaag	aagacactct	180
ggcttttaga	gttgccagaa	ttcttgtgct	ggttctttct	catctgtgtt	cactgatttt	240
cctttacttt	ttgacattgc	tgtccttttg	atgaagctat	ttgcttttat	attctttgat	300
gttcttgagg	gtttgaaggc	agtataaatt	gtgtttagtt	gattgacttc	atttctggat	360
gctttcagga	ggccaaggct	cagcttagca	ctcctgagct	tcatgctaatt	gccttgggga	420
ctgggactgg	gcatatggct	ttgttctttg	acctc			455

<210> 43

<211> 1040

<212> DNA

<213> Homo sapiens

<400> 43

gtgattgtct	ctttctgttt	tgagttttgt	ttgcgtgtat	catttttgtt	ctacattttg	60
ggaggggaaa	cattttccgt	taaggaagg	tggtgccagt	ggatttgact	ccaagggact	120
agagtgtcgt	ggtgggggtg	gggaggggct	gcagggtgat	cattggctac	tgagcctcca	180
caragagcat	gtggtgccct	gcctttggga	gggtattttg	ctctcgttag	ttttgtgggc	240
agcctcagat	tccctgttga	gttgctgtta	agaaatggag	atttctggct	ctcattgggt	300
aagggttttct	gagttttata	tcttattaga	tcacatccct	ttaccagaa	caaagtcttc	360
actgtcttct	gattggcagt	actcctgttg	ctttgtgcct	tgactcattt	tggtgtcttc	420
agccttgaag	gccccttccc	acatggactg	acatccactc	atgtgcctga	tccctgaagc	480
ctcccagcac	ccattcagtt	gcatccccag	ggcacaggac	tttgatctct	tctgttgccc	540
tcgctagggt	ctccctgggtg	ggtagtgct	ttgtatctgt	ctctctgccc	ctcactaatt	600
ctacacccat	gagaattaga	cattattctc	cttaaatata	taaggacat	ataatctgta	660
tcttttttgt	gtgtgtatat	ggtatctggc	acatggatct	ctgattacca	gcctgacayc	720
aacaaatccc	ctcagttaca	acgtataggt	taaacaaagc	ttttaaaagc	tcagtgtgta	780
tgacctcaag	gttgctaacc	tggtcactca	tggttaattag	aaactctgat	tggcagcttt	840
gtatttcttg	actaaaaacc	taaataaact	gattaggttt	taggcgttct	ttcaaagagg	900
ttcttgagaa	gattgagaac	tatcctatct	gggtgcttagt	gaaaagattt	tgaattactg	960
tacgtaccag	ttgttgccat	ttctttatta	aattcagaag	tttttttgcc	aaaaaaaaaa	1020
aaaaaaaaaa	aactcgagcc					1040

<210> 44

<211> 3511

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (779)

<223> n equals a,t,g, or c

<400> 44

caccaagtgc	tcctccaccc	ctgataactt	gagccggact	cagtcaggct	ccagccttgc	60
cttgccctct	gcggcgacga	cagaaccgga	gagcgttcat	tccgggggca	caccctctca	120
gcgagtggaa	tcgatggaag	ccctgcccac	actgagccgt	aacccaagca	ggagcacaga	180
ccgagactgg	gagaccgcgt	cgscgrcatc	ttccctggcc	tcagtggccg	agtacacagg	240

tcccaagctc	tttaaggagc	ccagtagtaa	atcaaacaag	ccgattattc	acaatgccat	300
atcccattgc	tgcttggtgc	gaaaagtga	cgaacccac	aagaattcca	tattggagga	360
gctggagaag	tgtgatgcca	atcactacat	catactgttt	cgtgatgctg	gctgccagtt	420
cagggcgctt	tactgctact	atcctgatac	tgaggaaatc	tacaaactca	ctggcacggg	480
gcaaagaac	atcaccaaga	aaatgatcga	caaactgtat	aaatacagct	cagaccgaaa	540
acagtttaac	ttgatcccag	ccaaaaccat	gtctgtcagt	gtggacgcac	tcacaatcca	600
caaccacctg	tggcagccca	agcggcctgc	agtgccaaa	aaggcccaga	ctcgtaaatg	660
accccggtgc	agctggcgct	caaaggggtg	cccagactcg	taaatgatgc	ccttgtggct	720
ggcatccaga	gggtgccacg	gggtccttat	ttattgtttt	catctatttg	ggtacgaant	780
gtgcaaagtc	acagaccttt	tgcaaagagg	tttctagaca	gcagaagaaa	acccctctct	840
cagcgctcat	ctcacgcaga	ggatgccagg	caggggtgag	atgggggagt	agatgccgct	900
tttgcaagtg	ctcgcactgc	tgtggccact	gctgaccact	gaggctccca	gcggagggtg	960
ttcacagcca	ggtcccgggc	cacggagctc	ccttacttga	agttctcctt	cagcatagat	1020
tagacgtgat	ccactttgct	ttcttgcttc	tcacctcgcc	cccttgaca	ttgcctgaca	1080
ccctcatatt	ggccagctgt	aatctcgtga	ctatgggact	gaggctcaat	cttggcttgg	1140
ggtgtttgaa	tgtctatagc	aaaggaattc	ataatgggaa	atctttttca	tttgagaaat	1200
tgtatgatat	ttattggttg	tgtctactgc	caacatttat	atccaattct	aagatttctg	1260
aaaaaaaaatt	cttatccctt	gctgtctaga	aaaagtttac	ggaaaacacc	agttcactaa	1320
aagcaccgaa	atctgcaaa	cctgtcttcc	gctagaacaa	cgtctacaaa	tgtgaagatg	1380
atgacttctg	gcacgcggtc	atgaggggtg	ggaatggcac	taggagctga	tgtttgccct	1440
atttaaagta	ggcaagccga	gccaactgca	gccatcattc	attaagtttt	gggtagtgtc	1500
ctaatggttt	gttcacttta	ataaagacag	attttggtaa	agtagaatat	ttttcattct	1560
gagcatgttt	gtcccaaaag	gtgatgcact	taagctgaca	gtcccttcag	tggttttggt	1620
aggtcacggc	ttgtcctgtc	tggattctgc	atctggaagc	gctgcatgct	ctcagaggag	1680
cgtgccgttt	cccctgtaga	tggatacttt	tgttttgttg	cctattttaa	aacaattaag	1740
tggttatttg	cagttatttc	agaactccaa	gtaagtggat	ggctttgggt	tctttctgcc	1800
ttggtcccaa	tggtgttgat	gcttctgtgg	agcgcggaca	ttcccaggag	caggtgcgtg	1860
ccagccatgc	tgccagacac	tgtctgcaact	gaccagctgc	cggaagattc	tggagccact	1920
aacattagtt	ttgcacatat	tttcttgga	gtgttacttg	aatctatctc	aaactgcaga	1980
aaaaatcaaa	agatcaataa	ttgggagaaa	aagagacaaa	tttaactgtt	acataatttt	2040
agatagacaa	aaaacatgag	tgagtcgtgt	acataaggag	ggaacatggt	acagaaggct	2100
agaaggaatt	ataggtctta	ttcccccttc	ctcagtcctt	tgaagagaag	tacagtctct	2160
tgcgattttg	tatatatcgt	gttcgacaca	gccgctctct	gtcctgtaaa	tagggaacta	2220
aaggctgtat	gattttctca	gtgctgagtt	acacagtcct	gagtgagctt	tctgttacca	2280
tactttcaca	cgtgggcttt	atttctcact	gtatgtttga	tatgatatta	ctgtatttat	2340
tttaagaaag	cactaagatg	taataaagtg	atgaactaat	ttgctttaca	ttgaatcgta	2400
tgtgtgaggt	tgctgtggct	catttcgctg	accaggcgac	accaactcct	tgctttatag	2460
gagtttcaca	ttgttcttta	ccatggccct	atcgaagtca	gtggaattgg	attcttttta	2520
atgaagagct	agaaaatatc	tggcatagag	ctggaaaatt	gcattcccat	gggacgtctg	2580
aatcaattct	ggattttctc	catggaatga	gtcagtggtg	ggaacatcct	gaaacttgct	2640
cttaagcgtg	tagttttcac	tgttcgttgc	gagtaagcac	taatgtggca	tggacattcc	2700
tgatgtccca	agtccccagg	ccagtgttcg	cctaattgatt	gacagaagcg	tccckgcgtt	2760
cttcakgctt	ggacacagca	acccttttaa	ttagtcttga	aaagtttcag	acacaggatt	2820
aattttcgtg	gtggtgcttt	tgggcctttc	tggcttgggt	ggtggtaaa	tcatgatttt	2880
gcagttgata	acactgactt	ataactctgt	ttatcaatgt	ctcctatatt	caaagcccct	2940
gcagtggtat	ttgtgtctcg	ttgcaaattt	ctttcagcgg	aaagcttgca	caactttcgt	3000
tgtgtctcag	aattctaacc	ttgttattta	agacaagctg	ctctacccat	ttaggataata	3060
actttgtaaa	gaaagtgtaa	acccaaaakga	ttcaatgtat	ggatgaagtt	tatgtgtaaa	3120
tccttggtaa	tgctagaawt	ctgggagccc	cagaaggggt	gaaagagaaa	tgaaacttgc	3180
gtgagtccca	ttatttttac	catgtatgtg	cagatacggt	ctaccacac	gtgtgcgtgc	3240
acatggctgt	gtgcgtgcac	caaagatgga	ctgctttcca	tgtgtccttt	tgactttctg	3300

cacgtgtcac	gcggtgcagt	ctcttagcag	acttcaggcc	caaactgtat	tcttcactca	3360
ggcaaaattg	aaaagtggaa	taattctaaa	ttacttctag	gttatacttt	tacctccctg	3420
aaattgtagt	gtgcacttgg	agggcaaaat	atttattgaa	ataaaatfff	ctgttaaaaa	3480
ttcaaaaaaa	aaaaaaaaaa	aaaaaaaaatt	c			3511

<210> 45

<211> 1530

<212> DNA

<213> Homo sapiens

<400> 45

gaggggcact	ctcccagctg	agccccgata	tgagggtgtg	ggagcccagc	atgggagcag	60
ggctgagccc	agataccact	gcctgcaagc	ctcagtggct	tgcgccact	gccctgtctg	120
cgcctcagtg	tccctatctt	taaaattcag	agattgaatt	gggggctcta	gcaaacacag	180
tggacctggg	gatggctggg	ctggcccggg	ccgaaggatg	tttcccggcc	ggctgtgcct	240
cctctgtccc	catccctccc	tcggaagccc	agagtgcagt	tttccaatat	acccagcct	300
catgtggggg	cactggggac	aacacacagg	gaggcaaggc	cctgtccctt	ccaccagtct	360
ctcccactgt	ggctgcccga	gtctgtcctg	gaactggcag	aggaagacat	tagggcagac	420
gtcaggggag	gggggggtcac	cgtccactgt	catggcccct	ctcccaccc	ccctcactgc	480
tctggggggc	tcacaccttc	ccttccgctg	cctctcctgc	ctggatgcct	gcctcttcct	540
gtgggggttat	ctaaactctg	cccaccctat	aggggccagc	tagaccctc	ctcctcagcc	600
ccaaagagga	gcttggggtcc	ggctcacagg	cgaggggagc	ctggaagccg	tgagtcctga	660
ggaactaact	gctgggcaga	agggaggcaa	ccggggctga	gtaaccgaga	tcctgagact	720
ccagggtctc	ccaccacaga	acagccccag	gagtcctagc	catgtgggtg	gggtagagct	780
atgtggacca	gcctccatgg	ctcagtttcc	ccactggctc	ctgtgcaccc	ccatggcccg	840
gagcagggag	cggaggagtg	gtcctctctg	cctcagtttc	cccaccggct	cctgggcacc	900
cctcatggcc	cagagcaggg	agcagaggag	tggtcctctc	tgctgactc	agtttcccca	960
ctggtcctctg	tgacccctc	gcggcccggg	gcagggagca	gagcagtggg	cctccgccgc	1020
cccctctgaa	ggtccctcaa	gccctgctgg	acccctcct	gcctcagcct	gggttcacgc	1080
tcttctccaa	gaccaagacc	ccagctgccc	caggacagct	ctacaggtgt	ggaggcctgg	1140
tccagccaca	gtccagctt	acttgctgtg	tgacctcggg	cgatgctgga	cccttctgga	1200
aaatggaccg	gctggaccat	cttcaggggc	tggaaccggc	gatctccgag	ggaaaggagg	1260
cacatttatt	tgtgagacca	ttgtctttcc	atctggggat	gccagctcca	aggcagccag	1320
gtcctctctg	gctttgtccc	aggctccagg	tagggcacac	agttggccct	tgtctgccat	1380
cagcgtcccc	aggggtggtct	ctcacctccc	gccctccctc	cccaggaggc	tggaagaggt	1440
gggacagaac	caggtctcaa	tccaccagcc	ttgggaaagg	gacatccggg	gcagggcgcg	1500
gggagggggg	gcacgggtgct	gcctcgaggg				1530

<210> 46

<211> 1652

<212> DNA

<213> Homo sapiens

<400> 46

gggcagcttc	tggggacagc	cacaaggagg	gtaccagggg	tccccgccg	ctgcctacag	60
acatgcgcca	gatcagccag	gactttagcg	agctaagcac	ccagctgacg	ggtgtggccc	120
gggacctgca	ggaggagatg	ctgccaggaa	gctctgagga	ttggctggaa	ccccagggg	180
cagttgggag	accagccaca	gagcccccca	gggagggcac	aaccgagggg	gatgaggagg	240
atgccacgga	ggcatggcgc	ctgcaccaga	agcatgtctt	tgtgctgagt	gaggcagggg	300

```

agcctgtgta ctcccgctat ggggtctgagg aggcactttc cagcactatg ggtgttatgg 360
tgcccttggg gtccttcctg gaggcagaca agaacgccat ccgctccatc catgcagatg 420
gctacaagggt agtattcgtg cgccggagcc cgctggtgct agtggcgggt gctcgtacgc 480
ggcagtcggc acaagagctg gcgcaggagc tgctctacat ctactaccag atcctaagcc 540
ttcttaccgg tgcgcagctg agccacatct tccagcagaa gcagaactat gatttgccgc 600
gcctactctc ggggtcagag cgcatacccg acaacctgct gcagctcatg gcacgagacc 660
ccagcttcct gatgggggag gcacgggtgc tgcccttggc ggccggccgtg cgcgacactg 720
tgagcgccag cctgcagcag gcgcgtgccc gcagcctggt cttctccatc ctgctggccc 780
gcaaccagct cgtggcactc gtgcgcgcaa aggaccaatt tctgcacccc atcgacctgc 840
acctgctctt caacctcatt agttcctcct cgtcctttcg cgagggcgag gcctggacgc 900
ccgtgtgcct gcccaaattc aacgcagccg gcttcttcca cgcacacatc tcttacctag 960
agcctgacac tgacctctgc ctgctgcttg tctccactga ccgtgaggac ttctttgca 1020
tctctgactg ccgcgcgcgc ttccaggagc gccttcgcaa gcgcggagcc cacctggccc 1080
tgcgagaggc actgcgcaca ccctactaca gcgttgccca agtgggcatc cctgacctgc 1140
gtcacttcct ctataagtca aagagctcgg gactcttcac cagccctgag attgaggccc 1200
catacaccag tgaagaggag caggagcggc tgctgggcct ctaccagtac ttgcacagtc 1260
gtgcccacaa tgcctctcgc ccactcaaga ccatttacta cacgggcccc aacgagaacc 1320
tcctggcctg ggtgacaggc gcctttgagc tctacatgtg ttacagcccc ctggggacca 1380
aggcgtcagc cgtcagtgcc atccataagc tgatgcgctg gatccgcaa gaggaagacc 1440
gcctcttcat tctcacgccc ctcacctatt gatgggaatg tgtgcgggct cagccttcct 1500
ggacacacta ggtgtgggaa gccataggag cctccagatg ggggctggcc tctcttgccc 1560
agccagcggg cagggactgt ggggttgtga atgcattaaa gtgctttggg gaagacaaaa 1620
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1652

```

<210> 47

<211> 1178

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (138)

<223> n equals a,t,g, or c

<400> 47

```

gaaagcaggc tcatttgggg actgattcaa gcagggttct gaagaaagag ctagccact 60
gcgcagtggc ccacctggag aggtagcagt ctcctttcct gatgccagat ccaagcagag 120
gctaattgctg gagaccanga tgcccggtgg agaatccctg tagctagagg gaattatctg 180
gaagtaattt atccctgtac cgccttgtgg ggttggtgtt ttcttgccca ctgcatgagt 240
tggtattact ctaagagcga cagatacatg ttttcacatg ctttccatgt actagacact 300
ttctaggcat cagttctcaa catgacaaaag agatccttct cagggaaatc agatccctct 360
tccactgctg aaaaacccca cagtggctcc catttcactt ggcataaaca ccagtggcct 420
tgcaagtggc gccaaaggtca aacctctgc ctttctgctt cctgctcacc ctttctctc 480
atcttctcay ctttctgtc ttctccatag ctcacactcc cctagccaca ctgttctcct 540
tcctacaatg cagcactcgc ggcagtcttc taccacaggs cccttgacc agccgmacca 600
tctggttgac atgcttctcc cacagattct tgcttgcta actccgttgt gctctggttt 660
ttgtcaagca gtcacctct ccatgaggcc cacctgggcc accatattta aactgcagt 720
ctacactgcc tctctccca ccaccagca ctcccaggcc ctcactctgc ttcctttatt 780
tttccattt cgccagccat cttccaacac atgggaccac atccttattt attgagtgtc 840
ttgttgagg tctctaagac tgtgcctgcc ttgttactg atgtatctct agcgcctaca 900

```

acagggctcg	gcacagagta	ggagctcagt	aaatacttgt	ggaatgaatg	aatgagctca	960
ttttacctca	atcacaaactc	caggggtaga	catgggtgatt	tcactccatt	ttatgggtga	1020
agctcagaag	cttacggaac	ttgcccaagg	tcacatagtt	agtaagtggc	tgagtgacgc	1080
atcaacccaa	agcctgtctt	actctggggt	cctggatctt	aacaaaaaca	ctaagctctt	1140
ccctcctcca	ggtgagcccc	tggtcctgat	gcctcgag			1178

<210> 48

<211> 1121

<212> DNA

<213> Homo sapiens

<400> 48

ggcagcagtg	caaattatat	agccagctct	gcctgccacc	ttaagcttat	tgcttgcctt	60
ctagctcttc	cccccataag	agttacccca	taattgcaaa	gtagctctca	aagttccagg	120
catcaaatct	gtgtttgagg	caggaaatag	atggaagagt	tggtgatagc	aagcttttct	180
tttatgggtca	ttacgtttat	caggagttta	aaagtcttct	cagaaacatt	cagccaacat	240
tgggccccat	ggacactttt	agttgcaaca	aagtatggaa	caataagcat	ctggcataga	300
ggaatagaac	cttccaaacc	aatatctcgc	aaagaatacc	gtctaaggca	gggattggcc	360
aactttgtct	gtgaaagggc	cagataggct	ctggtggcta	tatatagtct	ctggtgcaat	420
cattcaactt	tgctgtctta	gtgcgaatgc	agacatagac	aacatgtaaa	caaatgggcc	480
tggctgtgtt	ccagaaaaac	ttcttcataa	aaattgtaag	tgggtcagac	taactgtggg	540
ctgtagtttg	ctgacccttg	cttagaactt	tatttcgctt	tggttaccac	atggtagacc	600
agggggatga	tgataattaa	gtaggtgcta	tttattgaat	gcctactgtg	tattcgtcac	660
ctgaagctga	acacattgcc	atctctaaaa	catatttgta	ttttcttata	aaggaagaaa	720
gcagtttggt	gagaaggcaa	gtagcggaat	ctgccacaac	acaaattaa	acttgattaa	780
aagagataca	aatgcataga	tggaaagcct	tgctattgta	aagataccac	ttttctccaa	840
attaatccac	aaattccatg	caattccaat	caacatttct	gtagtttttt	tatagaactt	900
gagcagtggg	tctgctcagt	ggatttttta	tggaaacacat	acatgtaaaa	agtaaaacat	960
caatactttt	ggtagaaatt	taaacttgaa	gcaggacaga	gcttaaaaaa	taagacacaa	1020
aaaacgtaag	caaaaaagga	acattttgat	gaatcggttt	tcattaaaaa	gaaaaacttt	1080
catagaataa	aaaggctcat	taaaaaaaaa	aaaaaaaaaa	a		1121

<210> 49

<211> 825

<212> DNA

<213> Homo sapiens

<400> 49

tgcaggaatt	cggcagcagc	cagagcagcc	ctcaaagcct	gggctgttga	gagtgcacat	60
cctggcctgc	ggtgacagcc	gtcagatggg	gaggggcccc	aggcgactgc	cccagcagca	120
gggcctggga	gctgcacagg	ggagaactcg	ataaggagca	tcatgagcat	agtgggtcca	180
ttgacaacat	gcagtcccca	cgggtggtgc	taatgacaaa	atgacatcat	gccacctgca	240
aaaaaagtaa	aatgatcag	aggcgagctt	gtcagagaag	ctttgaaacta	ggtgactgca	300
tgaaacatct	cagaggcgga	agagtgcctc	cccctccccg	ggactccac	ctggtgcctt	360
gagctcatca	tcccttctct	tgtagcatat	gctgtcaata	cccaggccct	tttcgaaacg	420
gcaatgggtc	cgaaggcctc	gggaccacct	ttcacacctc	ccctttatgc	agtgtccata	480
cctccttggt	gctcagctgc	tggtcagctc	catatgccct	gtggtccctg	ccctcccaag	540
gcctgtgaac	aatgcttag	tcccagatta	gagctctacgt	caatctggga	tgtgagctga	600
gtggcacctg	tcgtgaacca	ggccagagtc	tacgcaatct	ggggtgtgag	ctgagtggca	660

cctgtcgtga	acgtgcatgc	acatgggcat	tttgtcagtc	tgaccgggtg	aataaatgtc	720
gctgcatttg	ccagctgagt	gtcaccaggt	tccaggtccc	attacacatc	aggaattgtg	780
tccgactctt	ctggatccgc	tgattggacc	tgagggatcc	ctgac		825

<210> 50
 <211> 853
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (20)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (40)
 <223> n equals a,t,g, or c

<400> 50	
aattcctaac gcaaaagcan ccctggggaa gaacacagan acaggtgaca cgtgtcagac	60
tgggcccattg tcaggtacat gtatttccct tcacctcacc ctgaaatgtg ccatttcaga	120
aagtgggtgca ttaccagac aatttgggtt gatcatcatg ttagccactt ggcatctcag	180
tcaccatctt ggtcacctgg tcaacatagc aaccacatct cttggtcagc tagctttatt	240
tgcaccttga tactaagat agatgtcatc tgcaaagctg ttaataatc ttaataatgg	300
tctttattat ttccagatcc ctagagtaac cttagaacag caagaactat tcattcatcc	360
ataaattcca gcaaggtgct atagaaagca ctatggaaaa aagaggaaaa gagagggaga	420
acataattgta aaagtagaca gggattctgc tactgagaaa ttcaacacct ggcaaggggg	480
atgaacagga aagagaggtg ctggcagaat aaaatcactc cccagctccc cacacaatga	540
gcaatgagta tgctatttct attttgtgtc catgtgtcct tgctcatatt cttaatctgc	600
agcccaatgc tctacctctg agctataccc cctcctcctt gctcatactc ttacttgtga	660
cttgaagtga cttcctgctc ctgcctattg tcacctcccc catgaaggct tccccaatta	720
tcctgaagca gagacagtcc atccctccct cccctgtgca accagggccc ctgggctgac	780
ctcaagcttc tcacacttgg ccataactag cttttaggta tttatctccc acactagact	840
ctgagctcct cga	853

<210> 51
 <211> 1719
 <212> DNA
 <213> Homo sapiens

<400> 51	
ttaatttctt ttgtaggaag agcagtttga actatatgga atccttcaaa attctaagaa	60
agtgtttgcc ctgttctgta tatattctgc caaaagtgtg tcctaatagt ctagatattg	120
attctttatg taagttaggt ctttttaatc aaaagtgaag tgggaccaa ttgttcagt	180
gcttgttctc ttctaaattg ttttttagctg ataagatttg ggaaactttc tgggcttcca	240
caaataatat acaatacatc cttgaatact tgatgcttaa aaagtgtgt tactgcatgc	300
aatcaggag ctccagagct ttttgcaggc tccttgttcc tgagaagcaa tattgttttc	360
atattatctc ggttatacat tttatggttg tgacattgct ttctttttgt ttttgctgtt	420

gttttctgct	gctgctgatt	tagaaatgaa	ataagctaac	tcttaatttt	aacctgtttg	480
ctacctaaaa	tggtaatcat	cttgatgttc	tttcaagcag	gtcccagaga	tcttaaaatg	540
atccggaatc	actgagtgcca	cagttctctt	ttctcttggt	tatgtataga	tggagagtgg	600
tcttggcgtt	atattagtg	atgattcgta	tttgtttcat	aattaacttc	gaagtgaaaa	660
attgatgcga	gagcaaaggt	ttatttggt	tccataacta	tttactaatt	ttatgcttgc	720
cagattttta	gattaaactg	tttgccatct	cttgtaattt	ttcttcccat	aaaacctttg	780
gccatctaca	gtcacttttc	ctcaaactct	atgctgtaat	tcaaactgta	tattcttttt	840
gctgattgct	tctgtacctc	ttctgcttcc	agtgttcttt	tgcaagagt	tccacacagt	900
gggaagaaaa	cctgaacttg	actcatgaag	tgctgggcat	tcaaacacagt	gaatccttgc	960
aaaggatctt	gggagtagac	ccctgtgaat	tggtcttttc	aatttgtcca	cttaaagggc	1020
gtaatagatt	atgcagctgt	ttgggcttca	gcagggtatt	gtcccatatt	catgcctagt	1080
tgcaattatg	tgaattttca	gtttgttaca	aagacttccc	tttgatttca	aaacaatttt	1140
gttggttttg	tggttctaata	tttgagtttt	ctctgaggaa	aaatagttgc	aagattttga	1200
actttgaaaa	cttcaaatta	aaatgtttta	aggttttgtc	actttttatt	ttctgatgca	1260
aaccatacat	tgaaagcata	ttttaagaag	aagtcactct	aataagcttt	aatttcgagt	1320
ttatgaatca	caggattttt	ggtagaggta	aaaactatac	ttacaccgta	aattagacat	1380
taaagcccat	ttaatcagtc	agataatgat	taatgttaga	gtaatgtttg	atgggccaag	1440
ctgctaaaa	ataagcagtt	ctaattttaa	tatataaact	tatcacgtaa	aaatagcaaa	1500
cttagtaatg	tataaagtga	cagtaggtct	tttttgctta	aaaatcagag	ttcctgtgta	1560
gtgtctcttt	atgatctctg	tagtaaaaa	attatttaac	gtagcttagt	gagaagtta	1620
agaggagtat	accttttact	ttaggggtgcc	catgccactt	tgaagttatg	gagtgcaaa	1680
tagtttccac	acattaaaaa	aaaaaaaaaa	acggcacga			1719

<210> 52

<211> 2377

<212> DNA

<213> Homo sapiens

<400> 52

agctgtcgcg	rgcggcgccc	ggccttgctc	aacgcccagc	agtccccacc	gtcgtgccc	60
ccgccaccgc	cctcgccgcg	tgccgaggcc	tcctgcagcc	atcatgtccg	ccagcgccgt	120
ctacgtgctg	gacctgaagg	gcaaggtgct	catctgccgg	aactaccgtg	gcgacgtgga	180
catgtcagag	gtggagcact	tcattgccat	cctgatggag	aaggaggagg	aggggatgct	240
gtcgcctatc	ctggccacg	gggggggtccg	tttcatgtgg	atcaaacaca	acaacctgta	300
tctggttgcc	acatccaaga	agaacgcgtg	cgtgtcgctg	gtcttttctt	tcctctataa	360
ggtggtgag	gtgttttccg	agtacttcaa	ggagctggag	gaggagagca	tccgggacaa	420
ctttgttatc	atctacgagc	tgctggacga	gctcatggac	ttcggctacc	cccagaccac	480
cgacagcaag	atcctgcagg	agtacatcac	tcaggaaggc	cacaagctgg	aaacaggggc	540
cccgcggcca	ccagccaccg	tcaccaacgc	ggtgtcctgg	cgggtccgaag	gcatcaagta	600
tcggaagaat	gaggtgttct	tggacgtcat	cgagtctgtc	aacctcttgg	tcagcgccaa	660
cggcaatgtc	ctgcgcagag	atcgtgggct	ccatcaagat	gcgagtyttc	ctctcgggca	720
tgcccagagct	gcgcctgggc	ctcaacgaca	aggtcctctt	tgacaacacg	ggccgcggca	780
aaagcaaatc	cgtggagctg	gaggatgtga	agttccacca	gtgtgtgcgg	ctatcacgct	840
tcgagaatga	ccgcaccatc	tccttcatcc	cacccgacgg	cgagttcgag	ctcatgtcct	900
accgtctcaa	caccacgctc	aagcctttga	tatggatcga	gtcgggtgac	gagaagcact	960
cccacagccg	catcgagtac	atgatcaagg	ccaaaagcca	gttcaagcgg	cgggtcaacag	1020
ccaacaacgt	ggagatccac	attcccgtgc	ccaatgatgc	cgactcaccc	aagttcaaga	1080
cgacggtggg	gagcgtaag	tgggtccccg	agaacagcga	gatygtgtgg	tccatcaagt	1140
ccttcccggg	cggcaaggag	tacctgatgc	gggcccactt	cggcctgcct	agtgtggagg	1200
ccgaagacaa	ggagggcaag	cccccgatca	gtgtcaagtt	cgagatccct	tacttcacta	1260

cctccggcat	ccaggtgcgc	tacctgaaga	tcattgagaa	gagtgggtac	caggccctgc	1320
cctgggtgcg	ttatatcacg	cagaatggag	attaccagct	ccggacccag	tgaggggctg	1380
tcgcagccaa	caccccggcc	tcggggctcc	tggtggcagc	accaggggac	acacctgcca	1440
aaccaccag	atggaggggc	cctccctggt	ctctggccac	cctcccagcc	tctgcccagg	1500
gaccctgcc	ttccccaggc	catctgctct	gccgtcgaca	ctcgtctcag	aagccccttt	1560
cccagaagag	gctggtcttc	aagaagtctc	gtttctttgc	ccctgaagtc	agtttcaggg	1620
gaaggatgtg	aaatTTTTcc	gtgtagaggt	tacagccttt	tatgctgttg	agctcccagg	1680
tacaaaaaag	cttgccaac	gcttgccagc	cagccagctg	caggtggcat	ctgccacgaa	1740
ggaagcgcca	gcytcgccag	gccagcaggg	gcgtcgtttt	gttgccattt	tggtgaacgt	1800
tatgggttta	tggtgttcc	tggaacttgt	ctttgtgcat	tcgttgctgt	ttgtgttacc	1860
ctcactgtcc	ccatgtccca	cccacgtcct	acggcactca	ggaagcactt	ggtgaggacg	1920
agccctcacc	cttcttgtct	tccttcccag	cagcgcccg	agcgggccat	ttacacgtcg	1980
aggctggcac	ctggcgcgct	cggggggccac	tgtagcgtct	gcctgctccc	tggaactcgca	2040
ggcctgcctg	tggcgccttc	ccagggccag	cctgggtcac	gagatgctgt	cactcagcca	2100
gatcagtatt	gacccaccag	gggaggtggg	gtttggtgag	agacgccagc	ctcagacttt	2160
ttcccactga	gggtccagag	agcggggcca	cgtgtcaccc	acgtctgcgc	ttggtcaccc	2220
gtcctcccca	ccctgtgtgt	gtttatgtca	tagttacatt	aaattccatt	cattgaataa	2280
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2340
aaagaaaaaa	aataaaaaaa	aaaaaaaaaa	aactcga			2377

<210> 53

<211> 1703

<212> DNA

<213> Homo sapiens

<400> 53

ggcaaaaagc	taccacctgc	cagtctgaag	caccgagatg	acatggccgc	ttaccaacaa	60
gaagagcaga	tgcaacttcc	ccgagctgat	gccattcggt	cacgtctcat	cgatactttc	120
tctctcattg	agcatttgca	aggcttgagc	caagctgtgc	cgccggcacac	tatcaggggag	180
ttacttgatc	cttcccgcga	gaagaaactt	gtattgggag	atcaacacca	gstagtgcgk	240
ttctctataa	agcctcagcg	tatagaacag	atttcacatg	cccagaggct	gttgagcagg	300
cttcatgtgc	gctgcagtca	gaggccacct	ctttctttgt	gggccggatg	ggtccttgag	360
tgctctctct	tcaaaaactt	catcatcttc	ctggcttttt	tgaatacgat	catattgatg	420
gttgaaatag	aattgctgga	atccacaaat	accaaactat	ggccattgaa	gctgaccttg	480
gaggtggcag	cttgggttat	cttgcttatt	ttcatcctgg	agatccttct	taagtggcta	540
tccaactttt	ctgttttctg	gaagagtgcc	tggaatgtct	ttgactttgt	tgttaccatg	600
ttgtccctgc	ttcccagagg	tggtgtattg	gtaggggtaa	caggccaatc	ggtgtggcct	660
caacttctga	ggatctgccg	ggtgctgagg	tctctcaaac	tccttgacac	attccgtcaa	720
attcaaatta	ttatttttgt	cctggctcag	gccctcaaga	gcatgacctt	cctcttgatg	780
ttgctgctca	tcttcttcta	catttttget	gtgactgggt	tctacgtctt	ctcagagtac	840
accggttcac	ctcgtcagga	cctggagtac	catgtgttct	tctcggacct	cccgaattcc	900
ctggtaacag	tggtcattct	cttcaccttg	gatcattggt	atgcactgct	tcaggacgtc	960
tggaaggtgc	ctgaagtcat	tcgcatcttc	agcagcatct	atttcacatc	ttggttgggt	1020
cttggctcca	ttatcttttc	aagtatcata	gtagccatga	tggttactaa	ctttcagaat	1080
atcaggaaaag	agctgaatga	ggagatggcg	cgctggggag	ttcagctcaa	agctgacatg	1140
ttcaagcggc	agatcatcca	gaggagaaaa	aacatgtcac	atgaagcact	gacgtcaagc	1200
catagcaaaa	tagaggacag	gtcgtttgga	ctggggagact	cttgtgcacg	aaaatctgcc	1260
cgggctaattg	gaaatggatc	aggatgaccg	tggttgcccc	agagactcac	tcttccgata	1320
ttttgagttg	ctagaaaagc	ttcagtataa	cctagaggaa	cgtaagaagt	tacaagagtt	1380
tgcaagtgcag	gcactgatga	acttgaaga	caagtaaagc	aatggatggc	ttcacttcca	1440

cccttcctgc	aacctctact	gcctgattag	agtcctaatt	ttaccctctc	cctccctgat	1500
gcataggtaa	aggccccctct	gtggagtaag	gagatcttca	gagctgttag	tgtaactaat	1560
tgagaagtat	tgtttccatt	gcgtgttcca	ctcatgttgc	ttctcttggtg	aaccattaac	1620
tttaattgga	tattatTTTT	acctgttaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1680
aaaaaaaaaa	aaaaaaaaact	cga				1703

<210> 54
 <211> 1245
 <212> DNA
 <213> Homo sapiens

<400> 54						
gagcggtca	gacgcacatc	atcctcagtc	cctcgggact	ggagggactc	gtgagccgga	60
gcccagaaat	ccgggggtgg	ataagacacc	gcgtcccttc	caattcccgt	aagcaccctt	120
tgctccatcc	tgcgcccaa	tacctcagct	agcccccttc	cccacttctt	acactccaaa	180
ctcagccggg	acagacctct	gctgccgcg	ccccacgaa	cgtgtgacga	cggctggagg	240
ccaacagagt	ccctacaggt	ggtgctcacg	gtaatgcacc	gacaatgagt	ggctgttttc	300
cagtttctag	cctccgctgc	ctatctaggg	tgtgtcatgg	cctggtgcgg	gaggctctta	360
ctctcccaa	gccccactgc	ttctcctgct	gcccgttgc	ttcggactct	ggcagaaacc	420
ccacctgctg	acacgttcct	cctggggaat	tggtgttggg	tgtgccagcg	cctctggccg	480
tgggccgcta	accagcctct	cccggggcgg	ctcctgccgc	gccccctctc	gcttgccccc	540
tcctcctcct	cctcctgctg	ctctccccc	tgctcccagg	acggcaggat	ggccgcgcag	600
ggcgcgccgc	gcttcctcct	gaccttcgac	ttcgacgaga	ctatcgtgga	cgaaaacagc	660
gacgattcga	tcgtgcgcgc	cgcgccgggc	cagcggtcc	cggagagcct	gcgagccacc	720
taccgcgagg	gcttctacaa	cgagtacatg	cagcgctct	tcaagtacct	ggcgagcag	780
ggcgtgcggc	cgcgggacct	gagcgccatc	tacgaagcca	tccctttgtc	gccaggcatg	840
agcgacctgc	tgagtttgt	ggcaaaacag	ggcgctgct	tcgaggtgat	tctcatctcc	900
gatgccaaaca	cctttggcgt	ggagagctcg	ctgcgcgccg	ccggccacca	cagcctgttc	960
cgccgcaccc	tcagcaaccc	gtcggggccg	gatgcgcgtg	gccttcccgc	gccgcggcta	1020
ccccatgcac	cgctctcatt	caggaggccc	agaaggccga	gccagctcg	ttccgcgcca	1080
gcgtggtgcc	ctgggaaacg	gtgcagatgt	gcgcctccac	ctgcaacagg	tgtgaagtc	1140
gtgctgagtc	tggccgcctg	caggggggta	cccgggccaa	cggcgagggg	ggcggggaag	1200
ggagattcgg	caaagacagc	tttactaaaa	aaaaaaaaaa	aaaaa		1245

<210> 55
 <211> 825
 <212> DNA
 <213> Homo sapiens

<400> 55						
gcttacttgg	ttcagctcat	ggactggctt	cttaattctc	tgtatgctgg	ccttttgttt	60
ttttccataa	aagcactttt	ctttagtttc	cataaaatcc	attttcagaa	accagtgtgt	120
caaagcatag	aattttttta	aaaagatacc	tgcggatggt	agaggggatg	gggaaagtcc	180
tcactatgtg	gcaatattaa	taaatacaga	ttaagtattg	ggtatctttg	ctatttaata	240
tcctcaggct	actcttcact	gccctttccc	aggttccctc	ccactgcaca	tcctctctct	300
gactcctctt	tggtgccttc	cttctgccat	agcttggtct	cacatcctga	gttttgatt	360
tccccagaa	attccaaact	ttccaactag	gtcatacaaa	gcaattcagt	tctcttcagc	420
ctctattcgc	aaactctcct	tttgatatcc	acactcatcc	tggtgcttga	aggacccttt	480
atttgccata	atcaatcttc	cttagaaagt	agttattcag	gctgggtgcg	gtggctcatg	540

cttctaatacc	cagcattttg	ggaagccgag	gcaggcggat	catgagggtca	ggagttcgag	600
acccgccctg	ccaacacgga	gaaagctcgt	ctctactaaa	aatacaaaaa	ttagctgggc	660
gtggtggcgg	gcacctgtaa	ccccagctac	tcgtgargct	gaggttggat	aatcgcttga	720
acccaggagg	tggagggttc	agtgagccga	tatcccacca	ctgcactcca	gcctgggcaa	780
cagagcgaga	ctctgactca	aaaaaaaaaa	aaaaaaaaaa	ctcga		825

<210> 56
 <211> 811
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (5)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (6)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (107)
 <223> n equals a,t,g, or c

<400> 56	
aggcncccc	aggctttaca ctttatgctt ccggctcgta tgttgttggtg gaatttgtga 60
agcgataac	aattttccca caggaaacag ctatgaccat gattacncca aagctcgaaa 120
ttaaccctca	ctaaagggaa caaaagctgg agctccacgc ggtgscggcc gctctagaac 180
tagtggatcc	cccggtctgc aggaattcgg cagaggctg gaagtataat ggaggccagt 240
tgggggagga	gggggaaaag attcactcta agtctagatg ctctagcacc caccaggat 300
gtgtgcaagg	aagtgcagga tgctcctggt cttgcaaaact gtggtttgtg ggactccaaa 360
gcccctatcc	ttccacgatg ctttctgtcy tggtatcaca tttccttgga ggagarccca 420
gccttggtgg	agagccctgc yctggctttg tccctcsgca tgagatggca aaggatgggtg 480
ctgctgggag	accctcacrt ctgyrcactg ggggctgctt gccttctcca ttcctccttc 540
aagtatctga	gcagctcctg tgtgccagct gctgggtctac aagatggats ggtccttgga 600
gatcaygctg	tagcagagga ggcaggctgt agccacacg ccacaaccag cccctgcct 660
gttcacacaa	ataaagtttt attggaatac agccacaccc atttcagtgc atattgtctg 720
tggctgcttt	cctgctacaa tagagagttg aatagttggg acagagacct atggcctgca 780
aagctgaact	atttaccatc tggcyctcga g 811

<210> 57
 <211> 1968
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE

<222> (19)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (291)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (303)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (308)
 <223> n equals a,t,g, or c

<400> 57

gccgtgtaaa	tgacgtttna	aggcgagtgc	ggaaagtggc	ctggggagcc	tcggggagcg	60
gacgccctcc	gccctggtgc	tgacctgcct	ccctgcccc	tstgcctcct	gtmagcagag	120
gcctcggtc	cgcaactgcc	actcctcctc	gggggtgtgc	acaagtctcg	aggtcaccgg	180
cgaccccccc	tagcagcgcg	cctggctctg	gccccgcga	aggaggacgg	agtttgtgtg	240
ttgcatactt	tctaaggcgg	cggtgcagc	agcggctcca	tccagcccg	nagctcctcc	300
tgnaaggmat	ggctggctac	ctgagtgaat	cggactttgt	gatggtggag	gagggttmag	360
tacccgagac	ctgctgaagg	aactcactct	gggggcctca	caggccacca	cggacgaggt	420
agctgccttc	ttcgtggctg	acctgggtgc	catagtggag	aagcactttt	gctttctgaa	480
gtgcctgcca	cgagtccggc	ccttttatgc	tgtcaagtgc	aacagcagcc	caggtgtgct	540
gaaggttctg	gcccagctgg	ggctgggctt	tagctgtgcc	aacaaggcag	agatggagtt	600
ggtccagcat	attggaatcc	ctgccagtaa	gatcatctgc	gccaaccctt	gtaagcaaat	660
tgcacagatc	aaatatgctg	ccaagcatgg	gatccagctg	ctgagctttg	acaatgagat	720
ggagctggca	aaggtggtaa	agagccaccc	cagtgcgaag	atggttctgt	gcattgctac	780
cgatgactcc	cactccctga	gctgcctgag	cctaaagtgt	ggagtgtcac	tgaaatcctg	840
cagacacctg	cttgaataatg	cgaagaagca	ccatgtggag	gtggtgggtg	tgagttttca	900
cattggcagt	ggctgtcctg	accctcaggc	ctatgtcag	tccatcgag	acgcccggct	960
cgtgtttgaa	atgggcaccg	agctgggtca	caagatgcac	gttctggacc	ttggtggtgg	1020
cttccctggc	acagaagggg	ccaaagtgag	atttgaagag	attgcttccg	tgatcaactc	1080
agccttggtg	ctgtacttcc	cagagggctg	tggcgtggac	atctttgctg	agctggggcg	1140
ctactacgtg	acctcgccct	tactgtggc	agtcagcatc	attgccaaga	aggaggttct	1200
gctagaccag	cctggcaggg	aggaggaaaa	tggttccacc	tccaagacca	tcgtgtacca	1260
ccttgatgag	ggcgtgtatg	ggatcttcaa	ctcagtcctg	tttgacaaca	tctgccctac	1320
ccccatcctg	cagaagaaac	catycacgga	gcagcccctg	tacagcagca	gcctgtgggg	1380
cccgccggtt	gatggctgtg	attgctgtgc	tgaggccctg	tggctgccgc	aactacacgt	1440
aggggactgg	ctggtctttg	acaacatggg	cgcctacact	gtgggcatgg	gttccccctt	1500
ttgggggacc	caggcctgcc	acatcaccta	tgccatgtcc	cgggtggcct	gggaagcgct	1560
gcgaaggcag	ctgatggctg	cagaacagga	ggatgacgtg	gaggtgtgtg	gcaagcctct	1620
gtcctgcggc	tgggagatca	cagacaccct	gtgctgtggc	cctgtcttca	ccccagcgag	1680
catcatgtga	gtgggcctcg	ttccccccgg	agaatcccag	cggggcctca	gagatgcata	1740
tgggagaggt	ggggaagatg	gcaggcaagg	gtacccttgg	ccaggactct	ggtgcccacc	1800
ctgccacccc	cgcgtccac	ctgcagtgtt	tctgccctgt	aaataggacc	agtcttacac	1860
tcgctgtagt	tcaagtatgc	aacataaatc	ctgttccttc	caaaaaaaaa	aaaaaaaaaa	1920

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aactcgag

1968

<210> 58

<211> 2058

<212> DNA

<213> Homo sapiens

<400> 58

caggaattcg	gcacgaggtc	cctttggagt	ctgttaagcc	cagcagcctg	ccgcctctca	60
ttgtgtatga	ccggaatgga	ttcagaattc	tgctccactt	ctcccagacg	ggagcccctg	120
ggcaccacga	ggtacaggtg	ctgctcttga	ccatgatgag	cccggctccc	cagcctgtct	180
gggatatcat	gtttcaagtg	gctgtgccaa	agtcaatgag	agtgaagctg	cagccggcat	240
ccagctccaa	gcttcctgca	ttcagtcctt	tgatgcctcc	agctgtgata	tctcagatgc	300
tgctgcttga	caatccacac	aaagaacctt	tccgcttacg	gtacaagctg	acattcaacc	360
aaggtggaca	gcctttcagc	gaagtaggag	aagtgaagaa	cttcccagac	ctggctgtct	420
tgggcgcagc	ctaacttttc	acaagatgga	cccttcattt	caagcttagg	ctggcggtac	480
ttttgctgtc	tagtcaggac	taatcacggt	gtttcagtgc	ggagtgccaa	gagtcctatc	540
ctgacgtcag	gctctgggtg	tcaacctctg	acttattctg	cagatgctct	gtgtgtgtgt	600
gtgtgtgtgt	gtgttcgggg	agagggtggt	agcacagggc	ttgggataac	ggcagtgtgg	660
gaaatgcgaa	gcattttctc	tcatcatcat	ctctgttaca	gtcatgtttc	tgcagtgcag	720
cgagcgacac	tgctcctgcc	tcagggttga	ggttttatca	gccaaagtgt	ttttttcatg	780
tatcgttcgt	tccattcatc	cactctgtgc	cttgtcagcc	tttgaaaggc	ttggttgctc	840
ccaggctgct	gttctcaggg	accttaaaag	ggacctggtt	agtcttgggg	cagagagtat	900
ctacttgggc	actctcttcc	aagaaagacc	ttgtctccat	tttcattaga	caatgcttct	960
tgtgtgtgtt	ctggaagatc	ttctaaatgg	aatgcttggt	gcactgttcc	caggcgagtg	1020
gctgccatga	gacctgagga	ccacacttgg	gggaccaatc	atgtccttca	ccactgtgcc	1080
ttagaatcgc	ccctggacag	agttcctggg	cagaggggaa	agcagctccc	aggccttact	1140
caggcctcag	gtccatgggt	tgggcagcca	gtctgggccc	ttctcaggat	cctcatctcc	1200
atcctcatcc	tcttccttca	cagcatttac	ttggagctcc	ttgtgacaca	ccatgtcagt	1260
catgatgaat	cggccaacag	ccagcccttg	ccagctgacg	tcacagtcta	agatgggaaa	1320
ctgtggtaca	gatagacatg	aagagagctt	agcagtgatt	gaggtggtga	ctaaatatac	1380
agtcattgaa	taaataccat	gtagcaagtg	tactttgtgg	agtgttgagt	aagtggaaaa	1440
tggaaagcca	gttgcattta	gagatgatag	gcctaaaggg	aactgtcttc	tgctgagaag	1500
taaaggaaac	ttcatgaagg	atgtagaagc	ttagctgcct	cagagaagag	agaccctgaa	1560
gatctgaggc	aagctggaca	ggagaggtgg	atatttgttg	atggaagaat	tcaagtttat	1620
aatcaattcc	cacttagcac	ctactgtgtg	ctaggaactt	gaatgtgtat	gtttgacaag	1680
tcctgcttgg	cctgatgggt	gggagaagga	acctgagcct	ggctgagatg	gctaggcgga	1740
gggctttgaa	gtccaagcag	ctgaactggc	tgggtgggtt	tctacctttg	aaactgcaag	1800
acttgtttgg	agctcttaat	tacaatatct	gatattttta	cagtctgata	ttttgacttc	1860
tacatatagt	ggaaatctgc	caataactaat	tgggtggagat	gggaactgta	aaagatcaag	1920
tatgctaatt	ttaagcaaata	gtaaaaactc	ataaaacagg	taaacagtgg	ggtgatttca	1980
tttgccataa	ttcacataag	acgaatttta	atctaaaagt	actttcttgc	ttgtaaaaaa	2040
aaaaaaaaaa	aaaaaaaaaa					2058

<210> 59

<211> 48

<212> PRT

<213> Homo sapiens

34

<400> 59

Met Asn Ser Trp Lys Phe Gly Gly Leu Cys Leu Leu Leu Ile Ile Ser
1 5 10 15

Val Trp Leu Lys Gln Ser Trp His Gln Gly Arg Val Cys Cys Asp Asp
20 25 30

Ser Arg Glu Gly Asp Ser Gln Gly Val Ala His Gln Ala His Glu Ala
35 40 45

<210> 60

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (67)

<223> Xaa equals stop translation

<400> 60

Phe Leu Leu Lys His Gly His Pro Pro Leu Met Ala Thr Ala Glu Pro
1 5 10 15

Leu Gly Lys Glu Pro Phe Gly Ile Gln Asn Ser Gln Val Ala Ala Gln
20 25 30

Cys Gly Ile Trp Ser Met Thr Thr Lys Ala Phe Ser Gln His Leu Leu
35 40 45

Lys Glu Ser Gly Val Phe Tyr Thr Leu Leu Met Gly Thr Val His Glu
50 55 60

His Ile Xaa

65

<210> 61

<211> 12

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals stop translation

35

<400> 61

Met Ser His Cys Val Trp Ser Leu Ala Val Ser Xaa

1 5 10

<210> 62

<211> 32

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals stop translation

<400> 62

Met Pro Leu Val Pro Leu Leu Leu Ser Cys Pro Pro Thr Trp Leu Ala

1 5 10 15

Arg Phe Gly Val Ser Leu Pro Cys Ser Gly Ile Pro Val Leu Ala Xaa

20 25 30

<210> 63

<211> 79

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (79)

<223> Xaa equals stop translation

<400> 63

Met Ser Pro His Gln Pro Met Gln Val Ser Ser Ser Lys Thr Ile Leu

1 5 10 15

Trp Leu Val Leu Ser Cys Leu Cys Pro Ser Ser Pro His Pro Val Ile

20 25 30

Ser Gly Leu Pro Gln Trp Tyr Ile Gly Val Leu Ala Gly Ile Val Pro

35 40 45

Val Ala Pro Ile Arg Pro Gly Asp Ser Gly Leu Asp Leu Gln Arg Glu

50 55 60

Gly Pro Gln Pro Ile Leu Ser Gln Gly Leu Asn Arg Arg Thr Xaa

65 70 75

<210> 64
<211> 17
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> Xaa equals stop translation

<400> 64
Gly Pro Cys Asp Pro Ile Ser Trp Leu Leu Arg Leu Leu Ser Leu Phe
1 5 10 15

Xaa

<210> 65
<211> 25
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (25)
<223> Xaa equals stop translation

<400> 65
Met Trp Leu Trp Thr Ser Pro Trp Arg Ser Gly Leu Cys Trp Ile Leu
1 5 10 15

Leu Arg Gly Thr Ser Thr Glu Met Xaa
20 25

<210> 66
<211> 15
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (15)
<223> Xaa equals stop translation

<400> 66
Met Arg Lys Leu Ala Phe Gly Leu Arg Ile Ser Tyr Cys Ser Xaa
1 5 10 15

<210> 67
<211> 2
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (2)
<223> Xaa equals stop translation

<400> 67
Met Xaa
1

<210> 68
<211> 36
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (36)
<223> Xaa equals stop translation

<400> 68
Met Gly Thr Gln Leu Leu Phe Leu Leu Cys Ser Ile Leu Ile Pro Leu
1 5 10 15

Cys Val Glu Leu Asp Tyr Ile Phe Leu Lys Gln Ser Ser Leu Asn Asn
20 25 30

Leu Val Val Xaa
35

<210> 69
<211> 85
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (85)

38

<223> Xaa equals stop translation

<400> 69

Met Leu Val Ser Ser His Phe Leu Phe Leu Cys Phe Val Arg Leu Leu
 1 5 10 15

Ser Ser Leu Pro Leu Phe Leu Thr Ser Ile Thr Phe Leu Tyr Ser Pro
 20 25 30

Ser Ser Pro Ser Leu Phe Leu Ser Leu Tyr Ser Phe Ser Tyr Pro Ser
 35 40 45

Phe Ser Pro Leu Ser Phe Leu Pro Leu Xaa Leu Ile Ser Phe Pro Pro
 50 55 60

Pro Met Pro Ser Ser Leu Phe Pro Phe Pro Cys Phe Phe Pro Gln Pro
 65 70 75 80

Leu Phe Leu Phe Xaa
 85

<210> 70

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (58)

<223> Xaa equals stop translation

<400> 70

Met Thr Cys Ser Arg Ser Ser Ile Phe Leu Thr Leu Leu Leu Gly
 1 5 10 15

His Arg Ala Ile Phe Ser Asn Met Pro Glu Lys Leu Arg Ser Leu Ile
 20 25 30

Thr Asp Asn Leu Gln Leu Phe Thr Ser Lys Ser Phe Gly Gln Ile Met
 35 40 45

Pro Val Lys Glu Cys Lys Phe Tyr Lys Xaa
 50 55

<210> 71

<211> 15

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (15)

<223> Xaa equals stop translation

<400> 71

Val	Leu	Tyr	Tyr	Pro	Tyr	Leu	Ala	Ile	Tyr	Asn	Met	Lys	Val	Xaa
1				5					10				15	

<210> 72

<211> 12

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals stop translation

<400> 72

Met	Gly	Phe	Glu	Pro	Gly	Trp	Pro	Gly	Lys	Leu	Xaa
1				5				10			

<210> 73

<211> 40

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> Xaa equals stop translation

<400> 73

Met	Leu	Leu	Glu	Lys	Val	Ile	Arg	Leu	Arg	Cys	Ser	Cys	Phe	Val	Leu
1				5				10					15		

Leu	Cys	Phe	Ser	Leu	Ser	Trp	Val	Gly	Val	Ser	Ser	Ser	Asn	Asp	Val
			20					25					30		

Gln	Val	Asp	Leu	Phe	Ser	His	Xaa
		35				40	

<210> 74

<211> 81

<212> PRT

<213> Homo sapiens

40

<220>

<221> SITE

<222> (80)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals stop translation

<400> 74

Met	Leu	Val	Leu	Gly	Leu	Thr	Lys	Phe	Ala	Val	Gly	Ile	Val	Leu	Ile
1			5					10						15	

Leu	Leu	Val	Arg	Gln	Leu	Val	Gln	Asn	Leu	Ser	Leu	Gln	Val	Leu	Tyr
			20					25					30		

Ser	Trp	Phe	Lys	Val	Val	Thr	Arg	Asn	Lys	Glu	Ala	Arg	Arg	Arg	Leu
		35					40					45			

Glu	Ile	Glu	Val	Pro	Tyr	Lys	Phe	Val	Thr	Tyr	Thr	Ser	Val	Gly	Ile
	50					55					60				

Cys	Ala	Thr	Thr	Phe	Val	Pro	Met	Leu	His	Arg	Phe	Leu	Gly	Leu	Xaa
65					70					75				80	

Xaa

<210> 75

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 75

Met	Trp	Gln	Ser	Cys	Leu	Cys	Arg	Phe	Val	Leu	Leu	Ile	Glu	Gly	Leu
1				5				10						15	

Glu	Pro	Gly	Ala	Leu	Pro	Ala	Phe	Pro	Gly	Ser	Pro	Ser	Ser	Arg	His
			20					25					30		

Gly	Leu	Thr	Val	Ser	His	Val	Glu	Gly	Leu	Gly	Ser	Leu	Met	Lys	Cys
		35					40					45			

Gly Leu Xaa

41

50

<210> 76

<211> 63

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (63)

<223> Xaa equals stop translation

<400> 76

Met Ser Gly Ser Gln Val Val Ala Leu Phe Leu Leu Cys Val Arg Ile
1 5 10 15

Ser Lys Val Ile Ser Val Tyr Cys Leu Glu Ser Gly Leu Phe Cys Phe
20 25 30

Thr Pro Thr Phe Thr Glu Lys Asn Phe Phe Ser Gln Ala Thr Lys His
35 40 45

Leu Val Ser Gly Val Lys Glu Asp Phe Ile Ile Leu Glu Leu Xaa
50 55 60

<210> 77

<211> 20

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (20)

<223> Xaa equals stop translation

<400> 77

Met Val Thr Val Val Gln Thr Leu Leu Leu Leu Thr Gln Asn Arg Ser
1 5 10 15

Gly Ala Met Xaa
20

<210> 78

<211> 13

<212> PRT

<213> Homo sapiens

<220>

42

<221> SITE

<222> (13)

<223> Xaa equals stop translation

<400> 78

Met Thr Ser Val Gln Gln Phe Cys Ile Tyr Ser Glu Xaa

1

5

10

<210> 79

<211> 28

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (28)

<223> Xaa equals stop translation

<400> 79

Met Gly Arg Cys Thr Phe Val Cys Arg Ile Glu Ile Phe Phe Ser Pro

1

5

10

15

Tyr Leu Ile Pro Pro Glu Phe Gly Asp Tyr Leu Xaa

20

25

<210> 80

<211> 46

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (46)

<223> Xaa equals stop translation

<400> 80

Met Ala Ala Ala Lys Ala Leu Ile Ser Leu Trp Leu Val Ser Ala Cys

1

5

10

15

Gly Gln Trp Glu Thr Ser Phe Pro Ile Tyr Gly Gly Asp Met Glu Cys

20

25

30

Gln Ala Val Val Phe Trp Trp Leu Glu Glu Glu Arg Lys Xaa

35

40

45

<210> 81

<211> 64

<212> PRT

43

<213> Homo sapiens

<220>

<221> SITE

<222> (64)

<223> Xaa equals stop translation

<400> 81

Met Arg Leu Pro Leu Arg His Ser Ala Ser Leu Glu Ala Ser Val Ser
1 5 10 15

Arg Val Leu His Thr Pro Ser Gly Arg Asp Gly Pro Gly Thr Pro Cys
20 25 30

Asn Pro Ser Gly Gln Met Cys His Cys Pro Met Lys Ile Lys Gly His
35 40 45

His Ser Ser Ser Arg Arg Gln Asn Leu Asn Ser Asn Leu Ser Gln Xaa
50 55 60

<210> 82

<211> 37

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (37)

<223> Xaa equals stop translation

<400> 82

Met Leu Ser Cys Leu Arg His Trp Thr Trp Asn Leu Leu Val Leu Arg
1 5 10 15

Pro Leu Ala Ser Met Val Thr Pro Ala Pro His Leu Val Arg Arg Pro
20 25 30

Ser Val Ser Asp Xaa
35

<210> 83

<211> 56

<212> PRT

<213> Homo sapiens

<220>

44

<221> SITE

<222> (56)

<223> Xaa equals stop translation

<400> 83

Met Arg Glu Asn Phe Thr Ala Lys Val Trp Leu Ala Ile Pro Phe Leu
1 5 10 15

Ala Leu Gly Phe Leu Cys Val Ser Glu Pro Arg Tyr Thr Asp Phe Arg
20 25 30

Ser Lys Glu Ser Ser Ser Leu Pro Leu Gly Lys Thr Gly Arg Gly Met
35 40 45

Val Leu Tyr Gln Ser His Thr Xaa
50 55

<210> 84

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals stop translation

<400> 84

Met Arg Val Trp Arg Leu Ala Trp Phe Ala Trp Ala Trp Val Gly His
1 5 10 15

Gly Thr Ser Cys Thr Gly Val Gln Ser Thr Leu His Ile Val Thr Pro
20 25 30

Ser Xaa

<210> 85

<211> 46

<212> PRT

<213> Homo sapiens

<400> 85

Met Lys Ile Ser Phe Thr Phe Phe Ile Leu Leu Lys Asn Val Leu
1 5 10 15

Ala Ala Arg Lys Phe Lys Met Ile Asp Val Ala His Ile Met Phe Leu
20 25 30

45

Cys Asp Arg Leu Leu Trp Ile Lys Ser Arg Gln Thr Met Ala
35 40 45

```
<210> 86
<211> 32
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (32)  
<223> Xaa equals stop translation
```

<400> 86
Met Arg Leu Arg Asp Arg Arg Ala Gly Glu Gly Gln Arg Gln Leu Leu
1 5 10 15

Leu Leu Arg Leu Leu Leu Arg Thr Ser Phe Trp Gly Val Val Phe Xaa
20 25 30

```
<210> 87
<211> 67
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (67)  
<223> Xaa equals stop translation
```

<400> 87
Met Leu Gly Val Ser Ala Ser Gly Ser Leu Gln Leu Leu Gln Ser Gln
1 5 10 15

Arg Gly Leu Glu Arg Gly Pro Ala Pro Arg Gln Pro Ala Asp Thr Ser
20 25 30

Ser Ser Met Cys Glu Ser Leu Val Phe Thr Pro Thr Ala Pro Phe Ser
35 40 45

Gly Gly His Cys Pro Lys Ala Arg His Gly Arg Leu Thr Ser Pro Phe
50 55 60

Tyr Gly Xaa
65

46

<210> 88
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (73)
<223> Xaa equals stop translation

<400> 88
Met Pro Leu Gly Arg Leu Leu Pro Arg Leu Leu Phe Phe Leu Ile Val
1 5 10 15
Thr Tyr Arg Leu Gly Val Leu Gly Thr Glu Ser Ser Gln Leu Leu Gln
20 25 30
Tyr Glu Glu Thr Val His Leu Phe Cys His Leu Asp Leu Phe Ala Thr
35 40 45
His Leu Leu Tyr Phe Leu Tyr Trp Lys Ile Phe Leu Leu Val Leu Ser
50 55 60
Tyr Glu Phe Leu Phe Cys Phe Asn Xaa
65 70

<210> 89
<211> 35
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (35)
<223> Xaa equals stop translation

<400> 89
Met Leu Ile Ile Met Ala Gln Leu Leu Gln Trp Phe Ser Cys Trp Ser
1 5 10 15
Phe Leu Pro Leu Ala Ala Leu Asn Cys Glu Trp Tyr Arg Val Thr Glu
20 25 30
Leu Thr Xaa
35

<210> 90
<211> 17

47

<212> PRT

<213> Homo sapiens

<400> 90

Met Leu Met Pro Trp Gly Leu Gly Leu Gly Ile Trp Leu Cys Ser Leu
1 5 10 15

Thr

<210> 91

<211> 14

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> Xaa equals stop translation

<400> 91

Met Trp Cys Pro Ala Phe Gly Arg Val Phe Cys Ser Arg Xaa
1 5 10

<210> 92

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals stop translation

<400> 92

Met Pro Leu Leu Gln Trp Leu Ala Leu Leu Trp Pro Leu Leu Thr Thr
1 5 10 15

Glu Ala Pro Ser Gly Gly Cys Ser Gln Pro Gly Pro Gly Pro Arg Ser
20 25 30

Ser Leu Thr Xaa

35

<210> 93

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 93

Met Ala Pro Leu Pro Thr Pro Leu Thr Ala Leu Gly Ala Ser His Leu
1 5 10 15

Pro Phe Arg Cys Leu Ser Cys Leu Asp Ala Cys Leu Phe Leu Trp Gly
20 25 30

Tyr Leu Asn Ser Ala His Pro Ile Gly Ala Ser Xaa
35 40

<210> 94

<211> 38

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (38)

<223> Xaa equals stop translation

<400> 94

Met Gly Leu Arg Arg His Phe Pro Ala Leu Trp Val Leu Trp Trp Pro
1 5 10 15

Trp Cys Pro Ser Trp Arg Gln Thr Arg Thr Pro Ser Ala Pro Ser Met
20 25 30

Gln Met Ala Thr Arg Xaa
35

<210> 95

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals stop translation

<400> 95

Met Leu Leu Pro Gln Ile Leu Ala Trp Leu Thr Pro Leu Cys Ser Gly
1 5 10 15

49

Phe Cys Gln Ala Val Thr Phe Ser Met Arg Pro Thr Trp Ala Thr Ile
20 25 30

Phe Asn Thr Ala Val Tyr Thr Ala Ser Pro Pro Thr Thr Gln His Ser
35 40 45

Gln Ala Leu Thr Leu Leu Pro Leu Phe Phe Pro Phe Arg Gln Pro Ser
50 55 60

Ser Asn Thr Trp Asp His Ile Leu Ile Tyr Xaa
65 70 75

<210> 96

<211> 27

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (27)

<223> Xaa equals stop translation

<400> 96

Leu Trp Trp Leu Tyr Ile Val Ser Val Ala Ile Ile Gln Leu Cys Cys
1 5 10 15

Ser Ser Ala Asn Ala Asp Ile Asp Asn Met Xaa
20 25

<210> 97

<211> 35

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

<223> Xaa equals stop translation

<400> 97

Met Gln Cys Pro Tyr Leu Leu Gly Ala Gln Leu Leu Val Ser Ser Ile
1 5 10 15

Cys Pro Val Val Pro Ala Leu Pro Arg Pro Val Asn Lys Cys Leu Val
20 25 30

Pro Asp Xaa
35

<210> 98
<211> 26
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (26)
<223> Xaa equals stop translation

<400> 98
Met Ser Met Leu Phe Leu Phe Cys Val His Val Ser Leu Leu Ile Phe
1 5 10 15
Leu Ile Cys Ser Pro Met Leu Tyr Leu Xaa
20 25

<210> 99
<211> 22
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (22)
<223> Xaa equals stop translation

<400> 99
Cys Asp Ile Ala Phe Phe Leu Phe Leu Leu Leu Phe Ser Ala Ala Ala
1 5 10 15
Asp Leu Glu Met Lys Xaa
20

<210> 100
<211> 38
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals stop translation

<400> 100
Met Gly Leu Trp Val Phe Leu Glu Leu Val Phe Val His Ser Leu Leu
1 5 10 15

Phe Val Leu Pro Ser Leu Ser Pro Cys Pro Thr His Val Leu Arg His
 20 25 30

Ser Gly Ser Thr Trp Xaa
 35

<210> 101

<211> 175

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (175)

<223> Xaa equals stop translation

<400> 101

Met Thr Phe Leu Leu Met Leu Leu Leu Ile Phe Phe Tyr Ile Phe Ala
 1 5 10 15

Val Thr Gly Val Tyr Val Phe Ser Glu Tyr Thr Arg Ser Pro Arg Gln
 20 25 30

Asp Leu Glu Tyr His Val Phe Phe Ser Asp Leu Pro Asn Ser Leu Val
 35 40 45

Thr Val Phe Ile Leu Phe Thr Leu Asp His Trp Tyr Ala Leu Leu Gln
 50 55 60

Asp Val Trp Lys Val Pro Glu Val Ser Arg Ile Phe Ser Ser Ile Tyr
 65 70 75 80

Phe Ile Leu Trp Leu Leu Leu Gly Ser Ile Ile Phe Arg Ser Ile Ile
 85 90 95

Val Ala Met Met Val Thr Asn Phe Gln Asn Ile Arg Lys Glu Leu Asn
 100 105 110

Glu Glu Met Ala Arg Arg Glu Val Gln Leu Lys Ala Asp Met Phe Lys
 115 120 125

Arg Gln Ile Ile Gln Arg Arg Lys Asn Met Ser His Glu Ala Leu Thr
 130 135 140

Ser Ser His Ser Lys Ile Glu Asp Arg Ser Phe Gly Leu Gly Asp Ser
 145 150 155 160

Cys Ala Arg Lys Ser Ala Arg Ala Asn Gly Asn Gly Ser Gly Xaa
 165 170 175

<210> 102

<211> 303

<212> PRT

<213> Homo sapiens

<400> 102

Met Ala Trp Cys Gly Arg Leu Leu Leu Ser Pro Ser Pro Thr Ala Ser
 1 5 10 15

Pro Ala Ala Arg Leu Leu Arg Thr Leu Ala Glu Thr Pro Pro Ala Asp
 20 25 30

Thr Phe Leu Leu Gly Asn Trp Cys Trp Met Cys Gln Arg Leu Trp Pro
 35 40 45

Trp Pro Ala Asn Gln Pro Leu Pro Gly Gly Leu Leu Pro Arg Pro Leu
 50 55 60

Ser Leu Ala Pro Ser Ser Ser Ser Ser Cys Cys Ser Pro Pro Cys Ser
 65 70 75 80

Gln Asp Gly Arg Met Ala Ala Gln Gly Ala Pro Arg Phe Leu Leu Thr
 85 90 95

Phe Asp Phe Asp Glu Thr Ile Val Asp Glu Asn Ser Asp Asp Ser Ile
 100 105 110

Val Arg Ala Ala Pro Gly Gln Arg Leu Pro Glu Ser Leu Arg Ala Thr
 115 120 125

Tyr Arg Glu Gly Phe Tyr Asn Glu Tyr Met Gln Arg Val Phe Lys Tyr
 130 135 140

Leu Gly Glu Gln Gly Val Arg Pro Arg Asp Leu Ser Ala Ile Tyr Glu
 145 150 155 160

Ala Ile Pro Leu Ser Pro Gly Met Ser Asp Leu Leu Gln Phe Val Ala
 165 170 175

Lys Gln Gly Ala Cys Phe Glu Val Ile Leu Ile Ser Asp Ala Asn Thr
 180 185 190

Phe Gly Val Glu Ser Ser Leu Arg Ala Ala Gly His His Ser Leu Phe
 195 200 205

Arg Arg Ile Leu Ser Asn Pro Ser Gly Pro Asp Ala Arg Gly Leu Pro
 210 215 220

Ala Pro Arg Leu Pro His Ala Pro Leu Ser Phe Arg Arg Pro Arg Arg

53

225 230 235 240
 Pro Ser Pro Ala Arg Ser Ala Pro Ala Trp Cys Pro Gly Lys Arg Cys
 245 250 255
 Arg Cys Ala Pro Pro Pro Ala Thr Gly Ala Glu Val Val Leu Ser Leu
 260 265 270
 Ala Ala Cys Arg Gly Val Pro Gly Pro Thr Ala Glu Gly Ala Gly Lys
 275 280 285
 Gly Asp Ser Ala Lys Thr Ala Leu Leu Lys Lys Lys Lys Lys Lys
 290 295 300

<210> 103
 <211> 52
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (52)
 <223> Xaa equals stop translation

<400> 103
 Ile Ile Ser Leu Thr Pro Leu Trp Cys Leu Pro Ser Ala Ile Ala Cys
 1 5 10 15
 Ser His Ile Leu Ser Phe Gly Phe Pro Pro Glu Ile Pro Asn Phe Pro
 20 25 30
 Thr Arg Ser Tyr Lys Ala Ile Gln Phe Ser Ser Ala Ser Ile Arg Lys
 35 40 45
 Leu Ser Phe Xaa
 50

<210> 104
 <211> 55
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (31)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE

<222> (40)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (55)

<223> Xaa equals stop translation

<400> 104

Met	Cys	Ala	Arg	Lys	Cys	Arg	Met	Leu	Leu	Val	Leu	Gln	Thr	Val	Val
1				5				10						15	

Cys	Gly	Thr	Pro	Lys	Pro	Leu	Ser	Phe	His	Asp	Ala	Phe	Cys	Xaa	Val
			20					25					30		

Ile	Thr	Phe	Pro	Trp	Arg	Arg	Xaa	Gln	Pro	Trp	Trp	Arg	Ala	Leu	Xaa
		35					40					45			

Trp	Leu	Cys	Pro	Ser	Ala	Xaa
	50					55

<210> 105

<211> 39

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (39)

<223> Xaa equals stop translation

<400> 105

Met	Leu	Ser	Pro	Ser	Gln	Thr	Pro	Gly	Ser	Cys	Leu	Lys	Trp	Ala	Pro
1				5				10						15	

Ser	Trp	Val	Thr	Arg	Cys	Thr	Phe	Trp	Thr	Leu	Val	Val	Ala	Ser	Leu
			20					25					30		

Ala	Gln	Lys	Gly	Pro	Lys	Xaa
			35			

<210> 106

<211> 92

<212> PRT

55

<213> Homo sapiens

<220>

<221> SITE

<222> (92)

<223> Xaa equals stop translation

<400> 106

Phe Leu Ile Ile Ile Ile Ser Ala Thr Val Met Phe Leu His Val Ser
 1 5 10 15

Glu Arg His Cys Pro Cys Leu Arg Leu Glu Val Leu Ser Ala Lys Val
 20 25 30

Phe Phe Ser Cys Ile Val Arg Ser Ile His Pro Leu Cys Ala Leu Ser
 35 40 45

Ala Phe Glu Arg Leu Gly Cys Ser Gln Ala Ala Val Leu Arg Asp Leu
 50 55 60

Lys Arg Asp Leu Val Ser Leu Gly Ala Glu Ser Ile Tyr Leu Gly Thr
 65 70 75 80

Leu Phe Gln Glu Arg Pro Cys Leu His Phe His Xaa
 85 90

<210> 107

<211> 70

<212> PRT

<213> Homo sapiens

<400> 107

Gly Met Glu Leu Leu Ala Arg Leu Pro Pro Thr Leu Cys Thr Trp Leu
 1 5 10 15

Lys Ala Met Asp Pro Gln Asp Leu Gln Asn Thr Glu Val Pro Ile Ala
 20 25 30

Thr Thr Ala Lys Leu Val Asn Lys Val Ile Glu Leu Leu Pro Glu Lys
 35 40 45

His Gly Gln Tyr Gly Leu Ala Leu His Leu Ile Glu Ala Val Glu Ala
 50 55 60

Ile Ser Leu Pro Ser Leu
 65 70

<210> 108

<211> 70

56

<212> PRT

<213> Homo sapiens

<400> 108

Gly Met Glu Leu Leu Ala Arg Leu Pro Pro Thr Leu Cys Thr Trp Leu
 1 5 10 15

Lys Ala Met Asp Pro Gln Asp Leu Gln Asn Thr Glu Val Pro Ile Ala
 20 25 30

Thr Thr Ala Lys Leu Val Asn Lys Val Ile Glu Leu Leu Pro Glu Lys
 35 40 45

His Gly Gln Tyr Gly Leu Ala Leu His Leu Ile Glu Ala Val Glu Ala
 50 55 60

Ile Ser Leu Pro Ser Leu
 65 70

<210> 109

<211> 491

<212> PRT

<213> Homo sapiens

<400> 109

Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Asn Glu
 1 5 10 15

Cys Glu Lys Ala Phe Ser Arg Ser Glu Asn Leu Ile Asn His Gln Arg
 20 25 30

Ile His Thr Gly Asp Lys Pro Tyr Lys Cys Asp Gln Cys Gly Lys Gly
 35 40 45

Phe Ile Glu Gly Pro Ser Leu Thr Arg His Gln Arg Ile His Thr Gly
 50 55 60

Glu Lys Pro Tyr Lys Cys Asp Glu Cys Gly Lys Ala Phe Ser Gln Arg
 65 70 75 80

Thr His Leu Val Gln His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr
 85 90 95

Thr Cys Asn Glu Cys Gly Lys Ala Phe Ser Gln Arg Gly His Phe Met
 100 105 110

Glu His Gln Lys Ile His Thr Gly Gly Lys Pro Phe Lys Cys Asp Glu
 115 120 125

Cys Asp Lys Thr Phe Thr Arg Ser Thr His Leu Thr Pro His Pro Lys

130	135	140
Ile His Thr Gly Glu Lys Thr Tyr Lys Cys Asn Glu Cys Gly Lys Ala		
145	150	155 160
Phe Asn Gly Pro Ser Thr Phe Ile Arg His His Met Ile His Thr Gly		
	165	170 175
Glu Lys Pro Tyr Glu Cys Asn Glu Cys Gly Lys Ala Phe Ser Gln His		
	180	185 190
Ser Asn Leu Thr Gln His Gln Lys Thr His Thr Gly Glu Lys Pro Tyr		
	195	200 205
Asp Cys Ala Glu Cys Gly Lys Ser Phe Ser Tyr Trp Ser Ser Leu Ala		
	210	215 220
Gln His Leu Lys Ile His Thr Gly Glu Lys Pro Tyr Lys Cys Asn Glu		
	225	230 235 240
Cys Gly Lys Ala Phe Ser Tyr Cys Ser Ser Leu Thr Gln His Arg Arg		
	245	250 255
Ile His Thr Gly Glu Lys Pro Phe Glu Cys Ser Glu Cys Gly Lys Ala		
	260	265 270
Phe Ser Tyr Leu Ser Asn Leu Asn Gln His Gln Lys Thr His Thr Gly		
	275	280 285
Glu Lys Ala Tyr Glu Cys Glu Glu Cys Gly Lys Ala Phe Ile Arg Ser		
	290	295 300
Ser Ser Leu Ala Gln His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr		
	305	310 315 320
Gln Cys His Glu Cys Gly Lys Thr Phe Ser Tyr Gly Ser Ser Leu Ile		
	325	330 335
Gln His Arg Lys Ile His Thr Gly Glu Arg Pro Tyr Lys Cys Asn Glu		
	340	345 350
Cys Gly Arg Ala Phe Asn Gln Asn Ile His Leu Thr Gln His Lys Arg		
	355	360 365
Ile His Thr Gly Ala Lys Pro Tyr Glu Cys Ala Glu Cys Gly Lys Ala		
	370	375 380
Phe Arg His Cys Ser Ser Leu Ala Gln His Gln Lys Thr His Thr Glu		
	385	390 395 400
Glu Lys Pro Tyr Gln Cys Asn Lys Cys Glu Lys Thr Phe Ser Gln Ser		

58

405 410 415
 Ser His Leu Thr Gln His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr
 420 425 430
 Lys Cys Asn Glu Cys Asp Lys Ala Phe Ser Arg Ser Thr His Leu Thr
 435 440 445
 Glu His Gln Asn Thr His Thr Gly Glu Lys Pro Tyr Asn Cys Asn Glu
 450 455 460
 Cys Arg Lys Thr Phe Ser Gln Ser Thr Tyr Leu Ile Gln His Gln Arg
 465 470 475 480
 Ile His Ser Gly Glu Lys Pro Phe Gly Cys Asn
 485 490

<210> 110

<211> 493

<212> PRT

<213> Homo sapiens

<400> 110

Arg Asn Leu Arg Asn His Gly Leu Glu Arg Leu Cys Glu Ser Asn Asp
 1 5 10 15
 Gln Cys Gly Glu Ala Leu Ser Gln Ile Pro His Leu Asn Leu Tyr Lys
 20 25 30
 Lys Ile Pro Pro Gly Val Lys Gln Tyr Glu Tyr Asn Thr Tyr Gly Lys
 35 40 45
 Val Phe Met His Arg Arg Thr Ser Leu Lys Ser Pro Ile Thr Val His
 50 55 60
 Thr Gly His Lys Pro Tyr Gln Cys Gln Glu Cys Gly Gln Ala Tyr Ser
 65 70 75 80
 Cys Arg Ser His Leu Arg Met His Val Arg Thr His Asn Gly Glu Arg
 85 90 95
 Pro Tyr Val Cys Lys Leu Cys Gly Lys Thr Phe Pro Arg Thr Ser Ser
 100 105 110
 Leu Asn Arg His Val Arg Ile His Thr Ala Glu Lys Thr Tyr Glu Cys
 115 120 125
 Lys Gln Cys Gly Lys Ala Phe Ile Asp Phe Ser Ser Leu Thr Ser His
 130 135 140

Leu Arg Ser His Thr Gly Glu Lys Pro Tyr Lys Cys Lys Glu Cys Gly
 145 150 155 160

Lys Ala Phe Ser Tyr Ser Ser Thr Phe Arg Arg His Thr Ile Thr His
 165 170 175

Thr Gly Glu Lys Pro Tyr Lys Cys Lys Glu Cys Ala Glu Ala Phe Ser
 180 185 190

Tyr Ser Ser Thr Phe Arg Arg His Met Ile Ser His Thr Gly Glu Lys
 195 200 205

Pro His Lys Cys Lys Glu Cys Gly Glu Ala Phe Ser Tyr Ser Ser Ala
 210 215 220

Phe Arg Arg His Met Ile Thr His Thr Gly Glu Lys Pro Tyr Glu Cys
 225 230 235 240

Lys Gln Cys Gly Lys Thr Phe Ile Tyr Leu Gln Ser Phe Arg Arg His
 245 250 255

Glu Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Gln Cys Gly
 260 265 270

Lys Thr Phe Ile Tyr Pro Gln Ser Phe Arg Arg His Glu Arg Thr His
 275 280 285

Gly Gly Glu Lys Pro Tyr Glu Cys Asn Gln Cys Gly Lys Ala Phe Ser
 290 295 300

His Pro Ser Ser Phe Arg Gly His Met Arg Val His Thr Gly Glu Lys
 305 310 315 320

Pro Tyr Glu Cys Lys Gln Cys Gly Lys Thr Phe Asn Trp Pro Ile Ser
 325 330 335

Leu Arg Lys His Met Arg Thr His Thr Arg Glu Lys Pro Tyr Glu Cys
 340 345 350

Lys Gln Cys Gly Lys Ala Phe Ser Leu Ser Ala Cys Phe Arg Glu His
 355 360 365

Val Arg Met His Pro Glu Asp Lys Ser Tyr Glu Cys Lys Leu Cys Gly
 370 375 380

Lys Ala Phe Tyr Cys His Ile Ser Leu Gln Lys His Met Arg Arg His
 385 390 395 400

Thr Ala Glu Lys Leu Tyr Lys Cys Lys Gln Cys Gly Lys Ala Phe Ser
 405 410 415

60

Trp Pro Glu Leu Leu Gln Gln His Val Arg Thr His Thr Val Glu Lys
 420 425 430

Pro Tyr Glu Cys Lys Glu Cys Gly Lys Val Phe Lys Trp Pro Ser Ser
 435 440 445

Leu Pro Ile His Met Arg Leu His Thr Gly Glu Lys Pro Tyr Gln Cys
 450 455 460

Lys His Cys Gly Lys Ala Phe Asn Cys Ser Ser Ser Leu Arg Arg His
 465 470 475 480

Val Arg Ile His Thr Thr Glu Lys Gln Tyr Lys Cys Asn
 485 490

<210> 111

<211> 102

<212> PRT

<213> Homo sapiens

<400> 111

Met Ser Val Phe Tyr Pro Ile His Cys Thr Asp Tyr Leu Arg Ser Ala
 1 5 10 15

Glu Met Thr Glu Val Ile Met Asn Thr Gln Ser Met Asp Glu Ile Gly
 20 25 30

Leu Ser Pro Arg Lys Asp Ser Tyr Gln Ile Phe Pro Asp Pro Ser Asp
 35 40 45

Phe Glu Arg Cys Cys Lys Leu Lys Asp Arg Leu Pro Ser Ile Val Val
 50 55 60

Glu Pro Thr Glu Gly Asp Val Glu Ser Gly Glu Leu Arg Trp Pro Pro
 65 70 75 80

Glu Glu Phe Val Val Asp Glu Asp Lys Glu Gly Thr Cys Asp Gln Thr
 85 90 95

Lys Lys Glu Asn Glu Gln
 100

<210> 112

<211> 104

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 112

Met	Ser	Ile	Tyr	Phe	Pro	Ile	His	Cys	Pro	Asp	Tyr	Leu	Arg	Ser	Ala
1				5					10					15	

Lys	Met	Thr	Glu	Val	Met	Met	Asn	Thr	Gln	Pro	Met	Glu	Glu	Ile	Gly
			20					25					30		

Leu	Ser	Pro	Arg	Lys	Asp	Gly	Leu	Ser	Tyr	Gln	Ile	Phe	Pro	Asp	Pro
		35					40					45			

Ser	Xaa	Phe	Xaa	Arg	Cys	Cys	Lys	Leu	Lys	Asp	Arg	Leu	Pro	Ser	Ile
	50					55					60				

Val	Val	Glu	Pro	Thr	Glu	Gly	Glu	Val	Glu	Ser	Gly	Glu	Leu	Arg	Trp
65					70				75						80

Pro	Pro	Glu	Glu	Phe	Leu	Val	Gln	Glu	Asp	Glu	Gln	Asp	Asn	Cys	Glu
				85					90					95	

Glu	Thr	Ala	Lys	Glu	Asn	Lys	Glu
				100			

<210> 113

<211> 186

<212> PRT

<213> Homo sapiens

<400> 113

Gly	Ser	Leu	Gly	Val	Ser	Phe	Pro	Leu	Pro	Pro	Pro	Ile	Phe	Thr	Asn
1				5					10					15	

Tyr	Pro	Pro	Ala	Val	Pro	Pro	Gly	Ala	Val	Pro	Pro	Val	Phe	Thr	Gln
			20					25					30		

Pro	Thr	Ala	Asn	Ile	Met	Pro	Ser	Ser	Ser	His	Leu	Phe	Gly	Ser	Val
		35						40				45			

Ser	Trp	Arg	Pro	Pro	Val	Pro	Val	Ala	Gly	Asn	Ala	Phe	His	Tyr	Pro
	50						55				60				

Ser	Tyr	Pro	Gly	Thr	Met	Pro	Leu	Ala	Gly	Gly	Val	Pro	Gly	Gly	Val
65					70					75					80

His Ser Gln Phe Ile Pro Leu Gln Val Thr Lys Lys Arg Val Ala Asn
85 90 95

Arg Lys Asn Phe Glu Asn Lys Glu Ala Gln Ser Ser Gln Ala Thr Pro
100 105 110

Leu Gln Thr Asn Lys Pro Gly Ser Ser Glu Ala Thr Lys Met Thr Pro
115 120 125

Gln Glu Ser Pro Pro Ala Ser Ser Ser Ser Gln Ala Ala Gln Pro
130 135 140

Val Ser Ser His Val Glu Thr Ala Ser Gln Gly His Val Gly Ser Gln
145 150 155 160

Pro Arg Ser Ala Pro Ser Ser Ser Lys Arg Lys Ser Arg Lys Leu Ala
165 170 175

Val Asn Phe Ser Val Ser Lys Pro Ser Glu
180 185

<210> 114

<211> 188

<212> PRT

<213> Homo sapiens

<400> 114

Gly Ser Leu Gly Met Asn Phe Pro Leu Pro Ser Gln Val Phe Ala Asn
1 5 10 15

Tyr Pro Ser Ala Val Pro Pro Gly Thr Ile Pro Pro Ala Phe Pro Pro
20 25 30

Pro Thr Ala Asn Ile Met Pro Ser Ser Ser His Leu Phe Gly Ser Met
35 40 45

Pro Trp Gly Pro Ser Val Pro Val Pro Gly Lys Pro Phe His His Thr
50 55 60

Leu Tyr Ser Gly Thr Met Pro Met Ala Gly Gly Ile Pro Gly Gly Val
65 70 75 80

His Asn Gln Phe Ile Pro Leu Gln Val Thr Lys Lys Arg Val Ala Asn
85 90 95

Lys Lys Asn Phe Glu Asn Lys Glu Ala Gln Ser Ser Gln Ala Thr Pro
100 105 110

Val Gln Thr Ser Gln Pro Asp Ser Ser Asn Ile Val Lys Val Ser Pro

115	120	125
Arg Glu Ser Ser Ser Ala Ser Leu Lys Ser Ser Pro Ile Ala Gln Pro		
130	135	140
Ala Ser Ser Phe Gln Val Glu Thr Ala Ser Gln Gly His Ser Ile Ser		
145	150	155
His His Lys Ser Thr Pro Ile Ser Ser Ser Arg Arg Lys Ser Arg Lys		
165	170	175
Leu Ala Val Asn Phe Gly Val Ser Lys Pro Ser Glu		
180	185	

<210> 115
 <211> 122
 <212> PRT
 <213> Homo sapiens

<400> 115
 Thr Glu Met Val Ser Gln Pro Ser His Pro Gly Ser Glu Leu Lys Ala
 1 5 10 15
 Glu Asn Asn Ile Glu Ile Leu Ser Glu Ser Gln Ala Ala Lys Val Ile
 20 25 30
 Val Ser Val Glu Asp Ala Val Pro Ala Ile Phe Cys Gly Lys Ile Lys
 35 40 45
 Gly Leu Ser Gly Val Ser Thr Lys Asn Phe Ser Phe Lys Arg Glu Asp
 50 55 60
 Ser Val Leu Gln Gly Tyr Asp Ile Asn Ser Gln Gly Glu Glu Ser Leu
 65 70 75 80
 Gly Asn Ala Glu Pro Leu Arg Lys Pro Ile Lys Asn Arg Ser Ile Lys
 85 90 95
 Leu Lys Lys Val Asn Ser Gln Glu Ile His Met Leu Pro Ile Lys Lys
 100 105 110
 Gln Arg Leu Ala Thr Phe Phe Pro Arg Lys
 115 120

<210> 116
 <211> 122
 <212> PRT
 <213> Homo sapiens

64

<400> 116

Thr Glu Met Leu Ser Gln Pro Asn His Pro Ser Gly Glu Val Lys Ala
 1 5 10 15

Glu Asn Asn Ile Glu Met Val Gly Glu Ser Gln Ala Ala Lys Val Ile
 20 25 30

Val Ser Val Glu Asp Ala Val Pro Thr Ile Phe Cys Gly Lys Ile Lys
 35 40 45

Gly Leu Ser Gly Val Ser Thr Lys Asn Phe Ser Phe Lys Arg Glu Asp
 50 55 60

Ser Val Leu Gln Gly Tyr Asp Ile Asn Ser Gln Gly Glu Glu Ser Met
 65 70 75 80

Gly Asn Ala Glu Pro Leu Arg Lys Pro Ile Lys Asn Arg Ser Ile Lys
 85 90 95

Leu Lys Lys Val Asn Ser Gln Glu Ile His Met Leu Pro Ile Lys Lys
 100 105 110

Gln Arg Leu Ala Thr Phe Phe Pro Arg Lys
 115 120

<210> 117

<211> 134

<212> PRT

<213> Homo sapiens

<400> 117

Gly Leu His Ser Phe Lys Gly Thr Gln Thr Thr Leu Glu Lys Asp Glu
 1 5 10 15

Leu Lys Pro Leu Asp Ile Leu Gln Ser Lys Glu Tyr Phe Gln Leu Ser
 20 25 30

Arg His Thr Val Ile Lys Met Gly Ser Glu Asn Glu Ala Leu Asp Leu
 35 40 45

Ser Met Lys Ser Val Pro Trp Leu Lys Ala Gly Glu Ala Ser Pro Pro
 50 55 60

Val Phe Gln Glu Asp Ala Ala Leu Asp Leu Ser Leu Ala Ala His Arg
 65 70 75 80

Lys Ala Glu Ala Pro Pro Glu Thr Leu Tyr Asn Asn Ser Gly Ser Ala
 85 90 95

Asp Ile Gln Gly His Thr Ile Leu Glu Lys Leu Ser Ser Gly Met Glu

65

100 105 110

Met Pro Phe Ala Pro Ala Lys Cys Ser Glu Ala Ser Ala Met Met Glu
 115 120 125

Ser His Ser Ser Asn Ser
 130

<210> 118
 <211> 134
 <212> PRT
 <213> Homo sapiens

<400> 118

Gly Leu His Pro Phe Lys Gly Thr Gln Thr Pro Leu Glu Lys Asp Glu
 1 5 10 15

Leu Lys Pro Phe Asp Ile Leu Gln Pro Lys Glu Tyr Phe Gln Leu Ser
 20 25 30

Arg His Thr Val Ile Lys Met Gly Ser Glu Asn Glu Ala Leu Asp Leu
 35 40 45

Ser Met Lys Ser Val Pro Trp Leu Lys Ala Gly Glu Val Ser Pro Pro
 50 55 60

Ile Phe Gln Glu Asp Ala Ala Leu Asp Leu Ser Val Ala Ala His Arg
 65 70 75 80

Lys Ser Glu Pro Pro Pro Glu Thr Leu Tyr Asp Ser Gly Ala Ser Val
 85 90 95

Asp Ser Ser Gly His Thr Val Met Glu Lys Leu Pro Ser Gly Met Glu
 100 105 110

Ile Ser Phe Ala Pro Ala Thr Ser His Glu Ala Pro Ala Met Met Asp
 115 120 125

Ser His Ile Ser Ser Ser
 130

<210> 119
 <211> 33
 <212> PRT
 <213> Homo sapiens

<400> 119

Ser Asn Ala Ile His Asn Asn Leu Phe Gln Gly Ala Glu Asp Ser Glu
 1 5 10 15

66

Ala Gln Pro Gln Leu Leu Asp Leu Arg Ile Pro Arg Lys Pro Gln Glu
20 25 30

Pro

<210> 120

<211> 33

<212> PRT

<213> Homo sapiens

<400> 120

Ser Ser Thr Ile His Asn Asn Leu Phe Gln Gly Ala Glu Asp Pro Glu
1 5 10 15

Ala Gln Pro Gln Leu Leu Asp Leu Arg Ile Pro Ser Gln Pro Gln Ser
20 25 30

Pro

<210> 121

<211> 76

<212> PRT

<213> Homo sapiens

<400> 121

Leu Pro Phe Glu Ala Val Leu Gln Asn Leu Phe Pro Thr Gln Gly Ser
1 5 10 15

Leu Gly Pro Pro Pro Cys Gln Pro Pro Pro Gly Tyr Ala Pro Val Pro
20 25 30

Pro Gln Pro Phe Asn Ser Pro Leu Ser Pro Leu Val Pro Pro Ala Thr
35 40 45

Leu Leu Val Pro Tyr Pro Val Ile Val Pro Leu Pro Val Pro Val Pro
50 55 60

Ile Pro Ile Pro Val Pro Val Pro Gln Ser Thr Glu
65 70 75

<210> 122

<211> 33

<212> PRT

<213> Homo sapiens

67

<400> 122

Ser Ser Thr Ile His Asn Asn Leu Phe Gln Gly Ala Glu Asp Pro Glu
 1 5 10 15

Ala Gln Pro Gln Leu Leu Asp Leu Arg Ile Pro Ser Gln Pro Gln Ser
 20 25 30

Pro

<210> 123

<211> 362

<212> PRT

<213> Homo sapiens

<400> 123

Leu Thr Gln Phe Asp Ser Asn Ile Ala Pro Ala Asp Pro Asp Thr Ala
 1 5 10 15

Ile Val His Pro Val Pro Ile Arg Met Thr Pro Ser Lys Ile His Met
 20 25 30

Gln Glu Met Glu Leu Lys Arg Thr Ser Ser Asp His Thr Asn Pro Thr
 35 40 45

Ser Pro Leu Leu Val Lys Pro Ser Asp Leu Ser Glu Glu Asn Lys Ile
 50 55 60

Asn Ser Ser Val Lys Phe Pro Ser Gly Asn Thr Val Asp Gly Tyr Ser
 65 70 75 80

Ser Ser Asp Ser Phe Pro Ser Asp Pro Glu Gln Ile Gly Ser Ser Val
 85 90 95

Thr Arg Gln Arg Ser His Ser Gly Thr Ser Pro Asp Asn Thr Ala Pro
 100 105 110

Pro Pro Pro Pro Arg Pro Gln Pro Ser His Ser Arg Ser Ser Ser
 115 120 125

Leu Asp Met Asn Arg Thr Phe Ala Val Thr Thr Gly Gln Gln Gln Ala
 130 135 140

Gly Val Val Ala His Pro Pro Ala Val Pro Pro Arg Pro Gln Pro Ser
 145 150 155 160

Gln Ala Pro Gly Pro Ser Val His Arg Pro Val Asp Ala Asp Gly Leu
 165 170 175

Ile Thr His Thr Ser Thr Ser Pro Gln Gln Ile Pro Glu Gln Pro Asn

68

180						185						190					
Phe	Ala	Asp	Phe	Ser	Gln	Phe	Glu	Val	Phe	Ala	Ala	Ser	Asn	Val	Ser		
195						200						205					
Glu	Glu	Gln	Asp	Ser	Glu	Ala	Glu	Lys	His	Pro	Glu	Val	Leu	Pro	Ala		
210						215						220					
Glu	Lys	Ala	Ser	Asp	Pro	Ser	Ser	Ser	Leu	Arg	Ala	Ala	Gln	Ala	Asp		
225			230						235			240					
Ser	Lys	Ala	Glu	Glu	Lys	Thr	Ala	Thr	Asn	Val	Pro	Ala	Asn	Val	Ser		
			245						250			255					
Lys	Gly	Thr	Thr	Pro	Leu	Ala	Pro	Pro	Pro	Lys	Pro	Val	Arg	Arg	Arg		
			260						265			270					
Leu	Lys	Ser	Glu	Asp	Glu	Leu	Arg	Pro	Asp	Val	Asp	Glu	His	Thr	Gln		
275						280						285					
Lys	Thr	Gly	Val	Leu	Ala	Ala	Val	Leu	Thr	Ser	Gln	Pro	Ser	Ile	Pro		
290			295						300								
Arg	Ser	Val	Gly	Lys	Asp	Lys	Lys	Ala	Ile	Gln	Ala	Ser	Ile	Arg	Arg		
305			310						315			320					
Asn	Lys	Glu	Thr	Asn	Thr	Val	Leu	Ala	Arg	Leu	Asn	Ser	Glu	Leu	Gln		
			325						330			335					
Gln	Gln	Leu	Lys	Asp	Val	Leu	Glu	Glu	Arg	Ile	Ser	Leu	Glu	Val	Gln		
340						345						350					
Leu	Glu	Gln	Leu	Arg	Pro	Phe	Ser	His	Leu								
355			360														

```
<210> 124
<211> 363
<212> PRT
<213> Homo sapiens
```

```

<400> 124
Leu Asn Gln Thr Trp Pro Glu Leu Asn Gln Ser Ser Glu Asp Thr Ala
 1             5             10             15
Ile Val His Pro Val Pro Ile Arg Met Thr Pro Ser Lys Ile His Met
      20             25             30
Gln Glu Met Glu Leu Lys Arg Thr Gly Ser Asp His Thr Asn Pro Thr
      35             40             45

```

Ser Pro Leu Leu Val Lys Pro Ser Asp Leu Leu Glu Glu Asn Lys Ile
 50 55 60
 Asn Ser Ser Val Lys Phe Ala Ser Gly Asn Thr Val Ala Asp Gly Tyr
 65 70 75 80
 Ser Ser Ser Asp Ser Phe Thr Ser Asp Pro Glu Gln Ile Gly Ser Asn
 85 90 95
 Val Thr Arg Gln Arg Ser His Ser Gly Thr Ser Pro Asp Asn Thr Ala
 100 105 110
 Pro Pro Pro Pro Pro Pro Arg Pro Gln Pro Ser His Ser Arg Ser Ser
 115 120 125
 Ser Leu Asp Met Asn Arg Thr Phe Thr Val Thr Thr Gly Gln Gln Gln
 130 135 140
 Ala Gly Val Val Ala His Pro Pro Ala Val Pro Pro Arg Pro Gln Pro
 145 150 155 160
 Ser Gln Ala Pro Gly Pro Ala Val His Arg Pro Val Asp Ala Asp Gly
 165 170 175
 Leu Ile Thr His Thr Ser Thr Ser Pro Gln Gln Ile Pro Glu Gln Pro
 180 185 190
 Asn Phe Ala Asp Phe Ser Gln Phe Glu Val Phe Ala Ala Ser Asn Val
 195 200 205
 Asn Asp Glu Gln Asp Asp Glu Ala Glu Lys His Pro Glu Val Leu Pro
 210 215 220
 Ala Glu Lys Ala Ser Asp Pro Ala Ser Ser Leu Arg Val Ala Lys Thr
 225 230 235 240
 Asp Ser Lys Thr Glu Glu Lys Thr Ala Ala Ser Ala Pro Ala Asn Val
 245 250 255
 Ser Lys Gly Thr Thr Pro Leu Ala Pro Pro Pro Lys Pro Val Arg Arg
 260 265 270
 Arg Leu Lys Ser Glu Asp Glu Leu Arg Pro Glu Val Asp Glu His Thr
 275 280 285
 Gln Lys Thr Gly Val Leu Ala Ala Val Leu Ala Ser Gln Pro Ser Ile
 290 295 300
 Pro Arg Ser Val Gly Lys Asp Lys Lys Ala Ile Gln Ala Ser Ile Arg
 305 310 315 320

70

Arg Asn Lys Glu Thr Asn Thr Val Leu Ala Arg Leu Asn Ser Glu Leu
 325 330 335

Gln Gln Gln Leu Lys Asp Val Leu Glu Glu Arg Ile Ser Leu Glu Val
 340 345 350

Gln Leu Glu Gln Leu Arg Pro Phe Ser His Leu
 355 360

<210> 125

<211> 405

<212> PRT

<213> Homo sapiens

<400> 125

Trp Arg Ser His Arg Lys His Val Phe Val Leu Ser Glu Ala Gly Lys
 1 5 10 15

Pro Ile Tyr Thr Arg Tyr Gly Ser Glu Glu Ala Leu Ser Ser Thr Met
 20 25 30

Gly Val Met Met Ala Leu Val Ser Phe Val Glu Ser Asp Lys Asn Thr
 35 40 45

Ile Arg Ser Ile His Ala Asp Gly Cys Lys Val Ile Phe Leu Ala Lys
 50 55 60

Ser Pro Leu Val Leu Val Gly Val Ser Gln Thr Tyr Gln Ser Asp Lys
 65 70 75 80

Glu Leu Leu Arg Glu Leu Gln Tyr Ile Tyr Tyr Gln Ile Val Ser Leu
 85 90 95

Leu Thr Leu Thr Gln Leu Asn His Ile Phe Gln Asn Lys Gln Asn Tyr
 100 105 110

Asp Leu Arg Arg Leu Leu Ala Gly Ser Glu Tyr Leu Thr Asp Asn Leu
 115 120 125

Leu His Arg Leu Asp Arg Asp Pro Gly Leu Leu Leu Ser Ala Val Thr
 130 135 140

Cys Leu Pro Leu Ser Asn Ser Val Arg Asp Val Val Ser Ser Ser Leu
 145 150 155 160

Gln Ala Ala Lys Ala Lys Asn Leu Val Phe Ser Ile Leu Leu Ala Gly
 165 170 175

Asp Arg Leu Val Thr Leu Val Arg Lys Lys Asp Gln Phe Leu His His
 180 185 190

Ile Asp Leu His Leu Val Met Asn Leu Val Gly Ser Ser Ser Ser Phe
 195 200 205
 Arg Glu Gly Glu Gly Trp Thr Pro Ile Cys Leu Pro Lys Phe Asn Thr
 210 215 220
 Ala Gly Phe Phe His Ala His Ile Ser Tyr Leu Glu Ser Ala Ser Asp
 225 230 235 240
 Leu Cys Leu Ile Leu Val Ser Thr Asp Arg Glu Asp Phe Phe Asn Met
 245 250 255
 Ser Asp Cys Lys Gln Arg Phe Leu Glu Arg Leu Thr Lys Arg Thr Ala
 260 265 270
 Tyr Gln Ala Leu Lys Glu Ala Leu Lys Cys Pro Ser Tyr Ser Val Glu
 275 280 285
 Gln Val Gly Ile Pro Glu Leu Arg His Phe Leu Tyr Lys Ser Lys Ser
 290 295 300
 Ser Gly Leu Tyr Thr Ser Pro Glu Phe Pro Glu Leu Tyr Gln Ser Asp
 305 310 315 320
 Glu Glu Gln Glu Arg Leu Met Gly Leu Tyr Gln Asp Leu His Ser His
 325 330 335
 Leu His His Pro Val Arg Pro Leu Arg Phe Phe Tyr Arg Cys Thr Asn
 340 345 350
 Lys Glu Asn Leu Leu Ala Trp Val Thr Asn Gly Phe Gln Leu Tyr Leu
 355 360 365
 Cys Phe Ser Pro Leu Gly Thr Lys Ala Met Ala Val Ser Ala Val Asn
 370 375 380
 Lys Leu Leu Lys Trp Ile Arg Lys Glu Glu Asp Arg Leu Phe Ile Leu
 385 390 395 400
 Ser Pro Leu Thr Tyr
 405

<210> 126

<211> 405

<212> PRT

<213> Homo sapiens

<400> 126

Trp Arg Leu His Gln Lys His Val Phe Val Leu Ser Glu Ala Gly Lys

72

1	5	10	15
Pro Val Tyr Ser Arg Tyr Gly Ser Glu Glu Ala Leu Ser Ser Thr Met	20	25	30
Gly Val Met Val Ala Leu Val Ser Phe Leu Glu Ala Asp Lys Asn Ala	35	40	45
Ile Arg Ser Ile His Ala Asp Gly Tyr Lys Val Val Phe Val Arg Arg	50	55	60
Ser Pro Leu Val Leu Val Ala Val Ala Arg Thr Arg Gln Ser Ala Gln	65	70	75
Glu Leu Ala Gln Glu Leu Leu Tyr Ile Tyr Tyr Gln Ile Leu Ser Leu	85	90	95
Leu Thr Gly Ala Gln Leu Ser His Ile Phe Gln Gln Lys Gln Asn Tyr	100	105	110
Asp Leu Arg Arg Leu Leu Ser Gly Ser Glu Arg Ile Thr Asp Asn Leu	115	120	125
Leu Gln Leu Met Ala Arg Asp Pro Ser Phe Leu Met Gly Ala Ala Arg	130	135	140
Cys Leu Pro Leu Ala Ala Ala Val Arg Asp Thr Val Ser Ala Ser Leu	145	150	155
Gln Gln Ala Arg Ala Arg Ser Leu Val Phe Ser Ile Leu Leu Ala Arg	165	170	175
Asn Gln Leu Val Ala Leu Val Arg Arg Lys Asp Gln Phe Leu His Pro	180	185	190
Ile Asp Leu His Leu Leu Phe Asn Leu Ile Ser Ser Ser Ser Ser Phe	195	200	205
Arg Glu Gly Glu Ala Trp Thr Pro Val Cys Leu Pro Lys Phe Asn Ala	210	215	220
Ala Gly Phe Phe His Ala His Ile Ser Tyr Leu Glu Pro Asp Thr Asp	225	230	235
Leu Cys Leu Leu Leu Val Ser Thr Asp Arg Glu Asp Phe Phe Ala Val	245	250	255
Ser Asp Cys Arg Arg Arg Phe Gln Glu Arg Leu Arg Lys Arg Gly Ala	260	265	270
His Leu Ala Leu Arg Glu Ala Leu Arg Thr Pro Tyr Tyr Ser Val Ala			

275	280	285
Gln Val Gly Ile Pro Asp Leu Arg His Phe Leu Tyr Lys Ser Lys Ser		
290	295	300
Ser Gly Leu Phe Thr Ser Pro Glu Ile Glu Ala Pro Tyr Thr Ser Glu		
305	310	315
Glu Glu Gln Glu Arg Leu Leu Gly Leu Tyr Gln Tyr Leu His Ser Arg		
325	330	335
Ala His Asn Ala Ser Arg Pro Leu Lys Thr Ile Tyr Tyr Thr Gly Pro		
340	345	350
Asn Glu Asn Leu Leu Ala Trp Val Thr Gly Ala Phe Glu Leu Tyr Met		
355	360	365
Cys Tyr Ser Pro Leu Gly Thr Lys Ala Ser Ala Val Ser Ala Ile His		
370	375	380
Lys Leu Met Arg Trp Ile Arg Lys Glu Glu Asp Arg Leu Phe Ile Leu		
385	390	395
Thr Pro Leu Thr Tyr		
405		

<210> 127

<211> 232

<212> PRT

<213> Homo sapiens

<400> 127

Ser Glu Ile Val Gly Ser Ile Lys Met Arg Val Phe Leu Ser Gly Met			
1	5	10	15
Pro Glu Leu Arg Leu Gly Leu Asn Asp Lys Val Leu Phe Asp Asn Thr			
20	25	30	
Gly Arg Gly Lys Ser Lys Ser Val Glu Leu Glu Asp Val Lys Phe His			
35	40	45	
Gln Cys Val Arg Leu Ser Arg Phe Glu Asn Asp Arg Thr Ile Ser Phe			
50	55	60	
Ile Pro Pro Asp Gly Glu Phe Glu Leu Met Ser Tyr Arg Leu Asn Thr			
65	70	75	80
His Val Lys Pro Leu Ile Trp Ile Glu Ser Val Ile Glu Lys His Ser			
85	90	95	

74

His Ser Arg Ile Glu Tyr Met Val Lys Ala Lys Ser Gln Phe Lys Arg
 100 105 110
 Arg Ser Thr Ala Asn Asn Val Glu Ile His Ile Pro Val Pro Asn Asp
 115 120 125
 Ala Asp Ser Pro Lys Phe Lys Thr Thr Val Gly Ser Val Lys Trp Val
 130 135 140
 Pro Glu Asn Ser Glu Ile Val Trp Ser Val Lys Ser Phe Pro Gly Gly
 145 150 155 160
 Lys Glu Tyr Leu Met Arg Ala His Phe Gly Leu Pro Ser Val Glu Ala
 165 170 175
 Glu Asp Lys Glu Gly Lys Pro Pro Ile Ser Val Lys Phe Glu Ile Pro
 180 185 190
 Tyr Phe Thr Thr Ser Gly Ile Gln Val Arg Tyr Leu Lys Ile Ile Glu
 195 200 205
 Lys Ser Gly Tyr Gln Ala Leu Pro Trp Val Arg Tyr Ile Thr Gln Asn
 210 215 220
 Gly Asp Tyr Gln Leu Arg Thr Gln
 225 230

<210> 128
 <211> 232
 <212> PRT
 <213> Homo sapiens

<400> 128
 Ala Glu Ile Val Gly Ser Ile Lys Met Arg Val Phe Leu Ser Gly Met
 1 5 10 15
 Pro Glu Leu Arg Leu Gly Leu Asn Asp Lys Val Leu Phe Asp Asn Thr
 20 25 30
 Gly Arg Gly Lys Ser Lys Ser Val Glu Leu Glu Asp Val Lys Phe His
 35 40 45
 Gln Cys Val Arg Leu Ser Arg Phe Glu Asn Asp Arg Thr Ile Ser Phe
 50 55 60
 Ile Pro Pro Asp Gly Glu Phe Glu Leu Met Ser Tyr Arg Leu Asn Thr
 65 70 75 80
 His Val Lys Pro Leu Ile Trp Ile Glu Ser Val Ile Glu Lys His Ser
 85 90 95

His Ser Arg Ile Glu Tyr Met Ile Lys Ala Lys Ser Gln Phe Lys Arg
 100 105 110

Arg Ser Thr Ala Asn Asn Val Glu Ile His Ile Pro Val Pro Asn Asp
 115 120 125

Ala Asp Ser Pro Lys Phe Lys Thr Thr Val Gly Ser Val Lys Trp Val
 130 135 140

Pro Glu Asn Ser Glu Ile Val Trp Ser Ile Lys Ser Phe Pro Gly Gly
 145 150 155 160

Lys Glu Tyr Leu Met Arg Ala His Phe Gly Leu Pro Ser Val Glu Ala
 165 170 175

Glu Asp Lys Glu Gly Lys Pro Pro Ile Ser Val Lys Phe Glu Ile Pro
 180 185 190

Tyr Phe Thr Thr Ser Gly Ile Gln Val Arg Tyr Leu Lys Ile Ile Glu
 195 200 205

Lys Ser Gly Tyr Gln Ala Leu Pro Trp Val Arg Tyr Ile Thr Gln Asn
 210 215 220

Gly Asp Tyr Gln Leu Arg Thr Gln
 225 230

<210> 129

<211> 193

<212> PRT

<213> Homo sapiens

<400> 129

Met Ser Ala Ser Ala Val Tyr Val Leu Asp Leu Lys Gly Lys Val Leu
 1 5 10 15

Ile Cys Arg Asn Tyr Arg Gly Asp Val Asp Met Ser Glu Val Glu His
 20 25 30

Phe Met Pro Ile Leu Met Glu Lys Glu Glu Glu Gly Met Leu Ser Pro
 35 40 45

Ile Leu Ala His Gly Gly Val Arg Phe Met Trp Ile Lys His Asn Asn
 50 55 60

Leu Tyr Leu Val Ala Thr Ser Lys Lys Asn Ala Cys Val Ser Leu Val
 65 70 75 80

Phe Ser Phe Leu Tyr Lys Val Val Gln Val Phe Ser Glu Tyr Phe Lys

76

	85		90		95
Glu Leu Glu Glu Glu Ser Ile Arg Asp Asn Phe Val Ile Ile Tyr Glu					
	100		105		110
Leu Leu Asp Glu Leu Met Asp Phe Gly Tyr Pro Gln Thr Thr Asp Ser					
	115		120		125
Lys Ile Leu Gln Glu Tyr Ile Thr Gln Glu Gly His Lys Leu Glu Thr					
	130		135		140
Gly Ala Pro Arg Pro Pro Ala Thr Val Thr Asn Ala Val Ser Trp Arg					
145		150		155	160
Ser Glu Gly Ile Lys Tyr Arg Lys Asn Glu Val Phe Leu Asp Val Ile					
	165		170		175
Glu Ala Val Asn Leu Leu Val Ser Ala Asn Gly Asn Val Leu Arg Ser					
	180		185		190
Glu					

<210> 130
 <211> 193
 <212> PRT
 <213> Homo sapiens

<400> 130
Met Ser Ala Ser Ala Val Tyr Val Leu Asp Leu Lys Gly Lys Val Leu
1 5 10 15
Ile Cys Arg Asn Tyr Arg Gly Asp Val Asp Met Ser Glu Val Glu His
20 25 30
Phe Met Pro Ile Leu Met Glu Lys Glu Glu Glu Gly Met Leu Ser Pro
35 40 45
Ile Leu Ala His Gly Gly Val Arg Phe Met Trp Ile Lys His Asn Asn
50 55 60
Leu Tyr Leu Val Ala Thr Ser Lys Lys Asn Ala Cys Val Ser Leu Val
65 70 75 80
Phe Ser Phe Leu Tyr Lys Val Val Gln Val Phe Ser Glu Tyr Phe Lys
85 90 95
Glu Leu Glu Glu Glu Ser Ile Arg Asp Asn Phe Val Ile Ile Tyr Glu
100 105 110

77

Leu Leu Asp Glu Leu Met Asp Phe Gly Tyr Pro Gln Thr Thr Asp Ser
 115 120 125

Lys Ile Leu Gln Glu Tyr Ile Thr Gln Glu Gly His Lys Leu Glu Thr
 130 135 140

Gly Ala Pro Arg Pro Pro Ala Thr Val Thr Asn Ala Val Ser Trp Arg
 145 150 155 160

Ser Glu Gly Ile Lys Tyr Arg Lys Asn Glu Val Phe Leu Asp Val Ile
 165 170 175

Glu Ser Val Asn Leu Leu Val Ser Ala Asn Gly Asn Val Leu Arg Arg
 180 185 190

Asp

<210> 131

<211> 247

<212> PRT

<213> Homo sapiens

<400> 131

Pro Pro Phe Glu Tyr Phe Ile Met Ala Met Ile Ala Leu Asn Thr Val
 1 5 10 15

Val Leu Met Met Lys Phe Tyr Asp Ala Pro Tyr Glu Tyr Glu Leu Met
 20 25 30

Leu Lys Cys Leu Asn Ile Val Phe Thr Ser Met Phe Ser Met Glu Cys
 35 40 45

Val Leu Lys Ile Ile Ala Phe Gly Val Leu Asn Tyr Phe Arg Asp Ala
 50 55 60

Trp Asn Val Phe Asp Phe Val Thr Val Leu Gly Ser Ile Thr Asp Ile
 65 70 75 80

Leu Val Thr Glu Ile Ala Glu Thr Asn Asn Phe Ile Asn Leu Ser Phe
 85 90 95

Leu Arg Leu Phe Arg Ala Ala Arg Leu Ile Lys Leu Leu Arg Gln Gly
 100 105 110

Tyr Thr Ile Arg Ile Leu Leu Trp Thr Phe Val Gln Ser Phe Lys Ala
 115 120 125

Leu Pro Tyr Val Cys Leu Leu Ile Ala Met Leu Phe Phe Ile Tyr Ala
 130 135 140

Ile Ile Gly Met Gln Val Phe Gly Asn Ile Ala Leu Asp Asp Asp Thr
 145 150 155 160

Ser Ile Asn Arg His Asn Asn Phe Arg Thr Phe Leu Gln Ala Leu Met
 165 170 175

Leu Leu Phe Arg Ser Ala Thr Gly Glu Ala Trp His Glu Ile Met Leu
 180 185 190

Ser Cys Leu Ser Asn Gln Ala Cys Asp Glu Gln Ala Asn Ala Thr Glu
 195 200 205

Cys Gly Ser Asp Phe Ala Tyr Phe Tyr Phe Val Ser Phe Ile Phe Leu
 210 215 220

Cys Ser Phe Leu Met Leu Asn Leu Phe Val Ala Val Ile Met Asp Asn
 225 230 235 240

Phe Glu Tyr Leu Thr Arg Asp
 245

<210> 132

<211> 243

<212> PRT

<213> Homo sapiens

<400> 132

Pro Leu Phe Lys Asn Phe Ile Ile Phe Leu Val Phe Leu Asn Thr Ile
 1 5 10 15

Ile Leu Met Val Glu Ile Glu Leu Leu Glu Ser Thr Asn Thr Lys Leu
 20 25 30

Trp Pro Leu Lys Leu Thr Leu Glu Val Ala Ala Trp Phe Ile Leu Leu
 35 40 45

Ile Phe Ile Leu Glu Ile Leu Leu Lys Trp Leu Ser Asn Phe Ser Val
 50 55 60

Phe Trp Lys Ser Ala Trp Asn Val Phe Asp Phe Val Val Thr Met Leu
 65 70 75 80

Ser Leu Leu Pro Glu Val Val Val Leu Val Gly Val Thr Gly Gln Ser
 85 90 95

Val Trp Leu Gln Leu Leu Arg Ile Cys Arg Val Leu Arg Ser Leu Lys
 100 105 110

Leu Leu Ala Gln Phe Arg Gln Ile Gln Ile Ile Ile Leu Val Leu Val

115	120	125
Arg Ala Leu Lys Ser Met Thr Phe Leu Leu Met Leu Leu Leu Ile Phe		
130	135	140
Phe Tyr Ile Phe Ala Val Thr Gly Val Tyr Val Phe Ser Glu Tyr Thr		
145	150	155
Arg Ser Pro Arg Gln Asp Leu Glu Tyr His Val Phe Phe Ser Asp Leu		
165	170	175
Pro Asn Ser Leu Val Thr Val Phe Ile Leu Phe Thr Leu Asp His Trp		
180	185	190
Tyr Ala Leu Leu Gln Asp Val Trp Lys Val Pro Glu Val Ser Arg Ile		
195	200	205
Phe Ser Ser Ile Tyr Phe Ile Leu Trp Leu Leu Leu Gly Ser Ile Ile		
210	215	220
Phe Arg Ser Ile Ile Val Ala Met Met Val Thr Asn Phe Gln Asn Ile		
225	230	235
240		
Arg Lys Glu		

<210> 133
 <211> 138
 <212> PRT
 <213> Homo sapiens

<400> 133

Met Ala Ser Ser Arg Pro Pro Lys Tyr Leu Leu Val Phe Asp Phe Asp		
1	5	10
15		
Gly Thr Ile Ile Asn Glu Ser Ser Asp Asp Ser Ile Val Arg Ala Ala		
20	25	30
Pro Gly Gln Ala Leu Pro Glu His Ile Arg Gln Ser Phe Arg Glu Gly		
35	40	45
Phe Tyr Asn Glu Tyr Met Gln Arg Val Leu Ala Tyr Met Gly Asp Gln		
50	55	60
Gly Val Lys Met Gly Asp Phe Lys Ala Val Tyr Glu Asn Ile Pro Leu		
65	70	75
80		
Ser Pro Gly Met Pro Asp Leu Phe Gln Phe Leu Ser Lys Asn His Glu		
85	90	95

80

Leu Phe Glu Ile Ile Leu Ile Ser Asp Ala Asn Met Phe Gly Ile Glu
 100 105 110

Cys Lys Leu Arg Ala Ala Gly Phe Tyr Ser Leu Phe Arg Lys Ile Phe
 115 120 125

Ser Asn Pro Ser Ser Phe Asp Lys Arg Gly
 130 135

<210> 134

<211> 138

<212> PRT

<213> Homo sapiens

<400> 134

Met Ala Ala Gln Gly Ala Pro Arg Phe Leu Leu Thr Phe Asp Phe Asp
 1 5 10 15

Glu Thr Ile Val Asp Glu Asn Ser Asp Asp Ser Ile Val Arg Ala Ala
 20 25 30

Pro Gly Gln Arg Leu Pro Glu Ser Leu Arg Ala Thr Tyr Arg Glu Gly
 35 40 45

Phe Tyr Asn Glu Tyr Met Gln Arg Val Phe Lys Tyr Leu Gly Glu Gln
 50 55 60

Gly Val Arg Pro Arg Asp Leu Ser Ala Ile Tyr Glu Ala Ile Pro Leu
 65 70 75 80

Ser Pro Gly Met Ser Asp Leu Leu Gln Phe Val Ala Lys Gln Gly Ala
 85 90 95

Cys Phe Glu Val Ile Leu Ile Ser Asp Ala Asn Thr Phe Gly Val Glu
 100 105 110

Ser Ser Leu Arg Ala Ala Gly His His Ser Leu Phe Arg Arg Ile Leu
 115 120 125

Ser Asn Pro Ser Gly Pro Asp Ala Arg Gly
 130 135

<210> 135

<211> 36

<212> PRT

<213> Homo sapiens

<400> 135

Ala Asp Val Ala Phe Pro Arg Lys Gly Tyr Pro Met His Gln Met Thr

81

1 5 10 15

Gln Glu Met Glu Lys Lys Gln Pro Gly Thr Phe Gln Ala Thr Val Val

 20 25 30

Pro Trp Glu Ser

 35

<210> 136

<211> 38

<212> PRT

<213> Homo sapiens

<400> 136

Ala Gly Cys Ala Trp Pro Ser Arg Ala Ala Ala Thr Pro Cys Thr Ala

1 5 10 15

Leu Ile Gln Glu Ala Gln Lys Ala Glu Pro Ser Ser Phe Arg Ala Ser

 20 25 30

Val Val Pro Trp Glu Thr

 35

<210> 137

<211> 428

<212> PRT

<213> Homo sapiens

<400> 137

Gly Phe Thr Ala Lys Asp Ile Leu Asp Gln Lys Ile Asn Glu Val Ser

1 5 10 15

Ser Ser Asp Asp Lys Asp Ala Phe Tyr Val Ala Asp Leu Gly Asp Ile

 20 25 30

Leu Lys Lys His Leu Arg Trp Leu Lys Ala Leu Pro Arg Val Thr Pro

 35 40 45

Phe Tyr Ala Val Lys Cys Asn Asp Ser Lys Ala Ile Val Lys Thr Leu

 50 55 60

Ala Ala Thr Gly Thr Gly Phe Asp Cys Ala Ser Lys Thr Glu Ile Gln

65 70 75 80

Leu Val Gln Ser Leu Gly Val Pro Pro Glu Arg Ile Ile Tyr Ala Asn

 85 90 95

Pro Cys Lys Gln Val Ser Gln Ile Lys Tyr Ala Ala Asn Asn Gly Val

 100 105 110

Gln Met Met Thr Phe Asp Ser Glu Val Glu Leu Met Lys Val Ala Arg	115	120	125
Ala His Pro Lys Ala Lys Leu Val Leu Arg Ile Ala Thr Asp Asp Ser	130	135	140
Lys Ala Val Cys Arg Leu Ser Val Lys Phe Gly Ala Thr Leu Arg Thr	145	150	155 160
Ser Arg Leu Leu Leu Glu Arg Ala Lys Glu Leu Asn Ile Asp Val Val	165	170	175
Gly Val Ser Phe His Val Gly Ser Gly Cys Thr Asp Pro Glu Thr Phe	180	185	190
Val Gln Ala Ile Ser Asp Ala Arg Cys Val Phe Asp Met Gly Ala Glu	195	200	205
Val Gly Phe Ser Met Tyr Leu Leu Asp Ile Gly Gly Gly Phe Pro Gly	210	215	220
Ser Glu Asp Val Lys Leu Lys Phe Glu Glu Ile Thr Gly Val Ile Asn	225	230	235 240
Pro Ala Leu Asp Lys Tyr Phe Pro Ser Asp Ser Gly Val Arg Ile Ile	245	250	255
Ala Glu Pro Gly Arg Tyr Tyr Val Ala Ser Ala Phe Thr Leu Ala Val	260	265	270
Asn Ile Ile Ala Lys Lys Ile Val Leu Lys Glu Gln Thr Gly Ser Asp	275	280	285
Asp Glu Asp Glu Ser Ser Glu Gln Thr Phe Met Tyr Tyr Val Asn Asp	290	295	300
Gly Val Tyr Gly Ser Phe Asn Cys Ile Leu Tyr Asp His Ala His Val	305	310	315 320
Lys Pro Leu Leu Gln Lys Arg Pro Lys Pro Asp Glu Lys Tyr Tyr Ser	325	330	335
Ser Ser Ile Trp Gly Pro Thr Cys Asp Gly Leu Asp Arg Ile Val Glu	340	345	350
Arg Cys Asp Leu Pro Glu Met His Val Gly Asp Trp Met Leu Phe Glu	355	360	365
Asn Met Gly Ala Tyr Thr Val Ala Ala Ala Ser Thr Phe Asn Gly Phe	370	375	380

Gln Arg Pro Thr Ile Tyr Tyr Val Met Ser Gly Pro Ala Trp Glu Leu
 385 390 395 400

Met Gln Gln Phe Gln Asn Pro Asp Phe Pro Pro Glu Val Glu Glu Gln
 405 410 415

Asp Ala Ser Thr Leu Pro Val Ser Cys Ala Trp Glu
 420 425

<210> 138

<211> 65

<212> PRT

<213> Homo sapiens

<400> 138

Pro Arg Leu Glu Cys Ser Gly Gly Ile Ser Ala His Cys Asn Leu His
 1 5 10 15

Leu Leu Gly Ser Ser Asp Tyr Pro Thr Ser Ala Ser Arg Val Ala Gly
 20 25 30

Val Thr Gly Ala Arg His His Ala Gln Leu Ile Phe Val Phe Leu Val
 35 40 45

Glu Thr Ser Phe Leu Arg Val Gly Arg Ala Gly Leu Glu Leu Leu Thr
 50 55 60

Ser
 65

<210> 139

<211> 138

<212> PRT

<213> Homo sapiens

<400> 139

Val Pro Leu Glu Ser Val Lys Pro Ser Ser Leu Pro Pro Leu Ile Val
 1 5 10 15

Tyr Asp Arg Asn Gly Phe Arg Ile Leu Leu His Phe Ser Gln Thr Gly
 20 25 30

Ala Pro Gly His Pro Glu Val Gln Val Leu Leu Leu Thr Met Met Ser
 35 40 45

Thr Ala Pro Gln Pro Val Trp Asp Ile Met Phe Gln Val Ala Val Pro
 50 55 60

84

Lys Ser Met Arg Val Lys Leu Gln Pro Ala Ser Ser Ser Lys Leu Pro
 65 70 75 80

Ala Phe Ser Pro Leu Met Pro Pro Ala Val Ile Ser Gln Met Leu Leu
 85 90 95

Leu Asp Asn Pro His Lys Glu Pro Ile Arg Leu Arg Tyr Lys Leu Thr
 100 105 110

Phe Asn Gln Gly Gly Gln Pro Phe Ser Glu Val Gly Glu Val Lys Asp
 115 120 125

Phe Pro Asp Leu Ala Val Leu Gly Ala Ala
 130 135

<210> 140

<211> 138

<212> PRT

<213> Homo sapiens

<400> 140

Val Pro Leu Glu Ser Val Lys Pro Ser Ser Leu Pro Pro Leu Ile Val
 1 5 10 15

Tyr Asp Arg Asn Gly Phe Arg Ile Leu Leu His Phe Ser Gln Thr Gly
 20 25 30

Ala Pro Gly His Pro Glu Val Gln Val Leu Leu Leu Thr Met Met Ser
 35 40 45

Pro Ala Pro Gln Pro Val Trp Asp Ile Met Phe Gln Val Ala Val Pro
 50 55 60

Lys Ser Met Arg Val Lys Leu Gln Pro Ala Ser Ser Ser Lys Leu Pro
 65 70 75 80

Ala Phe Ser Pro Leu Met Pro Pro Ala Val Ile Ser Gln Met Leu Leu
 85 90 95

Leu Asp Asn Pro His Lys Glu Pro Ile Arg Leu Arg Tyr Lys Leu Thr
 100 105 110

Phe Asn Gln Gly Gly Gln Pro Phe Ser Glu Val Gly Glu Val Lys Asp
 115 120 125

Phe Pro Asp Leu Ala Val Leu Gly Ala Ala
 130 135

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08980**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :C07K 14/47, 15/52; C12N 5/10, 5/16, 15/12, 15/19, 15/63, 15/64

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.5, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST, CAS ONLINE, EMBASE**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — A	DAHMS et al. 46 kd Mannose 6-Phosphate Receptor: Cloning, Expresssion, and Homology to the 215 kd Mannose 6-Phosphate Receptor. Cell. 17 July 1987, Vol. 50, pages 181-192, especially page 184.	1-3, 7-11, 14-16 — 4-6, 12, 21

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

31 MAY 2000

Date of mailing of the international search report

07 AUG 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08980

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-12, 14-16 and 21 (SIQ ID NO: 11, SEQ ID NO: 59)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08980

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.5, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-12, 14-16, 21, drawn to a nucleic acid of SEQ ID NO:11 encoding a protein of SEQ ID NO:59, a vector, a host cell, a method of making the protein and the protein of SEQ ID NO:59.

Group II, claim 13, drawn to an antibody that binds the protein of SEQ ID NO:59.

Group III, claim 17, drawn to a method of treating a condition comprising administering the protein of SEQ ID NO:59.

Group IV, claim 18, drawn to a method of diagnosing a pathological condition using the polynucleotide encoding a protein of SEQ ID NO:59.

Group V, claim 19, drawn to a method of diagnosing a pathological condition by determining the amount of protein of SEQ ID NO:59.

Group VI, claim 20, drawn to a method of identifying a binding partner of the protein of SEQ ID NO:59.

Group VII, claims 22-23, drawn to a method of identifying an activity in a biological assay.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that

where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, a nucleic acid encoding a protein of SEQ ID NO:59, a vector, a host cell, a method of making the protein of SEQ ID NO:59, and the protein of SEQ ID NO:59. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.